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Abstract 
 
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in 
the western countries. The primary stage and therefore risk factor for NAFLD is 
an abnormal lipid accumulation in the liver, which is termed hepatic steatosis. 
Despite the high prevalence of NAFLD, there is no efficient treatment exist for 
this disease. Gaining insight into the molecular pathways and metabolic 
regulators involved in the development of NAFLD is hence a prerequisite to 
design and develop novel and effective therapeutic strategies.  
In this thesis, we have established the role of the nuclear receptor LRH-1 as a 
key regulator in the development of NAFLD by regulating both de novo 
lipogenesis and fatty acid oxidation, pivotal pathways in hepatic lipid 
metabolism. We observed that increasing the transcriptional activity of LRH-1 
under a refeeding condition led to SREBP-1c-dependent rise in the rate of fatty 
acid synthesis. On the other hand, loss of LRH-1 in the liver impaired fatty acid 
oxidation under fasting conditions. In turn both conditions led to hepatic 
steatosis. Moreover, two players in the above-mentioned phenotypes were 
identified as novel LRH-1 target genes, the oxysterol-binding protein OSBPL3 and 
the mitochondrial transporter SLC25A47.  
Furthermore, diet-induced NAFLD models presented increased and decreased 
levels of OSBPL3 and SLC25A47, respectively, suggesting that targeting these two 
proteins could be effective in the treatment of NAFLD. Furthermore, we 
characterized the biological role of the poorly studied mitochondrial transporter, 
SLC25A47, and identified this protein as an important determinant of liver 
mitochondria function.  
Collectively, these studies unveil the importance of fine-tuning LRH-1 
expression/activity to prevent the development of complex diseases such as 
NAFLD. Additionally, this thesis work highlights SLC25A47 as a novel target to 
treat or prevent NAFLD. Further studies will be required to fully understand the 
therapeutic significance of these druggable targets. 
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Resumo 
 
A doença do fígado gordo não alcoólico (DFGNA) é a doença do fígado mais 
comum nos países ocidentais. O primeiro estágio e portanto fator de risco para 
DFGNA é a acumulação anormal de lípidos no fígado, chamada de esteatose 
hepática. Apesar da elevada prevalência, atualmente não há nenhum tratamento 
eficiente para esta doença. Ganhar mais conhecimento sobre as vias e 
reguladores metabólicos que estão envolvidos no desenvolvimento da DFGNA é 
então um pré-requisito para planear e desenvolver estratégias terapêuticas novas 
e eficazes.  
Nesta tese, nós estabelecemos o papel do receptor nuclear LRH-1 como um 
regulador metabólico essencial no desenvolvimento da DFGNA ao regular tanto a 
síntese de lípidos como a oxidação dos ácidos gordos, vias metabólicas 
fundamentais no metabolismo lipídico hepático. Nós observamos que 
aumentando a atividade de transcrição de LRH-1 numa condição de realimentação 
(saciedade) levou a um aumento da síntese de lípidos dependente de SREBP-1c. 
Por outro lado, a perda de LRH-1 no fígado sob jejum comprometeu a oxidação 
dos ácidos gordos na mitocôndria. Ambas situações levaram a esteatose 
hepática. Além disso, dois intervenientes nestes fenótipos foram identificados 
como genes alvo da atividade de transcrição de LRH-1, a proteína de ligação a 
oxisteróis OSBPL3 e o transportador mitocondrial SLC25A47.   
Modelos de DFGNA induzidos por dietas apresentam níveis aumentados e 
diminuídos de OSBPL3 e SLC25A47, respetivamente, sugerindo que desenvolver 
compostos que atuem sobre estas proteínas poderão ser eficientes no tratamento 
de DFGNA. Adicionalmente, nós caracterizamos o papel biológico de SLC25A47, 
um transportador mitocondrial muito pouco estudado até agora, e identificamos 
esta proteína como um determinante da função mitocondrial hepática.  
Coletivamente, estes estudos desvendam a importância de “afinar” 
corretamente a expressão/atividade de LRH-1 para prevenir o desenvolvimento 
de doenças complexas como a DFGNA. Mais ainda, o trabalho nesta tese destaca 
SLC25A47 como um novo alvo para tratar ou prevenir DFGNA. Estudos adicionais 
são necessários para compreender o significado terapêutico destas proteínas.   
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Chapter I General Introduction 
I. Section 1 Nonalcoholic fatty liver disease 
 
I.1.1 NAFLD and obesity 
From hunter-gatherers to farmers where food availability to survive was 
inconsistent and unpredictable, humans nowadays are facing a massive 
overnutrition. More and more the production of calories at low cost sustains the 
increase of the new world epidemic called obesity. Excessive consumption of 
calories has become a global phenomenon (Figure I.1). Currently, it is estimated 
that worldwide there are about 2 billion (34% of men and 35% of women) 
overweight and over 600 million (10% of men and 13% of women) obese adults 
with body mass indices over 30kg/m2 (World Health Organization).  
 
Considering human biology and the path that we have trailed since pre-
historical times, one can easily state that the human organism is not ready to 
cope with these overfeeding patterns. The resulting excess in body fat is the 
main trigger for metabolic disturbances that culminate in several diseases (Figure 
I.2). Being one of the obesity-associated morbidities, nonalcoholic fatty liver 
disease (NAFLD) is the most common liver disease and its prevalence increases 
with the growing obesity epidemic. NAFLD is now regarded as the liver 
manifestation of the metabolic syndrome. 
Figure I.1. World caloric intake distribution and prevalence (%) of non-alcoholic fatty liver 
disease (NAFLD) (1). 
 
Chapter I   General Introduction 
 6 
 
I.1.2   Definition of NAFLD  
 
 NAFLD is a spectrum of disorders, of which the earliest stage is characterized 
by the deposition of lipid droplets within the cytoplasm of the hepatocytes 
(hepatic steatosis – fatty liver). The progressive fat accumulation increases the 
susceptibility to hepatocyte damage and inflammation, a condition termed 
nonalcoholic steatohepatitis (NASH) that can progress to cirrhosis and may 
ultimately lead to hepatocellular carcinoma (HCC) (2-4) (Figure I.3).  
 Each stage within this disease has its own features (Figure I.3). While the first 
manifestation of the disease is mainly represented by lipid accumulation 
(steatosis), the next stages comprise a whole rearrangement of structure and 
Figure I.3.  The disease spectrum of NAFLD. Adapted from (2) 
 
 
Figure I.2. Medical complications related to obesity. 
NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; CVD, 
cardiovascular disease, CKD, chronic kidney disease; T2DM, Type 2 Diabetes Mellitus.  
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compromised liver function. Inflammation, cell damage, fibrosis, along with 
excessive fat accumulation, characterizes NASH. Cirrhosis is the most severe 
stage of NAFLD and can be distinguished by a pronounced scarring of the tissue 
(fibrosis) that alters the whole morphology and polarization/zonation of the 
hepatocytes.   
 
I.1.3   Prevalence and risk factors of NAFLD 
 
NAFLD is a complex disease that affects almost one third of the adult 
population worldwide, however, its prevalence is not fully predicted by the total 
caloric intake (Figure I.1) (1). This emphasizes the complexity of NAFLD and it 
hints at the importance of factors other than body mass index or daily caloric 
excess in the pathophysiology of NAFLD. Of interest, multiethnic population-
based studies showed that NAFLD varies in prevalence among ethnic groups, with 
African Americans having the lowest (24%) and Hispanics the highest (45%) 
prevalence (5, 6), validating genetic susceptibility as an important contributing 
factor. Hepatic steatosis, NASH, and cirrhosis cluster in families, with the 
heritability of NAFLD being estimated to be ~39% (7). 
Although single-gene mutations cause rare forms of severe steatosis, the 
increased prevalence of NAFLD in the general population over the past 30 years is 
due to changes in the quantity and composition of food. Diets high in fat are 
major contributors to NAFLD but carbohydrates in general and fructose in 
particular, play important roles as well. Fructose is a highly lipogenic sugar found 
in food and beverages consumed worldwide. Glucose and fructose differ in 
several ways. Fructose is poorly absorbed in the small intestine and is cleared 
from the blood in the liver on the first pass and metabolized in the hepatocytes. 
The mechanism of transport and utilization are independent of insulin action and 
phosphofrutokinase regulation step (8-10). The action of frutokinase is also 10 
times faster than glucokinase (GCK) and hexokinase leading to the accumulation 
of fructose-1-phosphate in the liver and a rapid drop of ATP levels. Fructose-1-
phosphate can then be converted into substrates for gluconeogenesis, glycolysis 
and de novo lipogenesis (DNL) in a relatively unregulated fashion (9). Therefore, 
high fructose intake leads to increased hepatic lipogenesis rapidly promoting 
lipid accumulation.  
Due to the close association of NAFLD with the presence and severity of 
obesity, studies in morbidly obese people (BMI> 35kg/m2) undergoing bariatric 
Chapter I   General Introduction 
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surgery reported the incidence of NAFLD of 91% (11). 70% of type 2 diabetes 
mellitus (T2DM) patients present NAFLD (12) (Figure I.4). This rising trend of 
NAFLD is alarming, and it is of particular concern in the pediatric population 
where studies in children have verified a general prevalence of 3% that increases 
to 53% in obese children (13). 
Besides race and ethnicity, genetic variations and concomitant presence with 
other metabolic disturbances, gender (31% men vs 16% women) and age (46% in 
geriatric population) also seem to predispose to NAFLD (14).  
 
 
 
 
 
 
 
I.1.4   Diagnosis of NAFLD  
 
Analysis of liver biopsies has been proven to be the most effective method to 
diagnose fatty liver, however, it is a very invasive method to be applied in human 
diagnostics. Moreover, they are discretionary in nature and rely on histological 
scoring. Thus, several non-invasive diagnostic methods for NAFLD and NASH have 
been introduced recently in human studies. Non-invasive radiological methods 
used to assess the prevalence of fatty liver include magnetic resonance imaging 
(MRI) and ultrasonography (15-17). Other studies rely on the monitoring of the 
liver enzymes, alanine aminotransferase (ALAT) and aspartate aminotransferase 
(ASAT) in the blood, as non-invasive indicators of NAFLD (18-20). Finally, 
classification protocols exist based on measured clinical variables, such as Fatty 
Liver Index (FLI) composed of BMI, waist circumference, triglycerides (TG) and 
gamma-glutamyl-transferase (GGT) (21), and Lipid Accumulation Product (LAP) 
with waist circumference and fasting TG (22).  
Although these methods have been applied to diagnose this liver condition, 
NAFLD is often an asymptomatic disease in which blood tests may be completely 
normal. Furthermore, radiological methods are known to be sensitive only when 
more than one third of the liver is affected by steatosis (13). These facts have 
made studies on prevalence of NAFLD very difficult emphasizing how 
underestimated the prevalence of NAFLD may be. Therefore and since invasive 
Figure I.4.  Prevalence of NAFLD. Adapted from (13). 
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40
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liver biopsies are still the only method to accurately diagnose NAFLD, there is an 
urgent need to find novel biomarkers that could surpass this diagnostic 
challenge, ultimately leading to better and earlier treatment.  
 
I.1.5   Natural history of NAFLD  
 
 The long-term prognosis of NAFLD largely depends on the stage of the 
disease, ranging from mild to very severe (Figure I.5).  On the other hand, NAFLD 
has a good short-term prognosis. From patients presenting simple hepatic 
steatosis, only 12-40% will develop NASH with early fibrosis in 8 to 13 years. 13% 
of patients presenting with NASH will develop cirrhosis and/or evidence of 
hepatic decompensation in the same time period. While about 50% of patients 
presenting cirrhosis will require a liver transplant or die from liver failure, 7% will 
develop HCC within 10 years (Figure I.5). For this reason, the described relation 
between HCC, obesity and diabetes can only be partly explained by NAFLD (23).  
 
 
 I.1.6   Pathogenesis of hepatic steatosis 
 
In the course of evolution, TG have turned into the preferred and most reliable 
source of stored energy as a mean to cope with variations in energy demand and 
availability. TG provide the greatest amount of energy (9 kcal/g) compared to 
other macronutrients, proteins and carbohydrates, and their hydrophobic nature 
allows efficient accumulation and storage without engendering osmotic effects on 
the cell. TG are primarily stored in adipocytes but can accumulate in other cell 
types upon specific and unusual conditions. For instance, migratory birds 
accumulate TG in their liver (fois gras) as a preparation for their seasonal flights. 
Humans also accumulate TG in their liver after caloric excess; however, this 
condition has no physiological advantage. Because the liver does not serve as a 
prime location for fat storage, the steady state concentration of hepatic TG is low 
Figure I.5. Natural history of NAFLD over 8-13 years. 
NASH, nonalcoholic steatohepatitis; HCC, hepatocellular carcinoma; LT, Liver Transplant. 
Adapted from (13). 
Steatosis NASH Advanced 
Fibrosis
Cirrhosis
Liver-related 
Death/ LT
HCC
12-40% 5-10% 0-50%
25-50%
7%14% 25%
8% 13%
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under physiological conditions. TG are assembled via ester bonds between fatty 
acids and glycerol. Hepatic TG formation relies on the supply of fatty acids from 
three sources: diet, adipose tissue or de novo synthesis (Figure I.6). 
The excessive accumulation of TG in the liver is a consequence of an 
imbalance between the acquisition and disposal of fatty acids (FA). Increased 
hepatic uptake of adipose tissue or diet-derived fatty acids, defective breakdown 
via β-oxidation, reduced very-low density lipoproteins (VLDL)-triglyceride 
secretion or induced activity of master regulators of DNL, such as the 
transcription factor sterol element binding protein 1 (SREBP-1) and carbohydrate 
responsive element-binding protein (ChREBP), are factors that contribute to the 
development of steatosis (2) (Figure I.6).  
I.1.6.1   Source of FA in the liver 
 
Chylomicrons  
After eating, dietary fat is hydrolyzed to fatty acids and monoacylglycerols by 
Figure I.6. Metabolic pathways impacting on NAFLD. 
(A) Normal liver. (B) Liver with NAFLD. DNL, de novo lipogenesis; TG, triglycerides; TCA cycle, 
tricarboxylic acid cycle; FFA, free fatty acids; VLDL, very low density lipoproteins; ATGL, 
adipose triglyceride lipase; HSL, hormone sensitive lipase.  Adapted from (2). 
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intestinal lipases and then absorbed by the enterocytes. Here, they can be re-
esterified and packed into chylomicron lipoprotein particles for distribution to the 
other tissues. There has been an increased awareness about the importance of 
the fed-state events in the development and/or exacerbation of many diseases. 
Indeed, postprandial hypertriglyceridemia poses as an independent risk factor for 
coronary atherosclerosis, obesity, T2DM and NAFLD (24). Data are emerging to 
show that a significant source of the liver TG derive from dietary lipids. Diets high 
in fat content have long been associated with obesity and NAFLD (25). Using 
multiple stable isotopes followed by liver biopsies, it was calculated that 8-12% of 
meal-TG reach the liver in healthy patients after a single meal, and that in 
patients with NAFLD a greater burden (10-16%) of dietary TG is taken up by the 
liver in the postprandial state (24). This could be due to lower peripheral 
clearance of the dietary lipids in NAFLD and increased fatty-acid transport 
proteins (FATPs and fatty acid translocase or CD36) in the liver (26).    
 
De novo lipogenesis  
High insulin levels and increase substrate availability by carbohydrate feeding 
promotes de novo synthesis of fatty acids from acetyl-CoA in liver cells. Insulin is 
responsible for the induction of SREBP1c gene expression and activity through 
the liver X receptor (LXR) transcriptional regulation and through signaling 
involving RAC-beta serine/threonine-protein kinase (AKT2) and the mechanistic 
target of rapamycin (mTOR) (27). SREBP1c in turn drives the expression of genes 
involved in lipogenesis, such as fatty acid synthase (Fasn) and stearoyl-CoA 
desaturase-1 (Scd-1) (28). Glucose also promotes DNL by activating the 
transcription factor ChREBP (29, 30). Hepatic ChREBP activation requires GCK-
dependent glucose metabolism, with glucose-6-phosphate being the major 
signaling metabolite responsible for ChREBP activation (31). The unique glucose-
sensing ability of this transcription factor is further emphasized by the fact that 
several independent glucose metabolites, such as xylulose-5-phosphate, fructose-
2,6-bisphosphate, acetyl-CoA and O-linked β-N-acetylglucosaminylation, can 
activate hepatic ChREBP (30). ChREBP stimulates the expression of several genes 
in the fatty acid biosynthetic pathway. In addition, ChREBP increases expression 
of liver pyruvate kinase, thus providing more substrate for FA and TG synthesis 
(29). An increase in DNL has been considered an important contributing factor to 
NAFLD development (32, 33). In fact, DNL is 5-fold greater in NAFLD than in 
normal livers and it fails to increase postprandially, a pattern present in healthy 
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individuals (32). In turn, inhibition of ChREBP and SREBP1c-stimulated lipogenesis 
has proven efficient in decreasing hepatic steatosis (34-36). 
 
Lipolysis 
During fasting, rising levels of glucagon and epinephrine stimulate TG 
hydrolysis from its storage in the adipose tissue. Adipocyte triglyceride lipase 
(ATGL) and hormone-sensitive lipase (HSL) are key enzymes involved in this 
mobilization (37). Free fatty acids (FFA) are then released into circulation, mostly 
bound to albumin and delivered to the liver. FATPs and CD36 are key 
contributors to the transmembrane process of fatty acid uptake (38). In the liver, 
FFA are converted into fatty acyl-CoAs and oxidized in the mitochondria, re-
esterified into TG and stored or secreted in VLDL. Of all the FATPs isoforms, 
FATP5 is liver-specific and genetic ablation of this transporter decreases the rates 
of fatty acid uptake (39). Humans with NAFLD have higher hepatic CD36 levels 
(40). Congenital generalized lipodystrophy is invariably associated with severe 
hepatic steatosis (41). Insulin resistance that is largely associated with obesity 
can favor hepatic FA overload due to dysfunctional adipose tissue with increased 
lipolysis (42). 
Patatin-like phospholipase domain containing 3 (PNPLA3, adiponutrin) is 
consistently associated with NAFLD and is one of the most common genetic 
variants triggering this condition (6). PNPLA3 is a member of the PNPLA family, 
most closely related to ATGL (PNPLA2). PNPLA3 is highly expressed in adipose 
tissue and liver and is transcriptionally regulated by insulin through a signaling 
cascade that includes LXR and SREBP1c (43). The frequency of this genetic variant 
accounts for the degree of susceptibility to this pathological condition that differs 
between Hispanics, African Americans and Europeans (6).  
Despite the role of ATGL in increasing lipolysis and consequent FA delivery to 
the liver, Jha et al demonstrated that lack of ATGL in the liver increases the 
susceptibility to diet-induced NAFLD by promoting hepatic inflammation (44), 
emphasizing the complexity and difficulty of intervention to counteract the 
development of this disorder. 
 
I.1.6.2   Disposal of FA from the liver 
 
VLDL secretion  
 
Hepatic TG leave the liver through assembly into VLDL for lipid fuel 
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distribution to peripheral tissues. Any mutations that would affect proteins or 
other constituents affecting the production or secretion of VLDL can lead to 
hepatic steatosis. The structural protein Apolipoprotein B (APOB) and microsomal 
TG transfer protein (MTP) responsible for adding TG into nascent VLDL are two 
examples of proteins whose mutations trigger steatosis. Indeed, individuals with 
a mutation in APOB protein have lower secretion of VLDL from the liver and a 
three-fold increase in hepatic steatosis compared to healthy subjects (45). 
Moreover, studies have reported that dysfunctional VLDL synthesis and release 
may be a key factor in the establishment and progression of NASH, this being 
decreased in patients with NAFLD (46). A structural component of cellular 
membranes, a metabolic substrate for other lipids and a ligand for nuclear 
receptors such as LRH-1, phosphatidylcholine (PC), is also a very important 
component of VLDL (47). Diets deficient in methionine and choline affect the 
secretion of VLDL leading to hepatic steatosis and more advanced stages of 
NAFLD (48).   
 
Fatty Acid Oxidation 
FA undergo mitochondrial β-oxidation to produce acetyl-CoA that can be 
further processed in the citric acid cycle and feed the electron transport chain 
(discussed in the next section) (49). Fatty acid oxidation (FAO or β-oxidation) 
itself also renders nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH
2
) that can increase oxidative phosphorylation. FA need to be 
activated by coenzyme A (CoA) and then enter the mitochondria in a carnitine-
dependent manner. Carnitine palmitoyltransferase-1 (CPT-1), present in the outer 
mitochondrial membrane, catalyzes the formation of Acyl-Carnitines and 
represents the first and rate–limiting step for FAO (49). Then, CoA replaces again 
carnitine inside the mitochondria before proceeding with β-oxidation. Several 
enzymes are responsible for the sequential break down of long chain acyl-CoAs 
to several Acetyl-CoA, NADH and FADH
2
. FAO poses as one of the main sources of 
fatty acid disposal, converting them into energy. Mitochondrial dysfunction, on 
the other hand, can lead to the dysregulation of this process or to incomplete β-
oxidation with consequent accumulation of FA (50).  Defects in the enzymes 
required for oxidation of FA in the mitochondria by β–oxidation also cause 
hepatic steatosis (41). Hepatic lipid accumulation is a common feature in patients 
with fatty acid oxidation disorders, including deficiency of medium-chain 
acylcoenzyme-A dehydrogenase (MCAD), long chain acyl-CoA dehydrogenase 
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deficiency (LCAD), very long-chain acyl-CoA dehydrogenase (VLCAD), long-chain 
3-hydroxyacyl-CoA dehydrogenase (LCHAD) or mitochondrial trifunctional protein 
(TFP) (51).  
 
Chapter I   General Introduction 
 15 
 
 
 
 
 
 
 
 
 
 
 
 
Section 2 
Mitochondria as the hub of intermediary 
metabolism 
 
 
 
 
 
 

Chapter I   General Introduction 
 17 
Chapter I General Introduction 
I. Section 2   Mitochondria as the hub of intermediary metabolism 
 
I.2.1.  Introduction on Mitochondria 
 
Mitochondria are eukaryotic bean-shaped organelles comprised of double and 
functionally distinct membranes (inner mitochondrial membrane-IMM and outer 
mitochondrial membrane-OMM), intermembrane space (IMS) and matrix 
compartments (Figure I.7). The endosymbiotic theory states that mitochondria 
arose from an alpha-proteobacterium engulfed by an eukaryotic progenitor that 
survived endocytosis and became incorporated in the cytosol (52). One of the 
remnants of this former life is the presence of a genome (mitochondrial DNA, 
mtDNA), organized into discrete nucleoids in the matrix that bears more 
sequence resemblance to its prokaryotic precursor than to its eukaryotic host.   
Figure I.7. Structure of a mitochondrion. 
The mitochondrial genome consists of a circular, double-stranded DNA 
molecule that is 15,000-17,000 base pairs long encoding thirty-seven genes. 
Twenty-four encode the translational machinery of the mtDNA itself (22 tRNAs 
and 2 rRNAs) and 13 genes encode for the electron transport chain complexes 
subunits (53). In mammals, mtDNA inheritance is exclusively maternal being the 
paternal mtDNA actively destroyed after fertilization by autophagy (54).  
Mitochondria are iconic structures in biochemistry and cell biology that caught 
the attention of scientists quite recently (Figure 1.8). Being first called by Altman 
“bioblasts”, mitochondrial biology has undergone major transformations probably 
unforeseen by the bioenergeticists who unveiled many of the mysteries of this 
organelle. Several scientists who contributed to the understanding of 
mitochondrial structure and function have been awarded a Nobel Prize 
emphasizing the importance of these findings (Figure 1.8). Indeed the simplistic 
Figure I.7. Structure of a mitochondrion 
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concept of mitochondria as discrete, kidney bean-shaped energy factories has 
given rise to that of a dynamic network that moves, fuses, divides and directs a 
plethora of functions central to life (53). 
Mitochondria are essential to metabolic homeostasis. In addition to converting 
nutrient flux into the energy molecule adenosine triphosphate (ATP), 
mitochondria generate intermediates for biosynthesis, reactive oxygen species 
(ROS) that serve as secondary messengers to mediate signal transduction and 
metabolism and play fundamental roles in fatty acid oxidation and apoptosis 
(55). Furthermore, mitochondria are able to integrate metabolism with signaling 
transduction, cell cycle, development and stress responses (53). 
Importantly, it has increasingly become clear that mitochondrial dysfunction 
underlies more than 50 inborn errors of metabolism (56, 57); strongly 
contributes to common diseases, including type 2 diabetes (58), 
neurodegenerative diseases (59), and cancer (60); and is essential to the aging 
process (61, 62). 
  
I.2.2.  Mitochondria as metabolic signaling centers 
 
Mitochondria are best known for the production of ATP via oxidative 
phosphorylation (OXPHOS). In the mitochondrial matrix, enzymes of the 
tricarboxylic acid cycle (TCA) generate electron carriers (NADH and FADH
2
) that 
Figure I.8. History of mitochondria. 
Timeline of important breakthroughs related to mitochondria from its first discovery to the 
scrutiny of its constituents and main functions, depicting the main scientists who played a 
part in it. * Nobel prize winners 
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donate electrons to the IMM-localized electron transport chain (ETC). The ETC 
comprises four protein complexes (I-IV), which through sequential redox 
reactions pump protons to the IMS. The two electron carrier molecules are 
ubiquinone [also known as coenzyme Q (CoQ) or ubiquinol when in the fully 
reduced state (CoQH2)] and cytochrome c (cyt c). The proton gradient generated 
by complex I, III and IV drives the rotation of a fifth complex (complex V) leading 
to phosphorylation of adenosine diphosphate (ADP), hence called ATP synthase 
(Figure 1.9). 
Beyond ATP production, the IMM-proton gradient generates an electrochemical 
potential that is a vital feature of this organelle. Any change in membrane 
potential affects other essential mitochondrial functions, such as mitochondrial 
import (63).  
These paramount organelles are not just the main source of energy in the cells 
but also the main source of ROS, including superoxide and hydrogen peroxide. 
Mitochondria require about 85% of oxygen consumed by cells and complex IV 
reduces it into water using electrons that stem from NADH and FADH
2
 and are 
transported in the respiratory chain (Figure 1.9). Complexes I and III are 
responsible for the generation of ROS as an inevitable byproduct that can damage 
lipids, DNA and proteins if not neutralized (65). Although mitochondria are 
exposed to constant generation of ROS, the mitochondrial antioxidant defense 
system, namely glutathione, glutaredoxin, thioredoxin and manganese 
superoxide dismutase, prevents oxidative damage generated during normal 
aerobic metabolism (66). Independent from its detrimental effects, ROS also 
coordinates several physiological processes and influences homeostatic signaling 
pathways to control cell proliferation, differentiation and adaptive stress 
responses (55). When the burden of ROS production surpasses the antioxidant 
capacity, cellular oxidative stress increases. Mitochondria have been intensively 
Figure I.9. Mitochondrial inner membrane complexes. Adapted from (64). 
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studied in the context of ROS biology and its link to diseases associated with 
mitochondrial dysfunction, like neurodegeneration (67).  
Mitochondria also house parts of the lipid metabolism, including fatty acid 
oxidation; are involved in pyrimidine and bile acids biosynthesis; and regulate 
levels of amino acids, metabolites and cofactors such as NAD+, important for key 
metabolic players such as sirtuins (class III deacetylases) (53, 68) (Figure I.10). 
Moreover, mitochondria play a pivotal role in iron metabolism, synthesizing heme 
and Fe-S clusters machinery (essential components of oxygen carriers), 
hemoglobin and DNA repair. Additionally, mitochondria buffer the second 
messenger calcium (Ca2+) hence coordinating its distribution from the plasma 
membrane and ER (53). 
Supercomplexes as highly organized ETC 
Mitochondrial electron transport chain was first seen as respiratory 
components that were more or less rigidly held together in a framework that 
would ensure the electron transport and proton gradient formation (solid model) 
(69). This model inspired the introduction of “oxysome” defined as “a functional 
unit for electron transfer and oxidative phosphorylation” (Figure 1.11) (70). 
However, the observation that isolated and reconstituted mitochondrial 
complexes are still functional led to the description of the fluid model, also 
known as random collision model (Figure 1.11) (71). During the last decade, 
Figure I.10. Metabolic pathways. 
Representation of metabolic pathways occurring within the cell, depicting the central role of 
mitochondria. (Mitochondrial Biology Unit, MRC, UK).  
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these models have been nevertheless the subjects of debate especially because 
they cannot explain the phenotypic consequences observed upon mitochondrial 
dysfunction. A prominent example of this is complex III deficiency that leads not 
only to the loss of complex III activity but also of complex I (72).  
The fluid model has become the textbook definition for the respiratory chain 
until the first blue native-polyacrylamide gel electrophoresis (BN-PAGE) was 
performed on isolated digitonin-permeabilized bovine mitochondria (74). The 
presence of the individual mitochondrial complexes in these gels was 
accompanied with some higher molecular weight bands indicating comigrating 
complexes (later called supercomplexes, SCs). The existence of supercomplexes 
was challenged by all the other model’s defenders stating that these were 
nothing but technical artifacts due to the sample preparation and use of 
detergents. However, laboratories working with mitochondria from diverse 
organisms (yeast, plants, vertebrates and invertebrates) found supercomplexes 
by BN-PAGE that were remarkably similar with a limited number of possible 
combinations between CI, CIII and CIV (Figure 1.11). Additionally, different 
detergents allowed the same visualization of supercomplexes. Final confirmation 
Figure I.11. Models (solid, random collision and plasticity) of the organization of the 
electron transport chain. 
The respiratory chain components are represented as opaque surfaces from their structural 
models and their colors are maintained throughout the schemes. Solid lines indicate the 
preferential routes for electrons. The plasticity model proposes that the CoQ and cyt c 
segmentation is incomplete and, therefore, the pools are promiscuous (dotted lines). This is 
promoted by the dissociation of the supercomplexes or just the escape of CoQ and cyt c from 
the assembled complexes. Adapted from (73).  
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was obtained when critical factors and conditions affecting superassembly were 
defined (e.g. assembly factors, mitochondrial shape, lipid composition of the 
IMM) (73). Single particle electron cryo-microscopy (cryo-EM) has led to a rise in 
relatively high-resolution structural models of the mammalian respirasome 
(arrangement of CI, CIII and CIV) (75, 76).  
The organization of the mitochondrial ETC into SCs increases the efficiency of 
the electron flux through the channeling of substrates and CoQ and cyt c pools, 
optimizing the use of available substrates and allowing for private electron 
pathways (Figure 1.11). Moreover, CI and CIII interactions minimizes ROS 
production (77). 
Nevertheless, the characterization of supercomplexes did not invalidate the 
functionality of individual complexes. Mitochondrial complexes are equally 
functional in free form and when incorporated into superassemblies. In fact, a 
screening study demonstrated a mutation of the supercomplex assembly factor 1 
(SCAFI) in a very common laboratory mouse strain, C57Bl/6J, which renders it 
inactive preventing complex IV assembly into supercomplexes. These animals 
without functional SCAFI are healthy but lack the refinement of their 
bioenergetics performance (78).  
 
Mitochondrial inner membrane transporters as the gatekeepers of mitochondrial 
metabolism 
Lipid membranes that delineate cells and certain organelles within the cell act 
as selective barriers and provide separation of pathways and specific processes 
through compartmentalization. The channeling of metabolites across 
compartments relies on specific transporters and channels. To achieve this 
purpose, a myriad of proteins is expressed, correctly folded and targeted to their 
final location. 
The OMM, which encloses the entire organelle, has a 1:1 protein-to-
phospholipid ratio similar to that of the plasma membrane (79). Voltage-
dependent anion channels called porins are integrated in the OMM, making this 
membrane permeable to solutes up to 5kDa. Larger proteins can enter the 
mitochondria if an N-terminus signaling sequence is recognized by translocase of 
outer membrane (TOM). In contrast, the IMM has a very high ratio protein-to-
phospholipid (3:1), similar to that of bacteria, comprising about 1/5 of the total 
protein content in a mitochondrion. IMM has also a distinct lipid composition that 
may vary between cell types. In pig heart, phosphatidylethanolamine (PE) is the 
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most abundant (37%), followed by PC (26.5%), while OMM is richer in PC (56%) 
than PE (28%). Additionally, the IMM is rich in an unusual phospholipid called 
cardiolipin (25.4%) which seems absent in the OMM (79). Cardiolipin has been 
shown to interact with mitochondrial respiratory complexes and substrate carrier 
proteins affecting mitochondrial bioenergetics (80). These features make the IMM 
selectively permeable to maintain efficient oxidative phosphorylation and 
membrane potential. The need to import substrates and cofactors and export 
products is overcome by a superfamily of mitochondrial carriers (MCs), in 
mammals called solute carrier family 25 (SLC25) (Figure I.12A) (81).  
SLC25 comprises a family of nuclear-encoded proteins that are mostly 
localized in the inner mitochondrial membrane and transport numerous 
metabolites, nucleotides, cofactors and inorganic anions in and out the 
mitochondria (Figure I.12B) (81). Out of around 53 members of this family, only 
few exceptions have been identified to be located in outer mitochondrial 
membrane (82, 83) and peroxisome (84). Some SLC25 have been identified and 
extensively studied, such as uncoupling protein-1 (UCP1 or SLC25A7) and 
ATP/ADP carrier protein 1 (AAC, SLC25A4), others are still orphan transporters 
and their function still needs to be characterized (Figure I.12A).  
Although they transport a wide variety of solutes, all SLC25 members have a 
common 3-fold repeated signature motif: three tandemly repeated homologous 
domains of about 100 amino acids in length with two hydrophobic 
transmembrane segments (α-helices) connected by a long hydrophilic matrix 
loop. Both N- and C-termini are located in the intermembrane space (Figure 
I.12C). Due to the plethora of molecules transported into and out of the 
mitochondria, MCs are involved in many important metabolic pathways, such as 
oxidative phosphorylation, citric acid cycle, fatty acid oxidation, amino acid 
degradation, gluconeogenesis, lipogenesis, transfer of reducing equivalents, 
synthesis and breakdown of mitochondrial DNA, RNA and proteins, urea cycle, 
heme synthesis, ketone body production and utilization, modulation of the 
nucleotide and deoxynucleotide pools, heat production, Ca2+ cell signaling and 
necrotic and apoptotic cell death (Figure I.12C) (81, 85). 
In many respects, the integrity of the membranes represents a critical element 
to cellular individuality, as does the preservation and transmission of the genetic 
information (86). The regulation of the transport of metabolites of intermediary 
metabolism across the membranes is key to a cell’s physiology and is the 
gatekeeper of its interface with the environment. Despite this central role and the   
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 fact that around 10% of our genome encodes for transport-related functions, 
transporters are still understudied and poorly understood, with SLCs in particular 
being the most neglected group of genes in the human genome (88). Most of 
SLCs carry small organic molecules and this feature is privileged with respect to 
small-molecule druggability (89). There are already some SLCs being targeted by 
drugs in active development in clinical trials. Given the therapeutical relevance of 
these transporters, more has to be learned about the orphan SLC25 members and 
their role in metabolic diseases. 
 
I.2.3.  Mitochondrial dysfunction as a determinant in NAFLD 
 
One of the main functions of the liver is to coordinate and fine-tune the energy 
demands of peripheral tissues. The metabolic flexibility of hepatocytes is 
 
Figure I.12. SLC25 superfamily of mitochondrial transporters. 
(A) Phylogenetic tree of human mitochondrial carriers (MCs, SLC25). The names of MCs and 
their acronyms are found on the terminal nodes with members that have been biochemically 
characterized represented in red. (B) Structural model of signature motif in the structure of 
SLC25 members. A, B, C, long matrix loops. a, b, short cytosolic loops. (C) Role of human 
SLC25 members. Processes are indicated in red whereas enzymes are abbreviated in green: 
GDH, glutamate dehydrogenase; OADH, 2-oxoadipate dehydrogenase. AXP, adenine 
nucleotides; CSA, cysteinesulfinate; HO-Lys, hydroxylysine; ADP, adenosine 3’,5’-diphosphate; 
SAM, S-adenosylmethionine; SAHC, S-adenosylhomocysteine. Dashed arrows indicate several 
steps. Adapted from (81, 87). 
B 
C 
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surprisingly high but can be disrupted upon metabolic stress. For instance, in the 
context of obesity and insulin resistance, significant alterations occur favoring 
hepatic triglyceride accumulation (90). Recent evidence suggests that liver 
mitochondria and its oxidative metabolism undergo an adaptive program in 
response to hepatic steatosis (50). Importantly, the adaptation and remodeling of 
mitochondrial bioenergetics is central to NAFLD (90). Recent studies 
demonstrated that simple steatosis triggered by either plasma or diet FFA and/or 
DNL correlates with increased mitochondrial function (91-93). Fatty acid 
degradation, TCA cycle, oxidative phosphorylation and ketogenesis work 
together to maintain mitochondrial homeostasis in a compensatory effort to 
dispose excess acyl-CoA (90-93). A “chronic” nutritional overload in turn leads to 
a failure in these mechanisms with concomitant decrease in mitochondrial 
function and energetics (90). More importantly, this mitochondrial (dys)function 
can dictate the disease progression (50, 90). Dysfunctional mitochondria are 
associated with lipotoxicity due to incomplete/reduced fatty acid oxidation. This 
then leads to the accumulation of acyl-carnitines, ceramides and diacylglycerols 
that can trigger inflammatory responses, key feature of NASH, a more advanced 
stage of NAFLD (94). Although in NASH mitochondrial ETC and ATP synthesis is 
lower and ketogenesis is impaired, hepatic TCA cycle remains upregulated as a 
futile attempt to sustain the high energy demanding anabolic processes during 
states of caloric excess (94). This persistent upregulation of the TCA oxidative 
flux together with the accretion of a variety of lipotoxic metabolites may underlie 
the potent mitochondrial milieu featuring NASH, fueling ROS production and 
hastening inflammation.  
Acknowledging the pivotal role of mitochondria in NAFLD has led to the 
interest of targeting this organelle to reduce hepatic steatosis and/or halt disease 
progression. Gariani et al. showed that the improvement of mitochondrial 
function by treating mice with NAD+ boosters, Nicotinamide Riboside (NR) or poly 
ADP-ribose polymerase inhibitors (PARPi), while on a high-fat high-sucrose diet 
(HFHS) was sufficient to prevent the development of NAFLD (95, 96). Moreover, 
modulation of key regulatory mitochondrial proteins expression, such as 
phosphoenolpyruvate carboxykinase (PEPCK) or mitochondrial pyruvate carrier 
(MPC), prevented hepatic inflammation triggered by high-fat diet (HFD) and 
reversed NASH and advanced fibrosis, respectively (97, 98). Additionally, liver-
specific mitochondrial uncoupler therapy led to improvements in hepatic 
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steatosis paralleled with ameliorated metabolic parameters, such as plasma 
glucose, insulin and inflammation markers (99, 100). 
Further identifying mitochondrial defects and/or major alterations during the 
development of NAFLD will unravel important and promising novel therapeutic 
agents/targets to manage NAFLD.  
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I. Section 3 LRH-1 in Health and Disease 
 
I.3.1 Liver receptor homolog-1 in control of liver metabolic pathways 
The adequate control of metabolic pathways is of extreme importance to 
accommodate systemic fuel requirements and availability. Nuclear receptors and 
their coregulators have been shown to play a key role in the transcriptional 
regulation of metabolic players expression integrating the responses to cellular 
nutrient and energy status (103). Liver receptor homolog-1 (LRH-1; also known as 
nuclear receptor subfamily 5 group A member 2, NR5A2) is a member of the 
nuclear receptors (NRs) superfamily. NRs are one of the largest families of 
transcription factors comprising 48 members divided into seven subfamilies 
(NR0-NR6) (101, 104). Based on its functions and/or localization and due to the 
fact that different groups have isolated and characterized LRH-1 independently, it 
is also known as fushi tarazu factor 1 (Ftz-F1) (105-110), pancreas homolog 
receptor 1 (111), α-fetoprotein transcription factor (112), human B1-binding 
factor (113) and CYP7A1 promoter binding factor (114). Similar to other NRs, 
LRH-1 has a conserved modular structure (Figure I.13) that includes the A/B 
domain; the highly conserved DNA-binding domain (DBD or C domain); the 
ligand-binding domain (LBD or E domain), which contains an equally conserved 
Figure I.13. Structure of LRH-1. 
(A) Structure of LRH-1 protein depicting the A/B, DNA-binding (DBD), Ftz-F1, Ligand-binding 
(LBD) and activation function-2 (AF-2) domains. (B) Structure of the hLRH-1 DBD-DNA complex 
demonstrating the importance of Ftz-F1 box for this interaction. CTE, C-terminal extension. 
(C) Empty ligand-binding pocket of mLRH-1 is shown in gray. Helix 12 (H12, green) 
determines the active state of a nuclear receptor. The extended NR5A-specific H2 (blue) 
provides an additional layer to the canonical LBD fold and stabilizes the active position of H12 
in the LRH-1 crystal structure. Adapted from (101, 102). 
C
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ligand-dependent activation function 2 (AF2) motif that mediates coactivator 
interaction; and the D domain, which serves as a flexible hinge between DBD and 
LBD (Figure 1.13A). Members of the NR5A or Ftz-F1 subfamily contain an 
additional Ftz-F1 box between the C and DE domains that confers high affinity to 
the DNA as monomers (Figure 1.13B). This hallmark feature of the NR5A 
subfamily distinguishes them from most NRs that form either homodimers (e.g. 
estrogen receptors) or heterodimers with retinoid X receptor (RXR or NR2B1) to 
bind DNA in the promoter region of their target genes (104). The crystal structure 
of hLRH-1 DBD obtained in complex with hCYP7A1 gene promoter demonstrated 
that the packing of the Ftz-F1 helix against the DBD is crucial for LRH-1 
transcriptional regulation (Figure 1.13B) (102). Furthermore, crystal structure of 
the mouse LRH-1 LBD confirmed a stable monomer but with an empty ligand-
binding pocket (Figure 1.13C), suggesting that LRH-1 acts without ligand binding 
rendering it constitutively active (101). The dispensable activation of LRH-1 by 
ligand binding emphasizes the importance of interactions with activators or 
repressors, and posttranslational modifications (PTM), such as phosphorylation, 
acetylation, ubiquitination and SUMOylation, to fine-tune the activity of LRH-1 
(115-118). While phosphorylation enhances LRH-1 activity, reversible covalent 
modification by small ubiquitin-like modifier-1 (SUMO-1) protein, or SUMOylation, 
in specific lysine residues by E3-SUMO ligases reduces its transcriptional activity 
(117-119).  
 LRH-1 is then an orphan member of the Ftz-F1 subfamily based on its 
constitutive activity and the absence of established physiological ligands. 
However, more recent studies have revealed that phospholipid species, including 
phosphatidyl glycerol, phosphatidyl ethanolamine and phosphatidyl choline, as 
well as the second messengers phosphatidyl inositols, can bind to the ligand 
binding pocket of LRH-1 (120-122). Importantly, studies specifically with the 
phospholipid dilauroyl phosphatidylcholine (DLPC) have identified it as a potent 
ligand of LRH-1 (123, 124). Numerous synthetic agonists and antagonists of LRH-
1 have been described (125-129), indicating the nuclear receptor is a druggable 
target.  
LRH-1 is mainly expressed in tissues of the enterohepatic axis, exocrine 
pancreas and ovaries, where it has a plethora of biological functions in 
development, differentiation and metabolism (130) (Figure I.14). LRH-1 can 
replace Oct4 in the generation of pluripotent stem cells from somatic cells (131) 
implicating LRH-1 in the control of stemness and pluripotency (132, 133). In the 
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pancreas, LRH-1 is essentially required for adequate production and secretion of 
the pancreatic digestive juice (134, 135). LRH-1 is a key player in female 
reproduction by regulating steroidogenesis (136-139), ovulation (140) and 
gestation (141). Moreover, LRH-1 has been associated with cell proliferation (142-
144), immunity response (145), hepatic endoplasmic reticulum (ER) stress 
resolution (146) and different cancers including intestinal (147), pancreatic (143), 
breast (142) and liver cancer (148). 
  
I.3.2 LRH-1 is central in Liver Metabolism 
 
Different metabolic pathways take place in the liver, including glucose, fatty 
acids (FA), cholesterol, bile acids (BA) and ketone bodies production and 
processing. Hepatocytes also exhibit immunoregulatory responses to several 
stress stimuli activating the hepatic acute phase response. LRH-1 plays a crucial 
role in many of the above-mentioned pathways presenting a complex regulatory 
circuit (Figure I.15).  
 
Bile Acid Homeostasis 
The synthesis and excretion of BA comprise the major pathway of mammalian 
cholesterol catabolism. Through this pathway, the hydrophobic cholesterol is 
Figure I.14. Overview of the functions of LRH-1. 
Metabolic Processes; Adaptive Stress Responses; Female Reproduction; Stemness, 
Development and Proliferation. Adapted from (130). 
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converted to a readily excreted water-soluble bile acid (149). Besides being 
fundamental for intestinal lipid absorption, BA are very important signaling 
molecules having a role in the regulation of glucose, lipid and energy 
homeostasis (150). This process involves many enzymes mainly expressed in the 
liver. Cyp7a1 and Cyp8b1, which are two important genes encoding enzymes 
fundamental for BA synthesis, were amongst the first LRH-1 target genes 
identified (114, 151). For this reason, LRH-1 has been placed as a master 
regulator of BA homeostasis. SHP, an atypical member of the nuclear receptor 
family that lacks a DNA-binding domain (152, 153), competes with peroxisome 
proliferator-activated receptor γ-coactivator-1α (PGC-1α) to bind the AF2 domain 
of LRH-1 in the liver and modulate the expression of Cyp7a1 (154) (Figure I.15).  
Importantly, liver-specific Lrh-1 knockout (KO) mice have altered bile acid 
composition with reduced ratio of cholic acid and its amino acid conjugate 
taurocholic acid to muricholic acid and ursodeoxycholic acid. This effect is 
attributed to the marked reduction of CYP8B1, but not CYP7A1 (155-157). 
Notably, this altered BA composition leads to a compromised intestinal lipid 
absorption and enhances the fecal excretion of lipids (155, 157). In addition to 
controlling BA biosynthesis, LRH-1 also activates the transcription of the bile salt 
Figure I.15. Scheme representing the main hepatic functions of LRH-1. 
RCT, reverse cholesterol transport; HDL, high-density lipoprotein; SR-BI, Scavenger receptor 
class B1; G5/G8, ABCG5/ABCG8; 7A1/8B1, CYP7A1/CYP8B1; FAS, fatty acid synthase. 
Corepressors are illustrated in red, coactivators in green. Adapted from (130). 
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export pump (BSEP, Abcb11 gene) in hepatocytes that encodes a transporter 
responsible for the canalicular secretion of BA from the liver (158). Furthermore, 
LRH-1 controls multidrug-resistance protein 3 (MRP3) expression in hepatocytes 
preventing hepatocellular injury induced by BA during cholestasis (159). MRP3 
exports BA from enterocytes and hepatocytes into the bloodstream, thereby 
preventing BA intracellular accumulation. 
 
Reverse cholesterol transport 
 The transport of excessive cholesterol from the peripheral tissues back to the 
liver and its eventual excretion in the bile is an anti-atherogenic mechanism, 
referred to as reverse cholesterol transport (RCT). LRH-1 governs the expression 
of genes involved in this process hence being involved in cholesterol 
homeostasis, including scavenger receptor class B type I (SR-BI) (160), ATP 
binding cassette (ABC) half-transporters ABCG5 and ABCG8 (161), apolipoprotein 
A1 (APOA1) (162), and apolipoprotein M (APOM) (163). Transcriptional regulation 
of SR-BI receptors, APOA1 and APOM increases the transfer of mature high-
density lipoprotein (HDL) particles from plasma into hepatocytes facilitating 
cholesterol clearance (160, 162, 163). ABCG5/8 limits intestinal absorption and 
facilitates extrahepatic cholesterol efflux avoiding sterol accumulation (161). A 
recent study from our lab reported that SUMOylation of LRH-1 promotes its 
interaction with prospero homeobox protein 1 (PROX1) and leads to the 
transrepression of hepatic RCT genes such as Scarb1, Abcg5, and Abcg8 (119). 
Of interest, a single point mutation in the Lrh-1 gene rendering a non-
SUMOylatable form of LRH-1 (LRH-1 K289R mouse model) in an atherosclerosis-
prone background displayed increased biliary sterol excretion and RCT 
decreasing the development of atherosclerosis (119). These studies emphasize 
LRH-1 as a relevant pharmacological target for atherosclerosis, which is the 
primary cause of myocardial infarction and stroke in humans.  
 
Methyl-pool Homeostasis 
Proper liver function also relies on a tight balance of labile methyl groups, 
present in choline, betaine, methionine and folate, which can supply for the 
synthesis of S-adenosylmethionine (SAM) in the one-carbon cycle (1CC). SAM acts 
as the reactive methyl donor in all necessary pathways, being the second most 
common enzymatic cofactor after ATP (47, 164). Besides the production of SAM, 
the 1CC falls at the crossroads of multiple other anabolic pathways, including 
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amino acids, purine and thymidine, phospholipids and the antioxidant 
glutathione synthesis, and homocysteine remethylation (47, 164). Moreover, gene 
expression can be directly affected by 1CC since histone and DNA methylation 
are sensitive to SAM levels. The production of phosphatidylcholines (PCs), which 
are ligands for LRH-1, also consume a significant amount of labile methyl groups. 
Moreover, a recent report identified LRH-1 as an essential element for methyl-
pool homeostasis in the liver by transcriptionally regulating glycine-n-
methyltransferase (Gnmt) and biliary phospholipid floppase multidrug resistance 
2 gene (Mdr2) (165). Upon hepatic loss of LRH-1, a blunted expression of GNMT 
and MDR2 favors an increase in the SAM/SAH ratio and a decrease in biliary PC 
secretion (165). Consequently, Lrh-1 liver specific KO mice fed a normal diet 
display similarities to WT mice fed a methionine and choline deficient (MCD) diet 
that harshly depletes methyl groups. On the other hand, the higher SAM levels 
present in Lrh-1 -/- mice makes them resistant to MCD detrimental effects, still 
presenting hepatic steatosis but being protected from hepatitis (165).   
 
 Hepatic Acute Phase Response 
Upon inflammatory stimuli due to injury, infection or chronic metabolic stress, 
immune cells secrete several cytokines into the bloodstream. In turn, the liver 
integrates this signal activating the hepatic acute phase response (APR) (166). 
This response comprises the induction and secretion of a number of acute phase 
proteins into the plasma for the restoration of homeostasis. As described above, 
SUMOylation of hepatic LRH-1 leads to the recruitment of different co-repressors.  
Binding of SUMOylated LRH-1 to the nuclear receptor corepressor 1 and histone 
deacetylase 3 (NCOR1/HDAC3) complex via G protein pathway supressor 2 (GPS2) 
mediates the induction of acute phase response genes (118, 167). Furthermore, 
LRH-1 exerts anti-inflammatory roles in the liver by inducing the expression of 
interleukin-1 receptor antagonist (IL-1RA), a robust inhibitor of IL-1 signaling 
(168).  
 
Glucose and fatty acid metabolism 
The concentration of glucose in the blood determines its availability to the 
liver. During the post-prandial phase, which lasts about 2h after a meal, 
glycaemia rises and the liver takes up approximately 10-25% of this glucose (30). 
Once inside the hepatocytes, glucose is phosphorylated to glucose-6-phosphate 
(G6P) by GCK and this constitutes the initial postprandial glucose-sensing 
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component that coordinates hepatic glucose metabolism. G6P can have multiple 
biochemical fates, including glycolysis, pentose phosphate pathway and glycogen 
synthesis (30). LRH-1 has also emerged as an important player in hepatic glucose 
sensing and intermediary metabolism by directly regulating Gck (169). Under 
postprandial conditions, liver-specific Lrh-1 KO mice display reduced availability 
of G6P, the end product of GCK, leading to reduced glycogen synthesis, 
glycolysis, and DNL (169). Reduced G-6-P in turn limits the nuclear translocation 
and consequent activation of the hepatic ChREBP (Figure I.16). Moreover, LRH-1 
acts a competence factor for LXR potentiating the expression of its target genes, 
such as Fasn (170). These studies pinpoint LRH-1 as a pivotal regulatory element 
for proper integration of postprandial glucose and lipid metabolism.  
  
 I.3.3 LRH-1 and metabolic disorders 
 
Metabolic functions of LRH-1 have also been described in obese and diabetic 
mouse models. LRH-1 activator DLPC improves glucose homeostasis and 
decreases hepatic steatosis in diet-induced and genetically obese and diabetic 
mice (124). The improvement in glucose tolerance and insulin resistance was not 
accompanied by a change in body weight and was lost upon liver-specific Lrh-1 
deletion (124). On the other hand, heterozygous Lrh-1+/-mice have a mild but 
Figure I.16. LRH-1 regulates central glucose-sensing system in the liver.  
LRH-1 transcriptionally regulates glucokinase (GCK) impacting on glucose-6-phoshphate 
(G6P) levels and therefore activation of carbohydrate response element binding protein 
(ChREBP). Acetyl-CoA, acetyl-coenzyme A; F2,6bisP, fructose-2,6-bisphosphate; F6P, fructose-
6-phosphate; UDP-GlcNAc, UDP-N-acetylglucosamine; X5P, xylulose-5-phosphate. Adapted 
from (30). 
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significant body weight gain when exposed to a high-fat diet, without changes in 
glucose or insulin tolerance (171). Furthermore, targeted deletion of Lrh-1 results 
in fatty liver in mice (146). 1CC has multiple links to lipid accumulation in the 
liver. Both SAM and PC are closely correlated with hepatic lipid accretion. SAM 
directly regulates gene expression through methylation, whereas PC is important 
for VLDL assembly and secretion (172) and activation of SREBP-1-dependent 
lipogenesis (173). The complex relation of LRH-1 with the 1CC impacts in the 
development of hepatic steatosis in mice fed a MCD diet (165).  
 Considering the plethora of metabolic functions LRH-1 coordinates in the liver 
(Figure I.15, I.16), one might envision a putative role for LRH-1 in NAFLD. 
Importantly, several pathways that can lead to lipid accumulation are regulated 
by LRH-1. Identifying the interplay of LRH-1 in NAFLD will aid in understanding 
the pathogenesis of this disease. 
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Chapter II   Research aims 
 
Although liver diseases in general, and NAFLD, in particular, are an emerging 
public health problem, there are no significant advances in treatment. 
Understanding the pathogenesis of NAFLD is thus crucial for unraveling new 
therapeutic avenues.  
The adequate control of liver metabolic pathways is pivotal to prevent lipid 
dysregulation. The nuclear receptor LRH-1 with its high expression in the 
hepatocytes and its important role in the transcriptional regulation of metabolic 
players makes it an excellent target to asses the contribution of different 
metabolic pathways to the development of NAFLD.  
With the general goal of providing more insight into this complex disease and 
identifying potential biomarkers and/or future therapeutic targets, we focused 
our work on the role of LRH-1 in coordinating hepatic lipid metabolism. To 
achieve this, we took advantage of both loss and gain-of-function of LRH-1 
models together with different nutritional cues (refed and fasted) and diets (diet-
induced NAFLD). Within this overarching aim, the specific aims were the 
following:  
 
1) To assess the regulatory role of LRH-1 in hepatic lipogenesis using a 
selective gain-of-function knock-in mouse model achieved by compromised 
SUMOylation at LRH-1 K289 residue – Chapter IV. 
 
2) To identify the repercussions of increased LRH-1 transcriptional activity in 
the development of NAFLD – Chapter IV.  
 
3) To determine the contribution of LRH-1 for proper mitochondrial function 
during fasting with a hepatocyte-specific knockout mouse model – Chapter 
V. 
4) To characterize SLC25 member 47 mitochondrial transporter as a potential 
target for hepatic steatosis alleviation  - Chapter V. 
 
 
Some additional results are presented in Chapter VI to support previous work 
and serve as a basis for future studies to complete the scientific work presented 
here. A general conclusion and future perspectives are included in Chapter VII to 
integrate the studies performed and highlight subsequent ones.  
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Chapter III   Material and Methods 
 
Lrh-1hep-/- mouse model generation. For the generation of Lrh-1 floxed (Lrh-1 
L2/L2) mice, genomic DNA covering the Lrh-1 locus (NCBI Gene ID: 26424) was 
amplified from the 129/Sv strain by using high-fidelity PCR. The resulting DNA 
fragments were assembled into the targeting vector and electroporated into 
129Sv embryonic stem (ES) cells. After selection and verification of karyotype 
several correctly targeted ES cell clones were injected into blastocysts from 
C57BL/6J mice. These blastocysts were transferred into pseudo-pregnant 
females, resulting in chimeric offspring that were mated to female C57BL/6J mice 
that express the Flp recombinase under the control of the ubiquitous 
cytomegalovirus (CMV) promoter. Offspring that transmitted the mutated allele, 
in which the selection marker was excised, and that lost the Flp transgene (Lrh-1 
+/L2 mice) were selected, mated with albumin-Cre mice (The Jackson Laboratory), 
and then further intercrossed to generate hepatocyte-specific LRH-1 KO (Alb-Cre; 
Lrh-1 hep-/-) and wildtype littermates (Lrh-1 hep+/+) mice.  
 
LRH-1 K289R  mouse model generation. To generate LRH-1 K289R mice, gDNA 
covering the Lrh-1 gene was amplified from the C57BL/6J strain by using high-
fidelity PCR. The point mutation of interest (AAG -> AGG) was introduced by PCR. 
The amplified DNA fragments were ligated into the targeting vector with a floxed 
Neo cassette (Institut Clinique de la Souris, Strasbourg). The construct was then 
electroporated into C57BL/6N ES cells. After selection, karyotype-verified ES cell 
clones were injected into blastocysts from BALB/c mice. These blastocysts were 
transferred to pseudo-pregnant females. Chimeric offspring were mated to 
female C57BL/6J mice expressing the Cre-recombinase under the control of the 
CMV promoter to delete the Neo cassette. Offspring transmitting the mutated 
allele, in which the selection marker was excised, and that lost the Cre transgene 
(Lrh-1 L-/+ mice) were selected and inbred with to obtain Lrh-1 L-/L- (LRH-1 
K289R) mice. LRH-1 K289R and LRH-1 WT mice were backcrossed for 6-7 
generations onto commercial C57BL/6J purchased from the Jackson Laboratory. 
 
Animal studies. Congenic male C57Bl/6J LRH-1 WT or LRH-1 K289R (119), as well 
as C57Bl/6J Lrh-1 hep-/- and Lrh-1 hep+/+ mice (174) and WT C57BL/6J (Janvier Labs) 
were housed with ad libitum access to food and water and kept under a 12h 
dark/12h light cycle.  
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Chapter IV studies: For fast-refeeding protocols 12 to 16-week-old male mice 
were initially fasted for 24 hours, followed by refeeding for 12 hours (8 pm to 8 
am), 6 hours (2 am to 8 am), or 2 hours (6 am to 8 am), and finally sacrificed 
together at 8 am to avoid confounding effects of the circadian rhythm. To induce 
a chronic hepatic steatosis, male mice were fed ad libitum with a HFHS diet 
(TD.08811, Harlan Laboratories) for 17 weeks and sacrificed at 9 am. To study 
the APR, male mice fed a chow diet received an intraperitoneal injection of either 
500 µl PBS or 40 µg LPS dissolved in 500 µl PBS. Mice were sacrificed 2.5 hours 
post injection and tissues collected.  
Chapter V studies: For fed-fasted protocols, 8- to 10-week-old male mice were 
fasted overnight (12h). To induce hepatic steatosis, male mice were fed ad 
libitum one week after AAV8 injections with either a choline-deficient diet, 20% 
Lard diet (TD.170068, Teklad Custom Diet, Envigo) for 4 weeks and sacrificed 
under normal fed condition or HFHS for 7 weeks and sacrificed after an ON 
fasting. The diet-induced NAFLD model found in Figure V.8A, C57Bl/6J mice were 
fed HFHS diet for 18 weeks to develop NAFLD/NASH as described previously (95).  
Respiratory exchange ratio (RER) was assessed using comprehensive lab 
animal monitoring system (CLAMS) one week before mice were sacrificed. Food 
intake was assessed over two days and normalized per day.  
All animal procedures were approved by the Swiss authorities (Canton of Vaud, 
animal protocols ID #2380, #2561 and #2768, #3187, #3221) and performed in 
accordance with our institutional guidelines. 
 
In vivo siRNA transfection. siRNA sequences are listed in the Supplemental table 
S4. 3 nmol HPLC-purified siRNAs (Microsynth) were tail-vein injected into each 
recipient mice using in vivo-JetPEI (Polyplus) according to the manufacturer’s 
instructions. Mice were fast-refed as described above and sacrificed 2 days post 
injection. 
 
Adenoviral infection. The Osbpl3 cDNA was cloned into a pENTR/D-TOPO 
plasmid (Invitrogen; the Topo primer is listed in Table 3) and then subcloned in 
the pAd/CMV-DEST plasmid (Invitrogen). After linearization with PacI, the 
construct was transfected into HEK 293A cells to produce the adenoviruses. Mice 
were tail-vein injected with Ad-gfp or Ad-Osbpl3, PFU 2.5 x 109, fast-refed as 
described above and sacrificed 3 days post injection. 
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AAV8 injections. The Osbpl3-siRNA sequence (Table 4) was engineered to create 
a pre-miRNA sequence targeting Osbpl3, which was cloned into an AAV vector 
construct driven by the liver-specific hAAT promoter. Slc25a47 cDNA was 
subcloned from a pCMV6-mSlc25a47 (Origene MC212109) into an AAV vector 
driven by hAAT promoter. AAV8-hAAT-mirOsbpl3 and AAV8-hAAT-mSlc25a47 
were generated, titrated as described previously (175, 176), and injected into the 
jugular vein under isoflurane anesthesia (5 x 1011 vg and 1x1012 vg respectively). 
For mirOsbpl3 experiments, two weeks after the injection, mice were fasted for 
24 hours followed by 6 hours refeeding, then sacrificed and tissues were snap-
frozen. For Slc25a47 experiments, five weeks after injection, mice were sacrificed 
after overnight fasting and tissues harvested. For the choline-deficient diet 
protocol, 3 weeks after the viral particles injection, mice were fed the diet for 4 
weeks more before sacrifice. 
 
Immunohistochemistry. Liver tissue was fixed overnight in phosphate-buffered 
10% formalin and embedded in paraffin, sectioned in 4 µm and stained for 
hematoxylin/eosin (H&E). Immunohistochemistry was performed to stain collagen 
with Sirius Red and CD45-positive cells using rat anti-CD45 antibody (eBioscience, 
no. 30-F11). Liver pieces were frozen while embedded in optimum cutting 
temperature (OCT) and later cut into 8-µm-thick serial cryosections for Oil-red O 
staining to visualize neutral lipids.  
 
Cell culture and LXR agonist treatment. Hepatocyte (AML12, and Hepa 1.6) and 
non-hepatocyte (HeLa) cell lines were obtained from American Type Culture 
Collection (ATCC) and kept in culture under standard conditions (37°C, 5% CO
2
, 
humidified incubator). DMEM with glucose (4.5 g/l), 10% fetal bovine serum (FBS) 
and penicillin-streptomycin (10 mg/ml) was used for Hepa 1.6 and HeLa cells. 
DMEM/F12 (Ham mixture) with 10% FBS, 400 µl of gentamicin solution (50 
mg/ml, Sigma), 100mM dexamethasone and insulin, transferrin and selenium 
supplement (Roche) was used for AML12 cells. Hepa 1.6 or AML-12 cells were 
treated with 1 µM of GW3965 (Selleckchem), a dual LXR-α and LXR-β agonist, for 6 
hours in full medium.  
 
Immunofluorescence. AML12 cells were transfected using JetPEI® DNA 
transfection reagent (Polyplus transfection) for 24h with pCMV6-
mSlc25a47mycDDK (Origene, MC212109) or pCMV6-empty-flag plasmids. 
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Immunofluorescence was then performed using FLAG antibody (Sigma, F1804) in 
goat serum (3% in TBS).  
 
Subcellular fractionation of liver tissues and Western blotting. To perform 
subcellular fractionation for protein enrichment, 50 to 100 mg of liver pieces 
were incubated in 400µl of hypotonic buffer (10mM HEPES-KOH pH 7.4, 10mM 
KCl, 1.5mM MgCl
2
, 0.5mM DTT, protease and phosphatase inhibitor cocktails 
(Roche)) and lysed with 10 strokes in a Dounce homogenizer. The supernatant 
fraction containing mainly cytoplasmic proteins was collected after centrifugation 
(1,400 x g for 5 min, 4°C), and the pellets were washed twice with hypotonic 
buffer. The pellets were resuspended in 100-200 µl of hypertonic buffer (50mM 
Tris-HCl pH 7.4, 150mM NaCl, 0.1 % NP-40, protease and phosphatase inhibitor 
cocktails) for 30 min on ice. The supernatant containing mainly nucleoplasm and 
membrane fractions was collected by centrifugation (2,000 x g for 5 min, 4°C), 
and the remaining insoluble pellet containing mainly chromatin was resuspended 
in 100 µl of hypertonic buffer and sonicated. For whole protein lysates, cells or 
tissues were homogenized with RIPA buffer (50mM Tris-HCl pH7.4, 150mM NaCl, 
0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, 2 mM EDTA and 50 mM NaF) 
supplemented with 1 mM PMSF and protease and phosphatase inhibitor cocktails 
(Roche), sonicated and centrifuged full speed for 15 min, 4°C. Before running 
SDS-PAGE, protein lysates were boiled for 5 min 95°C. Following proteins were 
used for Western blotting on Chapter IV: using anti-Hsp90, anti-SREBP-1 and anti-
P62 (BD Biosciences no. 610418, 557036, and 610497), anti-OSBPL3 (Novus 
Biologicals, no. NBP-155151), anti-FASN (Abcam, no. ab22759), anti-SCD1 
(Thermo Fisher, no. A13996), anti-alpha-TUBULIN, anti-PARP1 and anti-beta-ACTIN 
(Santa Cruz, no. sc-5286, sc-7150 and sc-47778). Anti-SREBP-1, anti-P62, and 
anti-PARP1 were blotted on nuclear/membrane fractions, all other antibodies on 
cytoplasmic fractions. Additional antibodies used for mitochondrial studies 
(Chapter V): anti- OPA1 (BD Biosciences no. 612606); anti-SLC25A47, PINK1 
(Novus Biologicals, NB100-5783, BC100-494); anti-TOMM20, TOMM40 (Santa 
Cruz, sc-11415, sc-11414); anti-VDAC, PGC-1α, OxPhos, SDHA and NDUFS3 
(Abcam, ab14734, ab54481, ab110413, ab14715, ab14711); anti-HSP60 (Enzo 
Life Science, ADI-SPA-806).  
 
Chapter III   Material and Methods 
 
 47 
Proteomics. SWATH-mass spectrometry (SWATH-MS) was used to quantify 
proteins with good reproducibility and quantification accuracy on liver lysates 
from Lrh-1 hep-/- and Lrh-1 hep+/+ mice as described previously (177).  
 
Gene expression and analysis. RNA was extracted from the livers using TRIZOL 
(Invitrogen) and purified with the RNeasy cleanup kit for microarray analysis 
(Qiagen). For RT-qPCR, cDNA was generated using the QuantiTect® Reverse 
Transcription Kit (Qiagen), and analyzed by Q-PCR using a LightCycler® 480 Real-
Time PCR System (Roche) and the primers listed in supplementary tables. 
Expression data were normalized to 36b4 or B2m mRNA levels. Microarray 
analysis was performed using the Affymetrix MouseGene 1.0 ST array and 
normalized using the Robust Multi-array Average (RMA) method. All microarray 
data presented from our study are accessible at the NCBI gene expression 
omnibus (GEO) database (GSE89877). For mtDNA/nDNA ratio, genomic DNA was 
extracted from liver tissues using NucleoSpin Tissue (Macherey-Nagel) and qPCR 
was performed for the expression analysis of 16S (mitochondrial) normalized to 
HK2 (nuclear gene). 
 
Bioinformatic analysis. Liver microarray data (Affymetrix Mouse Gene 1.0 ST) 
from a BXD mouse genetic reference population (178) fed normal chow diet and 
sacrificed under fasting conditions were analyzed for correlations with Slc25a47 
transcript expression using the GeneNetwork program 
(http://www.genenetwork.org). Raw microarray data are also publicly available on 
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo) under the 
accession number GSE60149. Significant top 20 correlating genes (p<1x10-8) were 
plotted in a network using Cytoscape v3.4.0 (179). Gene/Protein/Pathway 
enrichment analysis was performed with DAVID Bioinformatic Resources 
(https://david.ncifcrf.gov/) using respective background lists (180, 181). Mus 
musculus protein sequence alignments and phylogenetic tree were designed 
using Geneious v10.2 (http://www.geneious.com) (182). SLC25A47 protein 
sequence was aligned with SLC25A45, A48, A20, A29, A2 and A15, being the 
closest homologs considering both phylogenetic trees of Mus musculus and Homo 
sapiens. Mus musculus Slc25 family of transporters expression profiles was 
obtained from Expression Atlas (https://www.ebi.ac.uk/gxa/home/, 
reference: 22012392) (183). All heat maps were generated using heatmap.2 
including dendogram per row or using GENE-E 
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(http://www.broadinstitute.org/cancer/software/GENE-E/index.html), where rows 
were clustered using the ‘one minus Pearson correlation’ metric. Color code 
represents row z-score. Corrgrams were made using corrgram function in R. 
  
Homology modeling. The mitochondrial ADP/ATP carrier (AAC or SLC25A4, PDB 
ID 1OKC) was the first SLC25 structurally characterized. The HHPred server 
(doi: 10.1093/nar/gki408) identified this carrier as the best hit for performing 
homology modeling of the SLC25A47 protein, with E-values of 4.3x10-55. Using 
the sequence alignment provided by the HHPred server, structural models for the 
SLC25A47 protein were created with the Modeller program, version 9.13 (doi: 
10.1002/0471250953.bi0506s15). 100 models were created for each 
conformation (template), using the default optimization and refinement protocol, 
and for each conformation, the model with the lowest DOPE score was selected.   
 
Chromatin immunoprecipitation (ChIP)-PCR. ChIP analysis was performed as 
described previously with minor modifications (119). ChIPed DNA was purified 
using the PCR clean-up extraction kit (Macherey-Nagel), after which qPCR was 
performed as described previously (155). Data were normalized to the input (Fold 
differences=2- (Ct-sample - Ct-input)). ChIP primer sequences are listed in supplementary 
tables. For LXR ChIP assays an anti-LXRα antibody (Abcam, no. ab41902) was 
used. For LRH-1 ChIP experiments, a custom LRH-1 antibody was generated. A 
synthetic peptide ([H]-QEQSNRNRQEKLSAFG-[NH2]) was used to immunize two 
rabbits (AbFRONTIER). The antiserum with the highest ELISA titer was selected 
and used in ChIP experiments. The pre-immunization serum from the same rabbit 
was used as a negative control. 
 
Mitochondrial Isolation and digitonin-permeabilization assay. Mitochondria 
were isolated from the livers or cells as described in the literature (184). Briefly, 
livers or cells were homogenized in mitochondria isolation buffer (IBc) that 
contains 10ml of 0.1M Tris–MOPS, 1ml of EGTA/Tris and 20ml of 1M sucrose, up 
to 100 ml with distilled water, adjusting pH to 7.4. Homogenates are then 
centrifuged at 600-800g, 10 minutes at 4°C to discard the debris leaving 
mitochondria in the supernatant. Next, we spin down the supernatant at 7,000-
10,000 x g for 10 minutes at 4°C to pellet the mitochondria. The pellets were 
washed once with 1ml IBc. The mitochondria pellet was resuspended in RIPA 
buffer for western blot or in mir05 for the assessment of respiration or Ibc buffer 
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for digitonin-permeabilization assay. For the latter, isolated mitochondria were 
incubated for 15 minutes on ice with an increasing concentration of digitonin in 
100 µl mitochondrial isolation buffer as described before (185). The pellet was 
recovered by centrifugation (13,000 g, 10 minutes, 4°C).  
 
Oxygen consumption assessment with Oxygraph. Liver tissue was 
homogenized using Mitochondrial Respiration Medium (mir05) containing EGTA 
0.5mM, MgCl
2
.6H
2
O 3mM, Taurine 20mM, KH
2
PO
4
 10mM, HEPES 20mM, D-Sucrose 
110mM, BSA essentially fatty-acid free 1g/l, Lactobionic Acid 60mM, pH 7.1. 
Oxygen consumption rate was assessed in liver homogenates or isolated 
mitochondria in mitochondrial Respiration Medium (mir05: EGTA 0.5mM, 
MgCl
2
.6H
2
O 3mM, Taurine 20mM, KH
2
PO
4
 10mM, HEPES 20mM, D-Sucrose 
110mM, BSA essentially fatty-acid free 1g/l, Lactobionic Acid 60mM, pH 7.1) by 
High Resolution Respirometry (Oxygraph 2k, Oroboros Instruments) following 
manufactures’ instructions. For the Substrate-Uncoupler-Inhibitor Protocol (SUIT) 
compounds were added into the 2ml-chamber. Compounds used: Succinate 
(10mM), CI-inhibitor Rotenone (0.1 µM) and ADP+Mg2+ (1.25mM) for State
3ADP
 
respiration; FCCP (titration of 1µl each from 1mM stock) for maximal respiration, 
Oligomcyin (2 µg/ml) for uncoupled respiration. For fatty acid oxidation (FAO) 
assay, Palmitoyl-Carnitine (50µM) and Octanoyl-Carnitine (0.2mM) were used in 
the presence of ADP. Malate was added to sustain fatty acid degradation avoiding 
Acetyl-CoA accumulation. Full liver homogenates were used to assess State
3ADP  
and FAO. Isolated mitochondria were used to assess coupled and uncoupled 
respiration. 
 
Oxygen consumption assessment with Seahorse XF96. Cells were plated in a 
Seahorse Bioscience XF96-well plate (Agilent Technologies) 2 days before the 
experiment. The day after, cells were transfected as indicated in 
Immunoflouorescence section above. One day later and 30 minutes before the 
Seahorse run, cells were treated with Forskolin 20 µM and the plate was placed in 
a 37°C incubator without CO
2
. FCCP (10µM) was then injected and oxygen 
consumption recorded.  
 
Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE). Blue Native 
Polyacrylamide Gel Electrophoresis was performed as previously described (186). 
Briefly, 50 µg of mitochondria were gently ressuspended in 5µl NativePAGE 
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sample buffer 4x, 8µl 5% digitonin (Thermo Fisher Scientific) and 7µl water mix 
(8g/g digitonin/protein ratio). After staying on ice for 20 min, mitochondria were 
centrifuged for 10 min, 20,000 x g at 4°C. 2 µl of Coomassie Blue G-250 sample 
additive were then added to the supernatant and samples were loaded into a 
Native-PAGE gradient gel (3-12%). The run was performed using Dark Blue 
Cathode Buffer (0.044 g Coomassie Brilliant Blue G-250 in 220ml NativePAGE 
anode buffer) (Thermo Fisher Scientifc) for 30 min at 150V. Next, Dark Blue 
Cathode Buffer was replaced by a Light Blue Cathode Buffer (dilution of 1:10 of 
Dark Blue Cathode Buffer) and the run proceeded for 1hour at 250V.  Using iBlot 
gel transfer device (Invitrogen), the gel was transferred onto a PVDF membrane 
and blotted with OxPhos antibody cocktail (Thermo Fisher Scientific, cat. no. 45-
7999), and anti-MTCO1 antibody (Abcam, cat. no. ab14705). 
 
Clear-Native PAGE and In-Gel-Activity. To perform in-gel activity, the procedure 
to follow is very similar to BN-PAGE (186), differences being the amount of 
digitonin used and the cathode buffer during the electrophoresis run. 50 µg of 
mitochondria were ressuspended in 5µl NativePAGE sample buffer 4x, 4µl 5% 
digitonin (Thermo Fisher Scientific) and 11µl water mix (4g/g digitonin/protein 
ratio). For the run, light blue cathode buffer (1:10 dilution of the Dark Blue Buffer 
described above) was used for 30 minutes at 150V and then changed to clear 
NativePAGE running buffer to avoid excessive blue color of the Coomassie dye on 
the gel, which interferes with the color of the activity detected. The run 
proceeded for 150 minutes at 250V. After the run, the gel was incubated with 
Complex IV substrate solution: 50mg diaminobenzidine (DAB), 100mg 
cytochrome c and 90ml 50 mM phosphate buffer pH 7.4 to 10 ml with ddH
2
O. 
Then, the same gel was washed with water and incubated with complex I 
substrate solution: 40 µl 1M Tris-HCl, pH 7.4, 2mg NADH, 50mg Nitrotetrazolium 
Blue chloride (NTB) to 20ml with bisdistiled ddH
2
O. Another gel is needed to 
check complex II activity with complex II substrate solution: 200µl 1M sodium 
succinate, 25mg Nitrotetrazolium Blue chloride (NTB), 8µl 250mM phenazine 
methosulfate (prepare 250mM stock in DMSO), 50µl 1M Tris-HCl to 10ml with 
ddH
2
O. Reactions were stopped with 10% acetic acid wash for 5 min followed by 
water for 5 min more. Gels were scanned at different time points of incubation to 
follow kinetics of the signal before saturation. Quantification of the bands 
obtained through in in-gel activity was performed with ImageJ (1.47v) using 
coomassie blue band as a loading control. 
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ATP quantification. Cell or liver lysates were prepared by homogenization with 
RIPA buffer (see above recipe), sonicated and centrifuged full speed for 15 min at 
4°C. Supernatant was used for ATP quantification and Citrate synthase activity 
assay. ATP was quantified with CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega). 10µl of each sample were diluted with 90µl PBS in a 96-well plate. 
Then, 100µl of CellTiter-Glo® Reagent were added in each well, plate was 
incubated for 5 min at room temperature protected from light and luminescence 
was read.  
 
Oleic acid oxidation assessment. A piece of 100–200 mg liver tissue was 
homogenized in sodium chloride-Tris-EDTA buffer, centrifuged at 420×g for 
10 min at 4 °C, and the supernatant was incubated for 40 min at 37 °C in a 
reaction mixture containing 14C-radiolabeled oleic acid, 2 mM ATP, 0.5 mM 
dithiothreitol, and measured for acid-soluble metabolites and trapped CO
2
 as 
described previously (187). 
 
Lipid analyses and plasma parameters. Hepatic lipids were extracted according 
to the Bligh & Dyer protocol (188). TG, FFA and cholesterol contents in plasma 
and/or hepatic lipid fractions were quantified using enzymatic assays (Roche). To 
asses fatty acid synthesis rates in vivo, mice received sodium [1-13C] acetate via 
their drinking water (2%) 24 hours prior to sacrifice. FA derived from hepatic lipid 
extracts were liberated, derivatized, and subjected to GC-MS analysis in order to 
calculate the fractional synthesis rates from the incorporation of 13C-acetate as 
described previously (189). Hepatic acylcarnitines were determined by tandem 
mass spectrometry (190). ASAT and ALAT concentrations in blood were 
determined using standard clinical chemistry methods.  
 
VLDL secretion assay and glucose-6-phosphate quantification. The VLDL 
secretion assay was performed as described previously (189). 13-week-old male 
LHR-1 K289R or LRH-1 WT mice were subjected to the fasting-refeeding protocol 
and treated with 50 mg/ml Poloxamer-407 (Sigma Aldrich, no. 16758) 8 hours 
after refeeding was initiated. Blood samples were collected once before and every 
hour after Poloxamer treatment to determine the triglyceride content. Glucose-6-
phosphate content was determined using enzymatic assays as described 
previously (174). 
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Ex vivo lipolysis assessment. Fresh epididymal white adipose tissue explants 
(~20mg) from Lrh-1 hep-/- and their WT littermates were washed in PBS and 
incubated in a 96-well plate with low glucose DMEM supplemented with 2% BSA 
with and without forskolin (10 µM, positive control) for one hour at 37°C. 
Subsequently, tissues were transferred into a new 96-well with fresh media (with 
and without forskolin) for an additional hour. Supernatant was used to quantify 
the presence of glycerol and FFA using Free glycerol Reagent (Sigma, F6428) and 
NEFA-HR(2) (Wako Diagnostics), respectively. Tissue was dissolved in 0.3N NAOH/ 
1% SDS at 60°C for protein quantification and normalization of the results.  
 
Statistics. Data are expressed as mean ± S.E.M. Comparison of differences 
between two groups was assessed using unpaired two-tailed Student’s t-tests. 
Multiple group comparisons were assessed by ANOVA analysis and Bonferroni 
post-hoc t-tests. Differences under p < 0.05 were considered statistically 
significant (* p < 0.05, ** p < 0.01, *** p < 0.001). Other symbols may be used 
for different group comparisons but they will be specified on the legends. 
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Chapter IV   A SUMO-dependent LRH-1/OSBPL3 pathway promoting 
NAFLD 
 
IV.1   Introduction 
In the liver, LRH-1 is an important regulator of glucose, cholesterol and bile 
acid metabolism (130). Liver-specific Lrh-1 knockout mice display reduced 
glycolytic flux and de novo lipogenesis secondary to impaired GCK activity (174). 
On the other side, treatment of mice with the LRH-1 agonist, DLPC, protects 
animals from developing NAFLD and insulin resistance in genetic and dietary 
models of diabesity (123, 124). To address this apparent contradictory role of 
LRH-1 in hepatic triglyceride metabolism, we chose to study lipogenesis in our 
recently described Lrh-1 K289R knockin mouse model (LRH-1 K289R mice), which 
displays selective gain-of-function of LRH-1 as a result of impaired SUMOylation at 
K289 (119). 
In this study, we demonstrate that LRH-1 K289R induces the expression of 
oxysterol binding protein-like 3 (OSBPL3, encoded by Osbpl3, also known as 
Orp3), which in turn promotes the posttranslational activation of SREBP-1. As a 
consequence, LRH-1 K289R mice display increased de novo lipogenesis upon 
refeeding in comparison with WT mice. In fact, compared to LRH-1 WT mice, this 
chronic lipogenic stress promotes NAFLD in LRH-1 K289R mice accompanied by 
early signs of NASH when exposed to a lipogenic high-fat, high-sucrose (HFHS) 
diet.  
 
IV.2   Results  
Increased hepatic SREBP-1 processing in LRH-1 K289R mice 
In order to evaluate the role of an LRH-1 SUMO-defective pathway on 
intermediary liver metabolism, we subjected LRH-1 K289R mice, which exhibit 
partial gain-of-function of LRH-1, and control LRH-1 wildtype (WT) mice (119) to 
fasting-refeeding challenges, in which mice were fasted and then refed for a 
period of 6 hours. We then evaluated the expression of metabolic genes in refed 
livers of both genotypes using microarray analysis. Interestingly, the expression 
of many SREBP-1 target genes was increased in 6-hour-refed LRH-1 K289R 
compared to LRH-1 WT livers, whereas SREBP-2 targets were not altered (Figure 
IV.1A). Although no changes in Srebf1 mRNA (Figure IV.1B) or uncleaved 
precursor SREBP-1 (Figure IV.1C) could be observed between both genotypes, 
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refed LRH-1 K289R livers displayed significantly more of the cleaved and 
transcriptionally active SREBP-1 protein in comparison to the LRH-1 WT livers 
(Figure IV.1C), indicating that the posttranslational processing and maturation of 
SREBP-1 is increased in LRH-1 K289R mice.  
We then performed acute insulin challenges as well as shorter 2-hour refeeding 
experiments to analyze if early signaling events could explain the increased 
SREBP-1 activity. Insulin did not induce an additional increase in AKT 
phosphorylation or a consistent induction of early response genes, such as 
activating transcription factor 3 (Atf3) or early growth response 1 (Egr1) (Figure 
IV.2A, B) (175, 176) in LRH-1 K289R versus LRH-1 WT livers. Similarly, we did not 
observe differences in Srebf1a and Srebf1c expression in 2-, 6-, or 12-hour-refed 
LRH-1 K289R and LRH-1 WT mice (Figure IV.2C). Taken together these data 
suggest that LRH-1 K289R induces SREBP-1 signaling primarily at the 
posttranscriptional level independent of early insulin-AKT signaling. 
 
Enhanced de novo lipogenesis in LRH-1 K289R mice  
To verify whether the increased expression of lipogenic genes is accompanied 
by hepatic fat accumulation, we next quantified hepatic triglyceride content in 
LRH-1K289R and LRH-1 WT mice. The content of neutral lipids and triglycerides 
was significantly increased in LRH-1 K289R compared to LRH-1 WT livers upon 
refeeding  (Figure IV.3A, B). Of note, plasma triglycerides and free fatty acids did 
Figure IV.1. The posttranslational processing and maturation of SREBP-1 is increased in 
LRH-1 K289R mice. 
(A) Heat map showing the expression of genes involved in de novo fatty acid and cholesterol 
synthesis in refed WT and K289R mice, depicting SREBP-1 and SREBP-2 target genes; (B) 
Hepatic mRNA expression of Srebf1 in K289R and WT mice. (C) Left, Immunoblots of precursor 
and cleaved (cl) SREBP-1, SCD1, HSP90, and P62 in hepatic lysates of WT or K289R livers. 
Right, graph displaying the ratio of cleaved to precursor SREBP-1.  §P < 0.001 refed relative to 
fasted mice. 
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not show significant alterations between LRH-1 K289R and LRH-1 WT mice (Figure 
IV.3C, D). 
To verify whether the enhanced expression of lipogenic genes translates into 
increased de novo lipogenesis, animals received 13C-acetate prior to sacrifice to 
quantify de novo lipogenesis (174). In line with the increased lipogenic gene 
expression, de novo synthesis of palmitate (C16:0), stearate (C18:0) and oleate 
(C18:1) was significantly higher in LRH-1 K289R compared to LRH-1 WT livers 
(Figure IV.4A-C). Of note, chain elongation of pre-existing fatty acids was not 
altered between the two genotypes (Figure IV.4D, E). Collectively these data show 
that LRH-1 K289R mice display increased de novo lipogenesis and enhanced 
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Figure IV.2. LRH-1 K289R mice do not show changes in the early insulin response. 
(A, B) Phospho and total AKT immunoblots (A), and mRNA expression of early response genes 
(B) in livers from fasted WT or K289R mice that were injected with PBS or insulin 10 min prior 
to sacrifice. (C) Hepatic expression of the two Srebf1 isoforms, Srebf1a and Srebf1c, in fasted 
and refed WT and K289R mice.  
 
Figure IV.3. LRH-1 K289R mice display hepatic steatosis. 
(A) Representative images of liver sections of K289R or WT mice stained with Oil-red O to 
visualize neutral lipids. Scale bar, 200 µm. (B) Quantification of hepatic triglyceride content in 
WT and K289R mice. (C, D) Plasma triglyceride (TG, C) and free fatty acid (FFA, D) contents in 
WT and K289R mice. §P < 0.001 refed relative to fasted mice. 
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activation of SREBP-1 likely contributes to this process. 
SUMOylation-defective LRH-1 drives the expression of oxysterol binding protein-
like 3 (Osbpl3)  
We next analyzed the transcriptome of livers from refed LRH-1 K289R and LRH-
1 WT mice, and searched for transcripts that are linked to SREBP-1 processing. 
One of the top hits on the list of genes that was increased in LRH-1 K289R 
compared to LRH-1 WT livers corresponded to Osbpl3 (Orp3 gene), a member of a 
class of lipid transfer proteins recently implicated in the shuttling of lipids 
between the plasma and endoplasmic reticulum membrane (191-193). The 
expression of Osbpl3, and to a lesser extent Osbpl1a, was robustly induced in 
LRH-1 K289R livers while that of most other OSBP family members did not differ 
between the two genotypes (Figure IV.5A). Of interest, overexpression of certain 
oxysterol binding proteins has been suggested to increase SREBP-1 processing 
and hepatic lipogenesis (194). Analysis of livers of LRH-1 K289R versus LRH-1 WT 
mice confirmed the enhanced expression of Osbpl3 during fasting and refeeding 
(Figure IV.5B-D), while the expression of other OSBP family members did not 
differ between the two genotypes (Figure IV.5E). Notably, the expression of 
Osbpl3 is high during fasting and then reduced upon refeeding (Figure IV.5B). 
This postprandial suppression of Osbpl3 mRNA expression was also observed 
upon overexpression of Osbpl3 in mice using an adenovirus (Figure IV.5F), 
Figure IV.4. LRH-1 K289R mice display increased de novo lipogenesis. 
(A-C) Fractional de novo synthesis rates of palmitate (A), stearate (B) and oleate (C) in WT and 
K289R mice. (D, E) Fractional chain elongation (CE) of pre-existing palmitate to hepatic 
stearate (D) and oleate (E). §P < 0.001 refed relative to fasted mice. 
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suggesting that during the refed state Osbpl3 is regulated by post-transcriptional 
mechanisms occurring independently of LRH-1. Despite this feeding-dependent 
regulation of the mRNA, hepatic Osbpl3 mRNA levels are consistently higher in 
the LRH-1 K289R mice in all nutritional states, but particularly high in the 6-hour-
refeeding condition (Figure IV.5C), and these differences are translated into 
similar changes at the protein level (Figure IV.5D). 
To investigate whether Osbpl3 is directly controlled by LRH-1, we first analyzed 
the Osbpl3 genomic region in available ChIP-Seq data for potential LRH-1 binding 
sites (195, 196). We identified three main sites from the ChIP-Seq data from 
Holmstrom et al. (sites 1-3, (195)) and three additional sites with an LRH-1 
consensus sequence close to one of the transcription start sites of the Osbpl3 
gene (sites 4-6) were identified by computational analysis (Figure IV.6A). We then 
performed site-specific ChIP analysis to evaluate if these sites are bound by LRH-1 
in fasted and refed mice. LRH-1 was recruited at different sites in both nutritional 
conditions (Figure IV.6B, C), suggesting that Osbpl3 is a direct LRH-1 target gene. 
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Figure IV.5. SUMOylation-defective LRH-1 drives the expression of Osbpl3. 
(A) Heat map showing the hepatic expression of oxysterol binding protein family members in 
WT and K289R mice. (B, C) Expression of Osbpl3 mRNA in hepatic lysates of fasted and refed 
WT and K289R mice (B), and the fold change between the genotypes (C). (D) Expression levels 
of OSBPL3 protein in hepatic lysates of fasted and refed WT and K289R mice. (E) Hepatic 
mRNA expression of oxysterol binding protein family members in fasted or 6-hour-refed 
K289R and WT mice. (F) Osbpl3 expression in hepatic lysates of fasted or refed mice infected 
with Ad-GFP or Ad-OSBPL3. §P = 2 × 10–7 relative to WT. 
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 Based on the fact that LRH-1 and LXR have been shown to crosstalk in the 
regulation of hepatic acute phase response proteins (118, 167) and that various 
LRH-1 target genes, including lipogenic genes, are co-regulated by members of 
the LXR subfamily (170, 197, 198), we assessed the possibility that the LRH-1 
mutant may modulate the recruitment of LXRα to its target genes, Abca1, Chrebp, 
and Srebf1. Although recruitment of LXRα was detected on these promoters in 
the genomic lysates of LRH-1 K289R and LRH-1 WT livers, no differences were 
observed between both genotypes, suggesting that LXRα binding is not altered 
due to the LRH-1 K289R mutation (Figure IV.7A). Furthermore, Hepa 1.6 and AML-
12 cells treated with the LXR agonist GW3965 did not alter Osbpl3 expression 
(Figure IV.7B, C), indicating that Osbpl3 expression is not regulated by LXR.  
Osbpl3 silencing rescues the steatotic phenotype of LRH-1 K289R mice 
To establish whether the increased expression of OSBPL3 in LRH-1 K289R livers 
 
Figure IV.7. Crosstalk between LXR and LRH-1 pathways. 
(A) LXR chromatin immunoprecipitation on hepatic lysates from WT and K289R mice. (B, C) 
Expression of Osbpl3 and Abcg1 in Hepa 1.6 (B) or AML-12 (C) cells upon treatment with the 
LXR agonist GW3965.  
 
Figure IV.6. Osbpl3 is a direct LRH-1 target gene. 
(A) Scheme showing the genomic area containing the Osbpl3 gene and the sites used for 
ChIP-qPCR experiment (mouse genome assembly mm10). (B, C) Binding of LRH-1 to the 
different Osbpl3 promoter sites assessed by ChIP analysis using genomic DNA from fasted 
WT (B) and refed WT livers (C).  
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is causatively linked to the exacerbated de novo lipogenesis, we performed in 
vivo overexpression and silencing experiments. Adenoviral overexpression of 
OSBPL3 increased SREBP-1 cleavage in refed LRH-1 WT mice (Figure IV.8A), 
suggesting that elevated OSBPL3 levels promote SREBP-1 activation. We next 
silenced Osbpl3 in LRH-1 K289R mice using siRNAs in LRH-1 K289R mice under 
fast-refeeding conditions. The hepatic mRNA expression of Osbpl3 showed a 
clear trend of effective silencing (Figure IV.8B), while Srebf1 expression was not 
altered (Figure IV.8C). Importantly, we observed a robust decrease in OSBPL3    
protein, along with a reduction in the maturation of SREBP-1, and a blunted 
expression of the FASN transcript and protein in the livers of refed LRH-1 K289R 
mice treated with siOsbpl3 (Figure IV.8D, E). We next assessed the effect of 
Osbpl3 silencing under normal fed conditions.  
Western blot analysis revealed reduced OSBPL3 expression (Figure IV.9A), and 
a robust decrease in the lipogenic proteins FASN and SCD-1 in ad libitum fed LRH-
1 K289R mice treated with siOsbpl3 compared to control mice (Figure IV.9A). Of 
interest, expression of the lipogenic enzymes, acetyl-Coenzyme A carboxylase 
alpha (Acaca), Fasn, stearoyl-Coenzyme A desaturase 1 (Scd1), and glycerol-3-
phosphate acyltransferase (Gpam), was often normalized to values observed in 
LRH-1 WT mice (Figure IV.9B), suggesting that Osbpl3 silencing rescues the 
lipogenic phenotype of LRH-1 K289R mice. In line with the reduced expression of 
lipogenic genes, Osbpl3 silencing also decreased hepatic triglyceride and neutral 
lipid content (Figure IV.9C). As an additional approach to silence Osbpl3, we 
injected mice with an AAV8 viral vector containing a miRNA targeting Osbpl3 in 
Figure IV.8. OSBPL3 promotes the maturation of SREBP-1. 
(A) Immunoblots of OSBPL3, HSP90, precursor and cleaved (cl) SREBP-1, P62, and HDAC3 in 
hepatic lysates of fasted or refed WT + Ad-GFP or refed WT + Ad-OSBPL3 livers. (B, C) Hepatic 
mRNA expression of Osbpl3 (B) and Srebf1 (C) in refed K289R and WT mice. (D) Immunoblots 
of OSBPL3, FASN, β-ACTIN, precursor and cleaved (cl) SREBP-1, and PARP1 in hepatic lysates of 
refed K289R siScr or K289R siOsbpl3 livers. (E) Hepatic mRNA expression of Fasn in refed WT, 
K289R siScr or K289R siOsbpl3 mice.  
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the liver. Here again, we observed a robust silencing of Osbpl3, which was 
accompanied by the suppression of Fasn and a striking reduction of hepatic lipid 
droplets (Figure IV.9D-F). 
Finally, we also examined whether other mechanisms, directly or indirectly 
regulated by LRH-1, may contribute to the lipogenic phenotype. Of interest, both 
hepatic glucose-6-phosphate content (174) and VLDL secretion (199) were 
unchanged between LRH-1 K289R and LRH-1 WT mice  (Figure IV.10A-C), making 
it unlikely that these processes account for the exacerbated lipid accumulation in 
the liver.  
Altogether these data suggest that the LRH-1-OSBPL3 signaling axis 
contributes to the increased maturation of SREBP-1, the induction of lipogenic 
enzymes, and the hepatic accumulation of triglycerides observed in LRH-1 K289R 
mice.  
Figure IV.9. Osbpl3 silencing rescues the lipogenic phenotype of LRH-1 K289R mice. 
(A) Hepatic expression of OSBPL3, FASN, SCD1, and HSP90 in livers of ad libitum fed WT, 
K289R siScr or K289R siOsbpl3 mice. (B) Hepatic mRNA expression of genes involved in de 
novo lipogenesis in ad libitum fed WT, K289R siScr or K289R siOsbpl3 mice. (C) 
Quantification of hepatic triglycerides in hepatic lipid extracts from ad libitum fed WT, K289R 
siScr or K289R siOsbpl3 mice. (D, E) Hepatic mRNA expression of Osbpl3 (D) and Fasn (E) in 
6-hours refed WT, K289R or K289R mirOsbpl3 mice. (F) Representative Oil-red O stainings in 
liver cryosections from refed K289R mirScrambled or K289R mirOsbpl3 mice. Scale bar, 100 
µm.  
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LRH-1 K289R mice are prone to develop NAFLD upon lipogenic diet feeding 
Excessive de novo lipogenesis contributes to the development of NAFLD, a 
condition that can eventually progress to NASH (2, 4). In order to investigate if 
LRH-1 affects the development of NAFLD, LRH-1 K289R and LRH-1 WT mice were 
fed a highly lipogenic high-fat high-sucrose (HFHS) diet or a chow diet for 17 
weeks, and then sacrificed under normal fed conditions. Stainings of hepatic 
sections with hematoxylin and eosin (H&E) and oil red O revealed that LRH-1 
K289R mice develop a stronger steatotic phenotype compared to LRH-1 WT mice 
fed a HFHS diet (Figure IV.11A). While plasma cholesterol levels were unchanged 
(Figure IV.11B), triglyceride content in plasma (Figure IV.11C) or in VLDL fractions 
(Figure IV.11D) was reduced in HFHS-fed LRH-1 K289R mice. This reduction was 
accompanied with a robust accumulation of hepatic triglycerides (Figure IV.11E), 
as well as an induction of plasma levels of the enzymes alanine transaminase 
(ALAT) and aspartate aminotransferase (ASAT) in the HFHS-challenged LRH-1 
K289R mice (Figure IV.11F, G). Similar to our earlier observations in normal chow 
diet conditions (Figure IV.5A-D), Osbpl3 mRNA and OSBPL3 protein were 
significantly induced in LRH-1 K289R compared to LRH-1 WT mice fed a HFHS diet 
(Figure IV.11H, I), while the expression of other Osbp genes did not differ 
between the genotypes (Figure IV.11J). 
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Figure IV.10. No change in glucose-6-phosphate production and VLDL secretion in LRH-1 
K289R mice. 
(A) Quantification of glucose-6-phosphate (glucose-6-P) in hepatic lysates of fasted or refed 
WT and K289R mice. (B, C) Plasma triglyceride synthesis over time (B), and triglyceride 
production rate (TGPR) in WT and K289R mice (C).  
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The development of hepatic steatosis in mice is known to be highly 
heterogeneous (200). Therefore we analyzed the data from a study in which mice 
were fed a chow or high-fat diet, and then classified according to the 
development of NAFLD/NASH into low-fat low (LFL) responders, low-fat high (LFH) 
responders, high-fat low (HFL) responders, and high fat high  (HFH) responders 
(200). Interestingly, the expression of Osbpl3 was significantly induced in the 
HFH responders along with markers of inflammation and necrosis (Figure IV.12A), 
and was by far the most strikingly increased Osbp among all family members 
(Figure IV.12B). We also analyzed OSBPL3 expression in two cohorts of 
NAFLD/NASH patients. In the first cohort livers were categorized as mild or 
advanced NAFLD (Figure IV.13A) (201). In the second study, subjects had livers 
ranging from healthy controls to steatosis and further to NASH (Figure IV.13B) 
(202). OSBPL3 expression was low in healthy livers, but increased in advanced 
stages of NAFLD/NASH and clustered with markers of fibrosis, suggesting that 
OSBPL3 could be a novel biomarker for advanced liver diseases, such as NASH. 
Figure IV.11. LRH-1 K289R mice develop NAFLD upon HFHS diet feeding. 
(A) Representative images of liver sections of K289R or WT mice stained with hematoxylin and 
eosin (H&E) or Oil-red O to visualize the tissue structure and neutral lipids, respectively. Black 
scale bar, 200 µm; White scale bar, 50 µm. (B, C) Plasma cholesterol (B) and triglycerides (C) 
levels in WT and K289R mice fed a HFHS diet. (D) Triglyceride content in lipoprotein 
subfractions. (E) Quantification of triglyceride content in hepatic lipid extracts in WT and 
K289R mice. (F, G) Plasma levels of alanine transaminase (ALAT, F) and aspartate 
aminotransferase (ASAT, G) in mice fed a HFHS diet. (H, I) Expression of OSBPL3 mRNA (H) and 
protein (I) level in livers of WT and K289R mice fed chow and HFHS diets. (J) Hepatic mRNA 
expression of oxysterol binding protein family members in K289R and WT mice upon chow or 
HFHS feeding. §P < 0.001 refed relative to fasted mice. 
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Taken together, these data show that Osbpl3 is significantly increased in LRH-1 
K289R mice as well as in mice and humans with NAFLD/NASH. 
 
LRH-1 K289R mice display increased inflammation and early signs of fibrosis in 
response to lipogenic diet feeding 
Given the strong steatotic phenotype and the high levels of ALAT and ASAT 
markers in LRH-1 K289R mice fed a HFHS diet, as well as the clustering of Osbpl3 
with genes involved in inflammation and fibrosis in mice and humans with 
NAFLD, we next analyzed inflammatory and fibrotic markers in LRH-1 K289R and 
LRH-1 WT mice. Stainings of hepatic sections with Sirius Red and CD45 revealed 
that in contrast to LRH-1 WT mice, LRH-1 K289R mice develop small fibrotic 
lesions and accumulate CD45-positive immune cells upon HFHS feeding (Figure 
IV.14A). Moreover, LRH-1 K289R livers displayed higher levels of the 
inflammatory genes tumor necrosis factor alpha (Tnfα), monocyte 
chemoattractant protein-1 (Mcp1 or Ccl2), and macrophage inflammatory protein-
1 alpha (Mip1α or Ccl3) (Figure IV.14B), indicating increased inflammation in 
livers of HFHS-fed LRH-1 K289R mice.  
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Figure IV.12. Osbpl3 is significantly induced in high-fat diet responders and clusters with 
inflammation and fibrosis markers. 
(A, B) Heat map displaying the expression of all Osbps (A) or of Osbpl3 as well as markers of 
matrix degradation, fibrosis, and inflammation (B) in mice that were classified as into low-fat 
low (LFL) responders, low-fat high (LFH) responders, high-fat low (HFL) responders, and high 
fat high (HFH) responders according to the development of NAFLD/NASH upon chow or high-
fat diet feeding.  
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The expression of matrix metalloproteinases (MMPs), such as Mmp2 and 
Mmp13, as well as early markers of fibrosis, such as alpha-1 type I collagen 
(Col1a1) and transforming growth factor beta-1 (Tgfb1), was also elevated in LRH-
1 K289R in comparison to LRH-1 WT mice fed a HFHS diet (Figure IV.14C, D). 
Hepatic stellate cells are the primary hepatic cell type promoting fibrogenesis 
(203). The expression of different hepatic stellate cell markers, such as desmin 
(Des), glial fibrillary acidic protein (Gfap), and reelin (Reln), was also increased in 
HFHS-fed LRH-1 K289R compared to LRH-1 WT mice (Figure IV.14E), suggesting 
that HFHS-treated LRH-1 K289R mice exhibit early signs of NASH.  
Previous studies showed that LRH-1 and the SUMOylation machinery might 
affect the hepatic acute phase response (APR) (118, 167, 168). While induction of 
the APR by short exposure of lipolysaccharide (LPS) led to reduced hepatic 
expression of C-reactive protein (Crp) and Tnf in LRH-1 K289R compared to LRH-1 
WT mice, it did not alter the hepatic expression of other APR and inflammatory 
genes (Figure IV.15A). Moreover, no difference in plasma IL-6, MCP-1 (CCL-2) or 
TNF-α could be observed in LPS challenged LRH-1 K289R and LRH-1 WT mice 
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Figure IV.13. Osbpl3 is increased in advanced stages of NAFLD/NASH. 
(A) Expression of OSBPL3 and markers of matrix degradation, fibrosis, and inflammation in 
transcriptomic data from human patients that were categorized for mild or advanced NAFLD. 
(B) Expression of OSBPL3 and markers of matrix degradation, fibrosis, and inflammation in 
transcriptomic data from human subjects that had livers ranging from healthy controls to 
steatosis and further to NASH.  
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(Figure IV.15B), suggesting that the APR is likely not driving the observed 
inflammatory phenotype in our NAFLD-model. 
Taken together, these data show that SUMOylation-defective LRH-1 promotes 
the development of NAFLD and displays early signs of NASH in mice fed a HFHS 
diet. This process is at least partially driven by the LRH-1-OSBPL3 signaling axis, 
which contributes to increased maturation of SREBP-1, the induction of lipogenic 
enzyme expression and hepatic triglyceride accumulation in LRH-1 K289R mice 
(Figure IV.16) 
 
Figure IV.14. LRH-1 K289R mice display increased inflammation and early signs of 
fibrosis upon HFHS diet feeding. 
(A) Representative images of liver sections of K289R or WT mice stained with Sirius Red or 
CD45 to visualize collagen depositions and CD45-positive cells, respectively. Scale bars, 200 
µm; CV, central vein. (B - E) Hepatic mRNA expression of genes involved in inflammation (B), 
matrix degradation (C), fibrosis (D), and stellate cells (E) in K289R and WT mice.  
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IV.3   Discussion  
In this study, we analyzed the contribution of a selective LRH-1 gain-of-function 
on hepatic de novo lipogenesis and fatty liver development and identified Osbpl3 
as a critical component in the regulation of this process. While the hepatic 
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Figure IV.15. Hepatic acute phase response in LRH-1 WT and K289R mice. 
(A) Hepatic expression of the indicated acute phase response genes in WT and K289R mice 
that were challenged with either PBS or lipopolysaccharide (LPS) for 2.5 hours. (B) ELISA 
assays to determine the plasma content of IL-6, MCP-1 or TNF-α.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV.16. Graphical presentation depicting how the LRH-
1/OSBPL3 axis drives the accumulation of hepatic lipids. 
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expression of Osbpl3 is normally low in mice under basal conditions, LRH-1 
K289R mice express high levels of this specific OSBP family member. Consistent 
with our observations, the analyses of independent mouse and human 
transcriptomic datasets revealed that Osbpl3 expression is often induced in 
NAFLD/NASH. Our work furthermore strengthens the putative role of OSBPL3 in 
SREBP-1 maturation. As a consequence, LRH-1 K289R mice display increased de 
novo lipogenesis and accumulation of triglycerides upon refeeding in a manner 
that is independent of enhanced LXRα recruitment or activity. Importantly, 
silencing of OSBPL3 in vivo reverts the increased lipogenesis observed in these 
animals. Moreover, when exposed to a lipogenic HFHS diet, LRH-1 K289R mice 
develop NAFLD accompanied by early signs of NASH, most likely as a 
consequence of chronic fat accumulation (2, 4). 
The excessive accumulation of hepatic lipids and increased de novo 
lipogenesis could also have other causes. A previous study using liver-specific 
Lrh-1 knockout mice showed that LRH-1 promotes glucokinase expression, hence 
regulating glycolysis and de novo lipogenesis (174). However, we did not observe 
a difference in hepatic glucose-6-phosphate content between LRH-1 WT and LRH-
1 K289R mice, suggesting that the selective gain-of-function of LRH-1 driven by 
the K289R mutation does not increase substrate availability for the glycolytic 
pathway. Based on the finding that the primary corepressor of LRH-1 affects 
microsomal triglyceride transfer protein levels and consequently hepatic VLDL-
triglyceride secretion (199), we also performed in vivo VLDL-secretion assays, but 
could not detect any difference between refed LRH-1 K289R and LRH-1 WT mice. 
Finally, LRH-1 SUMOylation has been linked to the induction of the hepatic acute 
phase response (118, 167, 168), which could explain the excessive inflammation 
observed in the livers of mice receiving a chronic HFHS diet. To study the acute 
phase response in vivo, we challenged LRH-1 WT and LRH-1 K289R mice with 
lipopolysaccharide for 2.5 hours. Besides the reduction in Crp and Tnf, the 
inflammatory signature was comparable between the genotypes, suggesting that 
the exacerbated inflammatory phenotype of the LRH-1 K289R mice is most likely 
not driven by changes in the APR. 
While the induction of SREBP-2 processing has been well described, the 
mechanisms that trigger SREBP-1 processing are less well understood (28). Insulin 
receptor-AKT-mTOR signaling is considered as one of the main pathways 
triggering SREBP-1 signaling (204). A recent study showed that insulin promotes 
SREBP-1 activation and de novo lipogenesis via mTORC1-dependent 
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and -independent mechanisms (205). Others proposed that while insulin 
signaling is required for SREBP-1 activation in insulin-resistant conditions, it is not 
critical to induce the feeding-dependent induction of SREBP-1 under physiological 
conditions (206, 207). In breast epithelial cells the expression of oncogenic forms 
of the PI3K or K-Ras are sufficient to induce SREBP-1 maturation and de 
novo lipogenesis through induction of mTOR signaling (208). Whereas these and 
many other studies demonstrate that the expression of Srebf1 and the 
posttranslational maturation of SREBP-1 can be triggered by insulin signaling, 
other downstream or parallel pathways exist. One recent example is the induction 
of SREBP-1 processing upon depletion of phosphatidylcholine, whose synthesis is 
dependent on S-adenosylmethionine, a methionine derivative that is generated in 
the one-carbon cycle (173). We did not observe a difference in AKT 
phosphorylation between LRH-1 WT and LRH-1 K289R mice, suggesting other 
signaling pathways to induce the processing of SREBP-1. Indeed, our current 
study highlights the existence of an alternative mechanism of SREBP-1 activation 
involving a SUMO-dependent LRH-1/OSBPL3 pathway. 
The first oxysterol binding proteins were identified, purified and cloned in the 
1980s (209-211). Recent studies suggest that OSBPs act as sterol transfer and/or 
sensor proteins that may also play important roles in cell signaling (212, 213). 
OSBPL3, a member of subfamily III, contains a conserved sterol-binding OSBP 
homology domain (OHD) as well as a phosphatidylinositol lipid species-binding 
pleckstrin homology (PH) domain and two 2-phenylalanines in an acidic tract 
(FFAT) domains that bind to the vesicle-associated membrane protein-associated 
(VAMP-associated) protein (VAP) (212, 214, 215). Recently, it has been shown that 
this last interaction can activate R-RAS, thus reorganizing the actin cytoskeleton 
and affecting cell polarity and cell-cell adhesion (216). Future studies will be 
necessary to dissect the exact mechanisms by which OSBPL3 modulates SREBP-1 
processing, but its association with the ER could indicate a possible site of 
regulation. 
In addition to the identification of OSBPL3 as a target of LRH-1, our study also 
highlights the existence of complex regulatory mechanisms to which OSBPL3 is 
subjected. We observed a discrepancy between mRNA and protein levels of 
OSBPL3 between fasting and refed conditions despite its persistent increase in 
LRH-1 K289R mice. The marked reduction in mRNA levels upon refeeding was 
also noticed when OSBPL3 was overexpressed using an adenovirus, indicating 
that additional posttranscriptional mechanisms independent of LRH-1 regulate 
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the expression of OSBPL3. Moreover, while the expression of OSBPL3 is low in 
healthy livers, it is increased in NAFLD, suggesting that this protein could be a 
novel biomarker for NAFLD.  
In this study, we described a novel function of LRH-1 in the development of 
fatty liver disease. It is noteworthy that other nuclear receptors also contribute to 
the development of NAFLD by affecting steatosis, glucose homeostasis, 
inflammation and/or fibrosis in the liver. For instance, while activation of LXRs or 
pregnane x receptor (PXR) promote lipogenesis and the development of NAFLD, 
activation of other nuclear receptors such as peroxisome proliferator-activated 
receptors (PPARs) or farnesoid X-activated receptor (FXR) has opposite effects 
(reviewed in (217)). Clinical trials performed in NASH patients using PPARγ or FXR 
agonists showed that the beneficial effects observed on hepatic steatosis and 
inflammation were accompanied by adverse effects on obesity and 
hypercholesterolemia, respectively (218, 219), highlighting the functional 
complexity of nuclear receptors (217). Therefore, the development of drugs 
targeting specific nuclear receptors targets, such as OSBPL3, might provide 
alternative therapeutic options for treating NAFLD. 
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Chapter V   SLC25A47 as a novel determinant in hepatic steatosis 
 
V.1   Introduction 
In recent years, LRH-1 has emerged as an essential regulator of the hepatic 
glucose-sensing system. Lrh-1 liver-specific knockout (Lrh-1 hep-/-) mice fail to 
adequately induce glycolysis, glycogen synthesis and DNL in response to a 
standardized meal (169). In contrast to its role in postprandial hepatic 
metabolism, the physiological role of LRH-1 in the fasted state is still largely 
unknown. Furthermore, the impact of LRH-1 on mitochondria, key organelles in 
times of scarcity of nutrients, is largely unexplored. We hence decided to explore 
the role of LRH-1 in the fasted liver and its influence on mitochondrial function.  
Mitochondria are essential organelles for metabolic homeostasis being the 
prime location for FA oxidation and therefore lipid disposal. Their oxidative 
capacity and flexibility to environmental and/or endocrine signals are crucial for 
NAFLD and dictates the disease progression (50).  
SLC25 are mitochondrial transporters responsible for the import and export of 
almost all metabolites, cofactors and anions to and from mitochondria (81). Due 
to the plethora of molecules transported, SLC25 members are involved in many 
metabolic pathways, including oxidative phosphorylation, citric acid cycle and FA 
degradation (81, 87). Targeting mitochondria in general or SLC25 family 
members in particular could thus prove an efficient tool for NAFLD treatment 
(88).   
In this chapter, we demonstrate that mice lacking LRH-1 in hepatocytes present 
mitochondrial dysfunction exacerbated by fasting challenge. As a consequence, 
Lrh-1 hep-/- mice display fasting-induced steatosis. Finally, the expression of 
Slc25a47 is regulated by LRH-1 and its recovery in LRH-1-deleted livers rescues 
the steatotic phenotype (section V.2.1). Moreover, we identified a novel liver-
specific mitochondrial transporter (SLC25A47) that is induced upon fasting and 
improves mitochondrial FA oxidation. The identification of SLC25A47 as a pivotal 
player in oxidative catabolism proved to be also beneficial in the context of 
NAFLD, a condition in which this transporter is normally downregulated (section 
V.2.2).  
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V.2.   Results 
V.2.1   Fasting-induced steatosis driven by the loss of LRH-1 in the 
liver is rescued by SLC25A47  
 
Lrh-1 hep-/- mice display fasting-induced steatosis  
 In the liver, the fasted and fed states are examples of physiological conditions 
that differ significantly in biochemical responses. To explore the putative 
involvement of LRH-1 in liver intermediary metabolism during fasting, we 
subjected mice with a somatic deletion of LRH-1 in hepatocytes (Lrh-1 hep-/-) (169) 
and their control littermates (Lrh-1 hep+/+) to an overnight (ON) fasting challenge. 
Interestingly, fasting caused a robust lipid accumulation in the liver of Lrh-1 hep-/- 
mice (Figure V.1A) compared to Lrh-1 hep+/+ littermates. Fasting-induced steatosis 
was accompanied by a higher liver mass in Lrh-1 hep-/- mice but not by changes in 
body weight and eWAT mass (Figure V.1B-D). To further verify the content of 
lipids in the liver, we quantified hepatic TG levels and confirmed lipid 
accumulation (Figure V.1E) in the liver of fasted Lrh-1 hep-/- mice. Of note, plasma 
FA and TG did not show any significant alterations between the two genotypes 
(Figure V.1F, G), making it unlikely that decreased VLDL secretion in the liver 
could account for the steatotic phenotype.  
Figure V.1. Lrh-1 hep-/- mice display fasting-induced steatosis. 
(A) Representative oil red O stainings of Lrh-1 hep+/+ and Lrh-1 hep-/- mice in fed and fasted 
conditions to visualize neutral lipids. Scale bar: 200 µm (B-D) Body weight (B), liver (C) and 
epididymal white adipose tissue (eWAT) mass (D) of fed and fasted Lrh-1 hep+/+ and Lrh-1 hep-/- 
mice. (E) Quantification of hepatic triglyceride (TG) in lipid extracts of fed and fasted Lrh-1 
hep+/+ and Lrh-1 hep-/- mice. (F, G) Plasma free fatty acids (FA, F) and TG (G) levels in fed and 
fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice.  
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Lrh-1 hep-/- mice display mitochondrial dysfunction 
Excessive hepatic lipid accumulation during fasting can be due to a 
dysregulation of several processes, including adipose tissue lipolysis or hepatic 
fatty acid oxidation (2). To test if increased adipose tissue lipolysis accounts for 
the observed hepatic lipid overload in the Lrh-1 hep-/- livers, we next performed an 
ex vivo lipolysis assay. Free fatty acids and glycerol release in the medium from 
adipose explants was not significantly changed between Lrh-1 hep-/- and Lrh-1 hep+/+ 
mice (Figure V.2A, B), while there was a significant stimulation after forskolin 
treatment, indicating equal lipolysis rate.  
 
We then decided to evaluate the capacity of hepatic mitochondrial activity in 
these animals. First, we performed microarray analysis in the liver of fasted Lrh-1 
hep+/+ and Lrh-1 hep-/- mice. Liver transcriptome analysis exhibited an important 
representation of the transcripts for mitochondrial proteins (14%) among the 
most significantly altered genes upon loss of LRH-1 (Figure V.3A, shown in red). 
More importantly, gene ontology (GO: cellular compartment) showed 
mitochondria as the top compartment where genes downregulated in LRH-1-
deficient livers are mostly located (Figure V.3B). The most significantly 
downregulated mitochondrial genes are depicted in Figure V.3C. In addition, we 
performed proteomics in the liver of Lrh-1 hep+/+ and Lrh-1 hep-/- mice. KEGG pathway 
analysis of all the proteins downregulated in Lrh-1 hep-/- livers revealed fatty acid 
degradation as one of the most significant pathways affected by the lack of LRH-1 
(Figure V.3D). 
 High-resolution respirometry using either succinate and rotenone (State
3ADP
, 
Figure V.4A) or fatty acid oxidation (FAO) substrates (fatty acyl-carnitines, Figure 
V.4B) in the presence of ADP revealed that loss of LRH-1 in hepatocytes is 
associated with lower hepatic mitochondrial oxygen consumption rate (OCR).  
Figure V.2. Lrh-1 hep-/- mice don’t present altered white adipose tissue lipolysis rate. 
(A, B) Ex vivo lipolysis-associated glycerol (A) and free fatty acids (FA, B) released from Lrh-1 
hep+/+ and Lrh-1 hep-/- white adipose tissue explants.   
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Furthermore, oleic acid oxidation was significantly reduced in the liver of Lrh-1 
hep-/- mice (Figure V.4C). In line with these observations, Lrh-1 hep-/- mice showed an 
accumulation of hepatic acyl-carnitines when compared to those in the liver of 
Lrh-1 hep+/+ mice (Figure V.4D). This reduction in fatty acid oxidation was 
accompanied by lower levels of hepatic ATP in Lrh-1 hep-/- mice (Figure V.4E), 
suggestive of reduced substrate utilization to energy conversion. In parallel to 
the reduced mitochondrial OCR, expression and activity of the mitochondrial 
complexes were decreased in the liver of Lrh-1 hep-/- mice, especially CII (Figure 
V.4F-H). Together these data indicate that LRH-1-deficient livers display 
mitochondrial dysfunction that makes them inefficient in producing sufficient 
energy from the substrates available during a fasting condition.  
 
Figure V.3. LRH-1 regulates mitochondrial proteins transcripts. 
(A) Vulcano plot depicting in red the significant representation of mitochondrial transcripts 
among all genes in fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice liver microarray. FC, fold-change 
(WT/KO). (B) Gene ontology (GO, cellular compartment) of genes downregulated in livers from 
fasted Lrh-1 hep-/- in comparison with Lrh-1 hep+/+ mice. (C) Heat map of the most significant 
downregulated mitochondrial genes (from B) in fasted Lrh-1 hep-/- livers, FC>1.4 and P<1x104. 
(D) Pathway enrichment analysis (KEGG) of proteins downregulated in Lrh-1 hep-/- livers. 
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LRH-1 drives the expression of Slc25a47 
Mitochondrial solute carriers (SLC25) are very important for mitochondrial 
metabolism allowing the shuttling of substrates and products through the IMM 
thus establishing the communication between cytosol and mitochondria (81). 
Since LRH-1 deficient livers have compromised substrate utilization by the 
mitochondria, we next sought to verify whether any SLC25 family member is 
affected by the loss of LRH-1 in the liver. Since Slc25a47 is significantly 
downregulated in Lrh-1 hep-/- livers (Figure V.3C), we decided to further explore the 
molecular link between LRH-1 and Slc25a47. Intriguingly, Slc25a47 is 
downregulated in a similar manner as LRH-1 target genes such as Nr0b2, Cyp8b1 
Figure V.4.  Lrh-1 hep-/- mice display mitochondrial dysfunction. 
(A) Oxygen consumption rate (OCR) of fresh liver homogenates from fasted Lrh-1 hep+/+ and Lrh-1 
hep-/- mice by high-resolution respirometry in the presence of succinate, ADP (SA) and rotenone 
(ROT) - State3ADP. (B) OCR of fresh liver homogenates from fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice in 
the presence of fatty acid oxidation (FAO) substrates, palmitoyl- and octanolyl-carnitine, and 
ADP. (C) Oleic acid oxidation assay in the liver of fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (D) Liver 
acyl-carnitines content in fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (E) Hepatic ATP level of fasted 
Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (F) Immunoblots of mitochondrial complexes subunits ATP5A 
(CV), UQCRC2 (CIII), MTCO1 (CIV), SDHB (CII) and VDAC as a loading control in isolated 
mitochondria from fasted Lrh-1 hep+/+ and Lrh-1 hep-/- livers. (G) In-gel activity of mitochondrial 
complexes (I, II and IV) from Lrh-1 hep+/+ and Lrh-1 hep-/- fasted liver mitochondria. Complex I 
(purple); Complex IV (brown); complex II (blue). (H) Quantification of the bands in G normalized 
to coomassie blue staining bands.  
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and Gnmt (Figure V.5A) indicating that this carrier could be directly regulated by 
LRH-1. Analysis of livers of Lrh-1 hep-/- mice confirmed the decreased expression of 
Slc25a47 at both transcript (Figure V.5B) and protein level (Figure V.5C). To 
investigate whether SLC25A47 is directly controlled by LRH-1, we analyzed the 
Slc25a47 genomic region in available ChIP-seq data for potential LRH-1 binding 
sites (196). We identified 3 significant peaks with an LRH-1 consensus-binding 
site, one being close to the transcriptional start site of the Slc25a47 gene (Figure 
V.5D, black arrow). We then performed site-specific ChIP-qPCR analysis to 
evaluate whether the site with the most significant peak is bound by LRH-1 (black 
arrow). LRH-1 was recruited at the Slc25a47 promoter region when using liver 
chromatin from Lrh-1 hep+/+ mice  (Figure V.5E). However, loss of LRH-1 binding 
was observed when using LRH-1-deficient livers (Figure V.5E), suggesting that 
Slc25a47 is a direct LRH-1 target gene.   
 
Figure V.5. Slc25a47 is a direct target of LRH-1 transcriptional regulation.  
(A) Heat map depicting LRH-1 target genes expression between fasted Lrh-1 hep+/+ and 
Lrh-1 hep-/- livers. Normalized values are in log2 scale. (B, C) Slc25a47 gene (B) and protein (C) 
expression levels in the liver of fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (D) University of 
California at Santa Cruz (UCSC) genome browser (mm9) view displaying the occupancy of 
mouse Slc25a47 by LRH-1 and IgG (196). Significant peaks are underlined in red. (E) Binding 
of LRH-1 to Slc25a47 promoter region as assessed by Chip analysis using genomic DNA from 
Lrh-1 hep+/+ and Lrh-1 hep-/- livers. 
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Slc25a47 rescue in Lrh-1 hep-/- mice reverses fasting-induced lipid accumulation in 
the liver 
Overexpression of Slc25a47 in HepG2 cells has been suggested to decrease 
lipid accumulation (220). Based on the previous observations, we hence 
hypothesized that overexpression of hepatic Slc25a47 may counteract the lipid 
accumulation observed in the liver of Lrh-1 hep-/- mice. To explore this possibility, 
we performed rescue experiments using AAV8 viral vector-mediated gene 
transfer in Lrh-1 hep-/- mice and sacrificed the mice under fasting conditions five 
weeks later (Figure V.6A). Slc25a47 expression levels increased specifically in the 
liver of AAV8-Slc25a47 transduced Lrh-1 hep-/- mice (Figure V.6B), but not in other 
Figure V.6. Slc25a47 rescues the steatotic phenotype of Lrh-1 hep-/- fasted livers. 
(A) Scheme showing experimental design for in vivo AAV8-mediated gain-of-function of 
SLC25A47 in mice. (B) Gene expression of Slc25a47 in Lrh-1 hep+/+ and Lrh-1 hep-/- mice 
transduced with AAV8-Empty or AAV8-Slc25a47. (C) Liver weight of Lrh-1 hep+/+ and Lrh-1 hep-/- 
mice transduced with AAV8-Empty or AAV8-Slc25a47. (D-E) Hepatic ATP level (D) and 
triglyceride (TG) content (E) of Lrh-1 hep+/+ and Lrh-1 hep-/- mice transduced with AAV8-Empty or 
AAV8-Slc25a47. (F) Representative oil red O stainings in the liver of Lrh-1 hep+/+ and Lrh-1 hep-/- 
mice transduced with AAV8-Empty or AAV8-Slc25a47. 
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tissues. Overexpression of Slc25a47 showed a trend to decrease the liver mass of 
fasted Lrh-1 hep-/- mice (Figure V.6C). Importantly, ATP levels were recovered to the 
values observed in Lrh-1 hep+/+ mice in Slc25a47-overexpressing Lrh-1 hep-/- mice 
(Figure V.6D). Strikingly, both staining of liver sections with oil red O and 
quantification of TG content revealed that Slc25a47 upregulation in Lrh-1 hep-/- 
mice decreased significantly the hepatic lipid accumulation (Figure V.6E, F).  
To assess if hepatic OCR was increased in Slc25a47-rescued LRH-1-deficient 
livers independent on the number of mitochondria, we assessed OCR in isolated 
mitochondria from the livers of these animals. Oxygen consumption rate 
(State
3ADP
) was significantly improved in Lrh-1 hep-/- mice after Slc25a47 expression 
recovery (Figure V.7A). Consistent with enhanced mitochondrial respiration, 
 
Figure V.7. Slc25a47 improves mitochondrial function in Lrh-1 hep-/- livers. 
(A) Oxygen consumption rate (OCR) in liver mitochondria of Lrh-1 hep-/- transduced with AAV8-
Empty or AAV8-Slc25a47 by high-resolution respirometry in response to substrates (succinate, 
rotenone and ADP – SRA, State3ADP), oligomycin (Oligo, State4o) and the uncoupler carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, State3u) in freshly isolated liver 
mitochondria from AAV8-empty and AAV8-Slc25a47 transduced  Lrh-1 hep-/- mice. (B) In-gel 
activity of mitochondrial complexes (I, II and IV) from Lrh-1 hep+/+ and Lrh-1 hep-/- fasted liver 
mitochondria. Complex I (purple); Complex IV (brown). (C) Quantification of the bands in (B) 
normalized by coomassie blue staining bands. 
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mitochondrial complexes activity was also increased after Slc25a47 
overexpression in Lrh-1 hep-/- mice in comparison with Lrh-1 hep-/- mice transduced 
with control viral particles (Figure V.7B, C).  
Taken together, these data show that reconstitution of Slc25a47 in Lrh-1 hep-/- 
livers is sufficient to rescue the steatotic phenotype induced upon fasting by 
improving mitochondrial function. 
 
V.2.2   Liver-specific mitochondrial carrier SLC25A47 enhances fatty 
acid oxidation and is downregulated in NAFLD  
 
Slc25a47 is a liver-specific mitochondrial inner membrane carrier 
Despite the clear importance of SLC25 (88), there is a clear negligence in their 
characterization as shown in the phylogenetic tree of the family represented in 
Figure V.8.  
Figure V.8. Phylogenetic tree of mouse SLC25 family members. 
Uncharacterized members are represented in red. 
 
Slc25a47 is still one of the members that is not characterized (Figure V.8) we 
thus decided to further understand its function. Gene expression profiling of the 
entire mouse Slc25 family members depicted Slc25a47 as the most expressed 
solute carrier in the liver (Figure V.9A). Moreover, its expression both at the 
mRNA and protein level is liver-specific, as confirmed by RT-qPCR and 
immunoblotting (Figure V.9B, C). Also when checked in over 50 human tissues, 
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SLC25A47 is only confined in the liver (accessible on 
https://www.gtexportal.org/home/). 
  SLC25 transporters are mostly located in the IMM. However some SLC25 
family members have been exceptionally identified in the OMM, we next decided 
to confirm the IMM localization of SLC25A47. Permeabilization of mitochondria 
with increasing amounts of digitonin releases mitochondrial proteins from the 
OMM, IMS and then IMM in a concentration dependent-manner. This assay 
confirmed the detection of SLC25A47 in the inner mitochondrial membrane 
(Figure V.10A). Immunofluorescence of alpha mouse liver 12 (AML12) cells 
overexpressing Flag-tagged SLC25A47 additionally confirmed the staining of this 
transporter in a mitochondria-shaped network (Figure V.10B).  
Figure V.9. Slc25a47 mitochondrial transporter is liver-specific. 
(A) Heat map depicting relative mouse Slc25 family transcripts abundance in heart, testis, 
brain, cerebellum, liver and kidney. (B, C) Expression level of Slc25a47 transcript (B) and 
protein (C) levels in different mouse tissues.  
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To gain more insight into the function of the orphan SLC25A47, we followed 
the same strategies as the ones applied to discover the function of other SLC25 
family members. First, phylogenetic clustering of a particular carrier with others 
of known function can provide clues to be tested. Therefore, we assessed 
sequence similarity between SLC25A47 and its closest members of the family, 
SLC25A45, SLC25A48, SLC25A29, SLC25A20, SLC25A15 and SLC25A2 (Figure 
V.8), some of which with known functions. Although SLC25A47 is very conserved 
among species (~90% similar, Figure V.11A), protein sequence alignment 
indicated only about 30% similarity between SLC25A47 and its closest homologs 
(Figure V.11B), indicating that SLC25 family is more similar in structure rather 
than sequence. Moreover, one portion of the protein sequence of SLC25A47 
could not be found in the other transporters (Figure V.11B, evidenced with a 
black rectangle), highlighting another unique feature of SLC25A47. The 
mitochondrial ADP/ATP carrier (AAC or SLC25A4, PDB ID 1OKC) was the first 
SLC25 structurally characterized (221) and after that the structure of other SLC25 
family members has been obtained using it as a model. Homology modeling of 
SLC25A47 to AAC revealed this distinctive portion of the protein in a matrix-
localized loop (Figure V.11C), suggesting that this part of the sequence is 
exceptional even when comparing to other members of the family. Furthermore, 
the model emphasizes a positively charged core within the protein, suggesting 
that the solutes transported are most likely negatively charged (Figure V.11C, 
Figure V.10. SLC25A47 is localized in the inner mitochondrial membrane. 
(A) Immunoblots of SLC25A47 in liver mitochondria lysates after permeabilization with 
increasing amount of digitonin. PINK1 and VDAC for the OMM, OPA1 and SDHA for the IMM 
and HSP60 for the matrix are used as controls. (B) FLAG immunofluorescence staining of alpha 
mouse liver 12 (AML12) cells overexpressing FLAG-tagged SLC25A47. DAPI is used to stain 
nuclei. Scale bar: 10 µm. 
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representation on the right).  
 
Together, these data identify SLC25A47 as a liver-specific inner mitochondrial 
membrane carrier whose exclusive distribution and unique features suggest a 
crucial role for liver function.   
 
Slc25a47 is induced upon fasting 
Since the function of SLC25A47 is unknown, we decided to take advantage of 
published datasets to evaluate if the fasting/feeding cycle influences Slc25a47 
gene expression. Genome binding/occupancy for active transcription (222) and 
microarray analysis (223) throughout the diurnal cycle of the mouse liver 
demonstrated that Slc25a47 is a fasting-induced gene, with higher Pol II 
occupancy during the day (Zeitgeber Time 2 - ZT2, Figure V.12A) and peak of 
expression after an over day fasting (Figure V.12B). To verify the induction upon 
fasting at the mRNA level, we evaluated hepatic Slc25a47 in mice after a 24h-
fasting and confirmed a 5-fold upregulation (Figure V.12C).  
 
Figure V.11. SLC25A47 presents a unique loop in the mitochondrial matrix side. 
(A, B) Protein alignment of SLC25A47 within species (A) and between SLC25A47 and its closest 
homologs (B). Similarity color code: green, high homology; red, low homology. (C) 3-D 
structure of SLC25A47 depicting the new loop. Color code for the amino acids charge: blue, 
positive; white, neutral; red, negative. Black rectangle emphasizes the loop specific to 
SLC25A47.  
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The increase in Slc25a47 mRNA levels in response to fasting suggests that this 
carrier could be linked to catabolic pathways transporting solutes that promote 
the mobilization of energy sources. Accordingly, we found that Slc25a47 
correlates positively with genes involved in fatty acid degradation and PPAR 
signaling in fasting livers of the BXD mouse genetic reference population (178) 
(Figure V.13A, B). On the contrary, lipid biosynthesis pathways were amongst the 
ones in which the genes correlating negatively with Slc25a47 are enriched (Figure 
V.13C). Taken together these data indicate that this novel unknown 
mitochondrial carrier is induced upon fasting and positively linked to oxidative 
catabolism.  
 
SLC25A47 improves mitochondrial function  
Until now, the most successful strategy employed to identify substrate 
specificity of solute carriers with unknown function consists in reconstitution of 
recombinant protein into liposomes followed by radioactive transport assays, 
herein referred to as the “expression–purification-reconstitution-assay” (EPRA) 
method (87). Unfortunately, the reconstitution of SLC25A47 in liposomes turned 
out to be technically challenging due to the high content of cysteine residues in 
this transporter, resulting in disulfide bond formation and compromised native 
protein folding. Consequently, we focused on addressing the repercussions of 
Slc25a47 gene manipulation in vivo to better understand its function.  
Figure V.12. Slc25a47 is induced upon fasting. 
(A) Representation of Slc25a47 genomic area binding/occupancy by Pol II assessed by Chip-
seq (222) at ZT2 (9 AM) and ZT18 (1AM). (B) Heat map displaying the expression of genes 
important under fed and fasted conditions during circadian rhythm (223). (C) Gene expression 
analysis of Slc25a47 in the liver of fed and 24h-fasted mice (7am-7am). 
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 To achieve this, we enhanced hepatic Slc25a47 expression levels in vivo as 
described above (Figure V.6A). AAV8-Slc25a47 transduced mice didn’t present 
any changes in body weight or liver and epididymal white adipose tissue (eWAT) 
mass (Figure V.14A, B). Hepatic gene expression analysis demonstrated that 
Slc25a47 was upregulated in the liver together with important mitochondrial 
regulators, including mitochondrial transcription factor A (Tfam), peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (Pgc1a) and nuclear 
respiratory factor-1 (Nrf-1) (Figure V.14C). Accordingly, Slc25a47 overexpression 
increased mitochondrial respiration, as well as respiratory complex activity and 
expression (Figure V.14D-F), especially the supercomplex I+III
2
+IV
1
 (the 
respirasome), indicating that SLC25A47 could influence supercomplex formation. 
 
Figure V.13. Hepatic Slc25a47 positively correlates to fatty acid degradation. 
(A) Pathway enrichment (KEGG) of genes positively correlating with Slc25a47 using 42 BXD 
mouse strains fed chow diet and sacrificed under fasting. (B, C) Correlation network 
(pearson’s r) between Slc25a47 and top 20 most significantly correlating genes, positively 
(blue) and negatively (red). Thickness of the line is associated with higher significance. 
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Western blot analysis revealed increased expression of mitochondrial CI (NDUFB8, 
NDUFS3, CIII (UQCRC2) and CIV (MTCO1), along with the mitochondrial protein 
VDAC (Figure V.14G).  
Next, we decided to verify whether SLC25A47 activity could be further 
potentiated. The additional 30 amino acid-long stretch of SLC25A47 that defines 
a mitochondrial loop (Figure V.11B, C) can be a possible regulation site dictating 
the opening of the channel. With this hypothesis, we aimed at assessing 
phosphorylation sites in this loop that could regulate SLC25A47 activity. Since 
SLC25A47 is important for oxidative catabolism during fasting, we decided to 
search for possible protein kinase A (PKA) phosphorylation sites in this loop. We 
 
Figure V.14. SLC25A47 enhances mitochondrial function.  
(A, B) Body weight (A), liver and epididymal white adipose tissue (eWAT) mass (B) of mice 
transduced with Slc25a47 or control viral vectors. (C) Gene expression of mitochondria-
related genes, Tfam, Pgc1a and Nrf-1 in AAV8-Empty and AAV8-Slc25a47 transduced livers. 
(D) Oxygen consumption rate (OCR) in response to substrates (succinate, rotenone and ADP – 
SRA, State3ADP), oligomycin (Oligo, State4o) and the uncoupler carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP, State3u) in freshly isolated liver mitochondria from 
AAV8-Empty and AAV8-Slc25a47 transduced mice. (E, F) In-gel activity (CIV and CI, E) and 
Immunoblot (F) of mitochondrial complexes in AAV8-Empty and AAV8-Slc25a47 transduced 
liver mitochondria after blue-native polyacrylamide gel electrophoresis (BN-PAGE). CI activity 
(purple); CIV activity (brown). (G) Immunoblots of mitochondrial complexes subunits ATP5A 
(CV), UQCRC2 (CIII), MTCO1 (CIV), SDHB (CII), NDUFB8 and NDUFS3 (CI), and mitochondrial 
protein VDAC. HSP90 was used as loading control.  
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found a very particular and known consensus sequence for PKA phosphorylation 
(R-R-X-S/T) (224) for serine 137 (S137) within the unknown loop (Figure V.15A). 
This sequence is conserved for SLC25A47 within species but not present in any of 
SLC25A47 homologs, not even the closest A45 and A48 (Figure V.15A, B). The 
location of S137 within the loop can be seen in Figure V.15C.  
As PKA is activated by an increase in cellular cAMP levels, we next treated 
AML12 cells transfected with either empty or Slc25a47 vector with the adenylyl 
cyclase activator forskolin (20 μM) or vehicle just before measuring oxygen 
consumption in the Seahorse. Forskolin is very commonly used in biology to 
raise cellular cAMP levels (225). Maximum respiration was increased upon 
Slc25a47 overexpression and forskolin pre-treatment, indicating that 
mitochondrial function was further enhanced in Slc25a47-overexpressing cells 
with forskolin (Figure V.16). This observation suggests that SLC25A47 could be 
phosphorylated by PKA upon rising of cAMP levels leading to increased transport 
activity.  During fasting cAMP levels are known to rise in many tissues, including 
the liver (226, 227). Our results further strengthen the role of SLC25A47 during 
fasting and suggest that post-translational modifications, such as 
Figure V.15. SLC25A47 presents an unknown loop that could be a possible point of 
regulation. 
(A) Amino acid sequence alignment of the extra loop of SLC25A47 between species. PKA 
consensus phosphorylation site is indicated inside a rectangle. (B) Protein alignment between 
the loop region of SLC25A47 and its closest homologs. (C) Structure of SLC25A47 depicting 
the new matrix loop in which serine 137 (S137) can be phosphorylated by PKA.  
Figure V.16. Forskolin further enhances mitochondrial maximum respiration upon 
Slc25a47-upregulation in AML12 cells.  
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phosphorylation, can modulate its activity leading to improved mitochondrial 
response to nutritional cues. 
Collectively, these data show that Slc25a47 is an unknown transporter with 
unique features that boost mitochondrial function. 
 
Slc25a47 is downregulated in NAFLD  
Mitochondrial dysfunction contributes to the development of NAFLD (49, 90). 
Since SLC25A47 improves mitochondrial function under normal physiological 
conditions, we decided to evaluate the potential role for this carrier as a 
mitochondrial enhancer under pathological conditions, such as NAFLD. We first 
started by asking if Slc25a47 expression is altered in NAFLD and if the presence 
of this carrier could be associated with a better prognosis. Analysis of the liver 
transcriptome of mice fed a chow diet versus mice fed a HFHS diet (NAFLD model 
(95)) revealed a significant downregulation of Slc25a47 in the disease state 
(Figure V.17A). Moreover, mouse liver lipid species recently identified as 
biomarkers pro- and anti-NAFLD (unpublished data) correlated negatively and 
positively with Slc25a47, respectively (Figure V.17B). Together these two 
observations indicate that Slc25a47 could potentially protect from the deleterious 
effects of NAFLD.  
 
Slc25a47 enhances fatty acid oxidation in NAFLD model decreasing hepatic lipid 
accumulation  
To confirm the protective effect of SLC25A47 against hepatic steatosis and 
since Slc25a47 is decrease upon HFHS diet feeding, we fed mice HFHS for 7 
weeks after AAV8-Slc25a47 transduction. In agreement with our hypothesis, H&E 
staining of the livers of HFHS-fed Slc25a47-overexpressing mice revealed less 
Figure V.17. Slc25a47 is downregulated in NAFLD. 
(A) Liver gene expression of Slc25a47 in diet-induced NAFLD model (high-fat, high-sucrose 
diet for 18 weeks). Mice fed a chow diet are depicted as “healthy”. (B) Corrgram (pearson’s r) 
of Slc25a47 with hepatic lipid species assigned as anti- and pro-NAFLD. 
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lipid droplets (Figure V.18A), demonstrating a strong protection against hepatic 
steatosis formation. TG quantification confirmed a significant decrease in the 
lipid accumulation resultant of HFHS-feeding in AAV8-Slc25a47 transduced livers 
(Figure V.18B).   
To investigate whether overexpression of Slc25a47 protects mice from hepatic 
steatosis in another diet-induced NAFLD model, C57BL/6J mice transduced with 
AAV8-Slc25a47 were fed a choline-deficient diet (ChD) for 4 weeks (Figure 
V.19A). ChD-feeding was chosen based on the fact that this diet, in contrast with 
methionine-choline deficient diet, a well-known model of NAFLD, promotes 
hepatic TG accumulation without triggering body weight loss (48). Indirect 
calorimetry one week before mice were euthanized showed a low (~0.8) 
respiratory exchange ratio (RER) in accordance with more fatty acid utilization 
(Figure V.19B). Surprisingly, upregulation of Scl25a47 in the liver was sufficient 
to further decrease the RER, indicative of improved fatty acid oxidation (Figure 
V.19B). Slc25a47 was efficiently overexpressed in the liver of mice transduced 
with AAV8-Slc25a47 viral particles (Figure V.19C). There were no differences in 
food intake nor effects on body weight as well as liver and white adipose tissue 
mass (Figure V.19D-F). The latter observation suggests that enhanced lipolysis 
was not the main source of fatty acids being extensively used in the Slc25a47-
overexpressing livers. While plasma TG levels showed a tendency to be increased 
in mice transduced with AAV8-Slc25a47, plasma free FA were increased in the 
Slc25a47-overexpressing mice (Figure V.19G, H), presumably indicating that FA 
are not accumulating in the liver.  
Figure V.18. Slc25a47 decreases lipid accumulation in NAFLD model. 
(A) Representative images of liver sections of AAV8-Empty and AAV8-Slc25a47 transduced 
mice fed high fat high sucrose (HFHS) diet for 7 weeks stained with hematoxylin and eosin 
(H&E) to visualize the tissue structure. Scale bar, 200 µm. (B) Hepatic triglyceride (TG) 
content of HFHS-fed AAV8-Empty and AAV8-Slc25a47 transduced mice. 
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Consistent with what we observed in mice fed a normal chow diet, 
mitochondrial OCR was dramatically increased in ChD-fed Slc25a47-
overexpressing livers compared to control mice (Figure V.20A). Moreover, fatty 
acid oxidation substrates in the presence of ADP were used to reveal enhanced 
fatty acid oxidation capacity in the livers where Slc25a47 was boosted (Figure 
V.20A, B), observation that coincides with the RER previously assessed (Figure 
V.19B). Consequent to enhanced mitochondrial respiration, we observed 
increased ATP levels in Slc25a47-upregulated livers (Figure V.20C). mtDNA/nDNA 
ratio exhibited increased mitochondrial content in ChD-fed Slc25a47-
overexpressing livers (Figure V.20D). Consistent with improved fatty acid 
oxidation, hepatic TG content showed a clear tendency to be decreased in 
Slc25a47-overexpressing livers (Figure V.20E).  
Taken together, these data demonstrate that SLC25A47 ameliorates 
mitochondrial function enhancing fatty acid oxidation hence reversing hepatic 
lipid accumulation associated with NAFLD. 
 
Figure V.19. Hepatic Slc25a47 overexpression increases respiratory exchange ratio and 
shifts fuel utilization. 
(A) Scheme demonstrating experimental design for AAV8-Empty and AAV8-Slc25a47 in vivo 
transduction in mice fed choline-deficient diet (ChD) for 4 weeks. (B) Respiratory exchange 
ratio (RER) measured through indirect calorimetry (24h) in ChD-fed AAV8-Empty and AAV8-
Slc25a47 transduced mice one week before sacrifice. (C) Slc25a47 gene expression in ChD-
fed AAV8-Empty and AAV8-Slc25a47 transduced livers. (D) Food intake per day of ChD-fed 
AAV8-Empty and AAV8-Slc25a47 transduced mice. (E, F) Body weight (E) and liver and 
epididymal white adipose tissue (eWAT) mass (F) in ChD-fed AAV8-Empty and AAV8-Slc25a47 
transduced mice. (G, H) Plasma triglyceride (TG, G) and free fatty acids (FFA, H) content in 
ChD-fed AAV8-Empty and AAV8-Slc25a47 transduced mice. §adjusted p-value<0.05, relative to 
the night period. 
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V. 3   Discussion 
Hepatic LRH-1 is an established transcriptional regulator of glucose, 
cholesterol and bile acid metabolism (104, 155-157, 169). Here, we report that 
LRH-1 regulates liver lipid metabolism during the fasted state. Loss of LRH-1 in 
hepatocytes impairs mitochondrial fatty acid oxidation eliciting fasting-induced 
steatosis. Furthermore, we identified a mitochondrial carrier SLC25A47 as a 
direct target of LRH-1. More importantly, reconstitution of SLC25A47 in the livers 
of Lrh-1 hep-/- mice enhanced mitochondrial function and reversed lipid 
accumulation observed in the livers of these animals. Additionally, we identified 
this novel transporter as a liver-specific inner mitochondrial membrane carrier, 
which is upregulated during fasting and improves fatty acid oxidation. We also 
demonstrated that the unique features of SLC25A47 go well beyond its liver 
specificity. Indeed our studies revealed that SLC25A47 is endowed with a 
distinctive 3-D structure displaying a long loop in the matrix side that could be 
crucial for the modulation of the channel activity. Our work furthermore 
strengthens the putative role of SLC25A47 in NAFLD. Consistent with our 
hypothesis, the analysis of independent hepatic transcriptomics and lipidomics 
revealed that Slc25a47 is often decreased in NAFLD and positively correlates with 
Figure V.20.  Hepatic Slc25a47 enhances fatty acid oxidation in NAFLD model. 
(A) Oxygen consumption rate (OCR) of fresh liver homogenates from choline-deficient diet 
(ChD)-fed AAV8-Empty and AAV8-Slc25a47 transduced mice. Fatty acid oxidation (FAO) 
substrates (palmitoyl- and octanoyl-carnitine with malate to sustain FAO, POM) were added in 
the presence of ADP, followed by succinate (SUC) and rotenone (ROT) to achieve State3ADP
.
 
(B) Quantification of FAO-driven respiration assessed in (A). (C, D) Hepatic ATP level (C) and 
mtDNA/nDNA ratio (16S/HK2, D) of ChD-fed AAV8-Empty and AAV8-Slc25a47 transduced 
mice. (E) Hepatic triglyceride (TG) content of ChD-fed mice transduced with either AAV8-
Empty or AAV8-Slc25a47. 
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anti-NAFLD lipid biomarkers. Moreover, when exposed to steatotic diets, 
Slc25a47-overexpressing mice displayed improved mitochondrial function with 
enhanced fatty acid oxidation leading to decreased hepatic TG content (Figure 
V.21).    
The liver plays a crucial role in metabolic homeostasis meeting systemic fuel 
requirements by coordinating the synthesis, storage, breakdown, and 
redistribution of nutrients (228). The excessive accumulation of lipids in the livers 
of Lrh-1 hep-/- mice could be due to a dysregulation of one or more of these 
processes. Hepatic steatosis during a fasting condition rules out excessive TG 
from the diet delivered by chylomicrons to the liver as the main cause. 
Furthermore, our laboratory previously identified Gck as a target gene of LRH-1 
(169). As a consequence, Lrh-1 hep-/- mice display decreased DNL rates thus not 
explaining the hepatic steatosis observed. During fasting, the lack of insulin 
action promotes adipose tissue lipolysis, condition that when exacerbated is 
unequivocally linked to hepatic lipid overburden (41). However, we did not 
observe a difference in WAT mass nor in glycerol or FA released from white 
adipose tissue explants of Lrh-1 hep-/- when compared to WT littermates. Although 
the prime repressor of LRH-1, SHP, is known to affect VLDL-triglyceride secretion 
from the liver (199), we could not detect any significant difference in the level of 
plasma TG, indicating that TG are not being differently retained in the liver of 
LRH-1-deficient mice.  
In this study, we show that LRH-1 is important for proper mitochondrial 
function by regulating mitochondrial transcripts. Compromised fatty acid 
oxidation associated with mitochondrial dysfunction favors lipid accumulation. In 
addition to several proteins involved in fatty acid degradation being affected in 
Lrh-1 hep-/- livers, we detected a severe reduction in CII expression (SDHB) and 
Figure V.21. Graphical presentation showing how LRH-1 regulates Slc25a47 leading to 
normalization of lipid accumulation by enhancing the breakdown of fatty acids. 
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activity, mitochondrial complex which is especially active during fasting when 
fatty acids are the primary substrate for energy production (229). Of all the 
proteins significantly altered, SLC25A47 stood out as one of the most 
downregulated mitochondrial proteins in the liver of Lrh-1 hep-/- mice. Other 
mitochondrial carriers are known to be important for fatty acid oxidation such as 
SLC25A20 (carnitine-acyl-carnitine transferase, CACT) and SLC25A29 (CACT-like) 
(230, 231). However, besides the fact that afterwards SLC25A29 was shown not 
to have acyl-carnitine/carnitine transferase activity (232), both transporters are 
not abundantly expressed in the liver (81). Moreover, the expression of Slc25a20 
and Slc25a29 was not altered in Lrh-1 hep-/- livers.  
Still very little is known about the interactions between mitochondria and the 
cytosol. In 1965 (233, 234), pioneering studies suggested the existence of an 
ADP/ATP antiporter system embedded in the mitochondrial membrane whose 
sequence (235) and structure (221) was resolved later on. Since then, several 
other members of the SLC25 transporter family have emerged as gatekeepers of 
metabolites distribution between cellular compartments (81). SLC25 is a large 
family of nuclear-encoded mitochondrial inner membrane transporters. Out of the 
53 members, only a few of them have been identified to be located in the OMM 
(82, 83) and peroxisomes (84). Our study identified SLC25A47 as an inner 
mitochondrial membrane carrier involved in fatty acid oxidation. Slc25a47 was 
first cloned and identified in 2004 (236), being also called hepatocellular 
carcinoma-downregulated mitochondrial carrier protein (HDMCP), however, no 
studies on Slc25a47 and liver cancer were ever published. Jin et al. later reported 
two studies on Slc25a47 proposing that this carrier could have a role in hepatic 
steatosis (220, 237). However, these two studies present contradictory results, 
emphasizing the need for confirmation and further studies to support a role for 
SLC25A47 in NAFLD.  
Unfortunately, we could not rule out if the positive effect SLC25A47 has in FAO 
is due to the transport of fatty acyl-carnitines inside mitochondria for β-oxidation 
or if it is indirect through the transport of co-factors or other metabolites that 
favor FAO. The inability to reconstitute SLC25A47 in liposomes has hampered 
thorough characterization of its transport activity. Additionally, the increase in 
mitochondrial function by SLC25A47 could be accounted by a rise in 
mitochondrial content. We did observe augmented mtDNA content but the 
dynamic process of mitochondrial biogenesis is difficult to determine since it is 
usually also coordinated with the renewal of existing mitochondria through 
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mitophagy (238). Nevertheless, the beneficial influence of SLC25A47 in 
mitochondrial function was still observed in isolated mitochondria, which 
pinpoints this transporter as a potential target for drug discovery to treat/prevent 
hepatic mitochondrial disorders.  
Our results demonstrate SLC25A47 being involved in oxidative catabolism. In 
accordance to this, it was recently demonstrated that Slc25a47 is one of the main 
genes upregulated in the liver when lipolysis, fatty acid degradation and 
ketogenesis are activated by FXRα2 (239). Furthermore, single-cell RNA-seq 
performed to demonstrate the zonation of gene expression in the liver dividing 
the metabolic labor proved Slc25a47 localization in the portal node (240). The 
portal node is the most oxygenated area where enzymes for gluconeogenesis, 
ureagenesis, FAO and OXPHOS are located (240). The distinctive loop SLC25A47 
presented outside the inner membrane could provide an opportunity for PTM to 
modulate its activity. We showed that there is a consensus phosphorylation site 
for PKA within the mitochondrial loop and that forskolin (cAMP booster, activating 
PKA) further enhanced mitochondrial respiration upon Slc25a47 overexpression. 
PKA has been found in the mitochondrial matrix where it phosphorylates 
mitochondrial proteins, regulating ATP production (241).  Although PKA is a valid 
candidate for SLC25A47 activation, other PTM such as acetylation/deacetylation 
could occur. The fasting-responsive mitochondrial sirtuin 3 (SIRT3) is a vey 
interesting contender for SLC25A47 deacetylation and activation. The liver of 
mice lacking SIRT3 displays accumulation of acyl-carnitines and TG during fasting 
associated with decreased levels of fatty acid oxidation (187).  Further studies are 
needed to confirm the control over SLC25A47 activity by PKA and SIRT3. 
Our studies in isolated mitochondria also demonstrated that SLC25A47 
increases the expression and activity of mitochondrial complexes and 
supercomplexes, suggesting that this transmembrane carrier influences 
supercomplex formation. For example, SLC25A47 could interact with 
supercomplex assembly factors (78) or change mitochondrial ultrastructure 
determining cristae shape that is known to affect assembly and stability of 
supercomplexes (242). This latter could be accomplished by interaction with 
cristae-associated proteins, such as OPA-1 (242) or as a consequence of 
SLC25A47-mediated solute transport affecting membrane fluidity. Nevertheless, 
SLC25A47 beneficial effect on supercomplex assembly and activity impacts on 
the organization of electron flux between the mitochondrial complexes, 
optimizing the utilization of available substrates. Further studies using Slc25a47 
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KO mice will help to address the physiological and therapeutical role of this 
carrier.  
In this study, we described that loss of function of LRH-1 promotes the 
development of fasting-induced hepatic steatosis. On Chapter IV, we showed that 
LRH-1 selective gain-of-function favors the development of NAFLD by a different 
mechanism. This contradictory role of LRH-1 in this disorder emphasizes the 
intricacy of targeting a nuclear receptor for the treatment of complex diseases. 
Other nuclear receptors that also contribute to the development of NAFLD have 
failed to show beneficial effects without adverse effects on clinical trials (218, 
219). Therefore, the development of drugs targeting specific nuclear receptor 
targets, such as SLC25A47, might provide alternative therapeutic options for 
treating NAFLD.  
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Chapter VI   Additional results 
VI.1  High levels of Slc25a47 are associated to enhanced metabolic 
rate and decreased hepatic steatosis 
SLC25A47 is a novel mitochondrial transporter that is highly and specifically 
expressed in the liver. Although the cognate solutes are still unknown, we 
showed its function is tightly linked with mitochondrial FAO (Chapter V). While 
further attempting to characterize the physiological role, thus relevance, of 
SLC25A47 in the liver, we sought to evaluate its liver expression profile in 
different publically available datasets in GEO. We found four different datasets 
were Slc25a47 was significantly changed as depicted in Figure VI.1. 
Stearoyl-CoA desaturase (SCD-1) is a key lipogenic enzyme that is responsible 
for the synthesis of monounsaturated fatty acids, lack of which was reported to 
protect mice from obesity through enhanced oxygen consumption and energy 
expenditure. In SCD-1 KO mice, lipid oxidation genes are upregulated while other 
lipid synthesis genes are downregulated (243). Ki-ras-induced actin-interacting 
protein (KRAP) is a protein associated with the cytoskeleton that was described as 
being related to cancer. Mice lacking KRAP displayed enhanced metabolic rate 
Figure VI.1 Slc25a47 expression profiles show a beneficial role of this transporter for 
liver function. 
Slc25a47 expression profiles as obtained from stearoyl-CoA desaturase-1 (SCD-1) (243), ki-
ras-induced-induced actin-interacting protein (KRAP) (244), hepatocyte nuclear factor-4 (HNF4) 
(245) and steroid receptor coactivator-2 (SRC-2) (246) knockout (KO) liver transcriptomes.   
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and decreased adiposity paralleled by a downregulation of fatty acid synthesis 
genes in the liver (244). In both models, Slc25a47 expression levels are 
heightened. On the other hand, hepatocyte nuclear factor-4 (HNF4) steroid 
receptor coactivator-2 (SRC-2) KO mice present low levels of hepatic Slc25a47. 
SRC-2 stimulates liver fatty acid degradation and down-regulates cholesterol and 
steroid biosynthetic pathways (246). HNF-4 is a crucial hepatic transcription 
factor responsible for liver identity by orchestrating the hepatocyte gene 
expression program (245). HNF4 alpha liver-specific KO mice display severe 
hepatomegaly and hepatic steatosis (247). Taken together, the expression 
profiles where Slc25a47 is significantly changed point to a beneficial role of this 
mitochondrial carrier in the liver. 
Together these data corroborate the results presented on Chapter V indicating 
that Slc25a47 is a hepatocyte marker with a vital role in maintaining proper liver 
function, loss of which is related to hepatic steatosis.    
 
VI.2 SLC25A47 as the hepatocellular carcinoma-downregulated 
mitochondrial protein (HDMCP) 
 The data obtained so far have demonstrated SLC25A47 as important for 
proper liver function. Further proof of that is the fact that SLC25A47 is 
downregulated in liver cancer (hepatocellular carcinoma, HCC). For this reason, 
the name hepatocellular carcinoma downregulated carrier protein (HDMCP) has 
been proposed for this transporter, however no publication corroborates this 
information. To determine the validity of this nomination and to gain further 
insight into the vital role of this transporter, we decided to use datasets of HCC in 
humans to evaluate Slc25a47 expression profile (248). As the liver loses its 
characteristic morphology and progresses through the pathological stages of 
HCC, Slc25a47 expression levels are decreasing, being practically lost in 
advanced HCC (Figure VI.2A, B). This observation validates our previous 
hypothesis that SLC25A47 is a marker of normal liver. Moreover, these results 
show that hepatitis C virus (HCV)-induced HCC presents the same Slc25a47 
repression pattern derived from HCC from the metabolic disturbances associated 
with NAFLD progression (Figure VI.2B). 
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Using the dataset of HCV-induced HCC where Slc25a47 declines as disease 
progresses, we next assessed hepatic gene expression and pathway analysis of 
genes with the same or opposite profile as Slc25a47. In line with our previous 
analysis (Figure V.13), Slc25a47 positively correlates with genes involved in fatty 
acid degradation (Figure VI.3A), presenting the same pattern of downregulation 
as fatty acid degradation enzymes (Figure VI.3B). Indicative of a possible tumor 
suppressor role of SLC25A47 that is consistent with its downregulation in liver 
cancer, Slc25a47 correlated negatively with genes involved in cell cycle and DNA 
replication, common features of cancer cells (Figure VI.3C).  
It is known that cancer cells rely more on glycolysis to obtain energy with 
concomitant lactate production (249). Therefore it is expected that fatty acid 
degradation is one of the metabolic pathways repressed as HCC becomes more 
aggressive. Taken together these data confirm that SLC25A47 is critical for liver 
function and identity, and its loss is associated with hepatocellular carcinoma. 
 
 
Figure VI.2 Slc25a47 is downregulated in hepatocellular carcinoma (HCC) in an increasing 
severity manner. 
(A) Hepatic SLC25A47 gene expression profile in HCC-patients, GSE45436, Wang et al, 
unpublished data. (B) Hepatic SLC25A47 gene expression profile of hepatitis C-infected 
patients representing the stepwise carcinogenic process from preneoplastic lesions (cirrhotic 
and dysplasia) to advanced HCC, GSE6764 (248). 
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Figure VI.3 Slc25a47 correlates positively with fatty acid degradation enzymes in 
hepatocellular carcinoma (HCC). 
(A, C) KEGG pathway analysis of positive (A) and negative (C) correlating genes with Slc25a47. 
In B, a heat map displays the fatty acid degradation enzymes that correlate positively with 
Slc25a47 and present a similar pattern of expression upon progression of HCC. 
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Chapter VII   General conclusion and future perspectives 
 
The work presented here intended to establish the role of LRH-1 in fatty acid 
metabolism and NAFLD. To achieve this, we characterized the metabolic 
phenotype of both loss-of-function (Lrh-1 hep-/-) and gain-of-function (K289R) of 
LRH-1 upon different nutritional challenges or in the context of a setting that 
favors the development of hepatic steatosis.  During the transition of the fasted 
to the fed state, the rise in blood glucose triggers insulin secretion and activates 
DNL in the liver. Upon fasting, the shift from insulin to glucagon triggers robust 
changes in hepatic metabolism, being the most prominent effect increased fatty 
acid delivery to the liver and enhanced mitochondrial fatty acid breakdown. In 
turn, a dysregulation of any of these processes can contribute to fat deposition 
within the liver. Here we showed that LRH-1 regulates multiple aspects of hepatic 
lipid homeostasis. In particular, we demonstrated that, upon refeeding, LRH-1 
selective gain-of-function presented enhanced DNL rates. Consequently, under a 
lipogenic diet, LRH-1 K289R developed a more severe NAFLD phenotype. 
Moreover, loss of LRH-1 in the hepatocytes impaired mitochondrial fatty acid 
oxidation leading to exacerbated fasting-induced steatosis.  
In this thesis, we also identified two novel proteins to counteract NAFLD, i.e. 
OSBPL3 and SLC25A47, and identified these as direct transcriptional targets of 
LRH-1. Most notably, these two proteins behave differently, playing a diverse role 
in NAFLD. OSBPL3, which is upregulated in LRH-1 K289R mice, is also a constant 
elevated presence in the liver of mouse and humans with NAFLD. A normal liver 
represses the expression of this oxysterol-binding protein, which hints at the fact 
that an abnormal overexpression of this protein is deleterious for liver function. 
On the other hand, SLC25A47 is highly and only expressed in the liver, which 
highlights its importance and possible therapeutic relevance for treating liver 
diseases. In accordance, this transporter is downregulated in Lrh-1 hep-/- mice and 
in mouse models of NAFLD and its upregulation protects from the overload of 
lipids in the liver. The analysis of available datasets further emphasized the 
beneficial role of SLC25A47 in the liver. Additionally, we demonstrated how the 
loss of SLC25A47 relates significantly with the loss of liver morphology and 
function towards a tumorigenic state as in HCC. More importantly, we showed 
that overexpressing SLC25A47 in the liver improved mitochondrial function 
without causing any adverse and systemic effects. The development of 
compounds to target OSBPL3 and SLC25A47 will help determine the druggability 
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of these proteins and protection against this so common but so far not treatable 
disease. 
Currently, we are conducting additional studies to determine the physiological 
role of SLC25A47 by using the liver-specific knockout mouse model (Slc25a47 hep-/- 
mice). Transcriptomics, proteomics and metabolomics will be used to fully 
characterize both loss- (Slc25a47 hep-/-) and gain-of-function (AAV8-Slc25a47) of 
SLC25A47. Further studies will also help to unravel the regulation of SLC25A47 
activity by PKA and SIRT3. 
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“A single experiment can prove me wrong“ 
Albert Einstein 
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Introduction
Hepatic steatosis is characterized by the excessive accumulation 
of triglycerides as a consequence of an imbalance between the 
acquisition and disposal of fatty acids. Increased hepatic uptake of 
adipose tissue–derived fatty acids, defective breakdown via β-oxi-
dation, reduced VLDL-triglyceride secretion, and induced activity 
of master regulators of de novo lipogenesis, such as sterol element 
binding protein 1 (SREBP-1, encoded by Srebf1), are factors that 
contribute to the development of steatosis (1). Nonalcoholic fatty 
liver disease (NAFLD) comprises a spectrum of disorders, of which 
the earliest stage is characterized by the deposition of lipid drop-
lets within the cytoplasm of the hepatocytes. NAFLD increases the 
susceptibility to hepatocyte damage and inflammation, a condition 
termed nonalcoholic steatohepatitis (NASH), and can ultimately 
progress to cirrhosis and hepatocellular carcinoma (HCC) (1–4).
Liver receptor homolog 1 (LRH-1) is a nuclear receptor with 
diverse biological functions ranging from cell cycle regulation to 
the control of steroid homeostasis. In the liver, LRH-1 is an import-
ant regulator of glucose, cholesterol, and bile acid metabolism (5). 
Liver-specific Lrh-1 knockout mice display reduced glycolytic flux 
and de novo lipogenesis secondary to impaired glucokinase activity 
(6). On the other hand, treatment of mice with the LRH-1 agonist 
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) protects ani-
mals from developing NAFLD and insulin resistance in genetic and 
dietary models of diabesity (7, 8). To address this apparent contra-
dictory role of LRH-1 in hepatic triglyceride metabolism, we chose 
to study lipogenesis in our recently described Lrh-1 K289R knockin 
mouse model (LRH-1 K289R mice), which displays selective gain of 
function of LRH-1 as a result of impaired SUMOylation at K289 (9).
In this study, we demonstrate that LRH-1 K289R induces the 
expression of oxysterol binding protein-like 3 (OSBPL3, encoded by 
Osbpl3, also known as Orp3), which in turn promotes the posttrans-
lational activation of SREBP-1. As a consequence, LRH-1 K289R 
mice display increased de novo lipogenesis upon refeeding in com-
parison with WT mice. In fact, compared with what is seen in LRH-1 
WT mice, this chronic lipogenic stress promotes NAFLD in LRH-1 
K289R mice accompanied by early signs of NASH when mice are 
exposed to a lipogenic, high-fat, high-sucrose (HFHS) diet.
Results
Increased hepatic SREBP-1 processing in LRH-1 K289R mice. In order 
to evaluate the role of an LRH-1 SUMO–defective pathway on 
intermediary liver metabolism, we subjected LRH-1 K289R mice, 
which exhibit partial gain of function of LRH-1, and control LRH-1 
WT mice (9) to fasting-refeeding challenges in which mice were 
fasted and then refed for a period of 6 hours. We then evaluated 
the expression of metabolic genes in refed livers of both geno-
types using microarray analysis. Interestingly, the expression of 
Hepatic steatosis is caused by metabolic imbalances that could be explained in part by an increase in de novo lipogenesis 
that results from increased sterol element binding protein 1 (SREBP-1) activity. The nuclear receptor liver receptor homolog 
1 (LRH-1) is an important regulator of intermediary metabolism in the liver, but its role in regulating lipogenesis is not well 
understood. Here, we have assessed the contribution of LRH-1 SUMOylation to the development of nonalcoholic fatty liver 
disease (NAFLD). Mice expressing a SUMOylation-defective mutant of LRH-1 (LRH-1 K289R mice) developed NAFLD and 
early signs of nonalcoholic steatohepatitis (NASH) when challenged with a lipogenic, high-fat, high-sucrose diet. Moreover, 
we observed that the LRH-1 K289R mutation induced the expression of oxysterol binding protein-like 3 (OSBPL3), enhanced 
SREBP-1 processing, and promoted de novo lipogenesis. Mechanistically, we demonstrated that ectopic expression of OSBPL3 
facilitates SREBP-1 processing in WT mice, while silencing hepatic Osbpl3 reverses the lipogenic phenotype of LRH-1 K289R 
mice. These findings suggest that compromised SUMOylation of LRH-1 promotes the development of NAFLD under lipogenic 
conditions through regulation of OSBPL3.
Impaired SUMOylation of nuclear receptor LRH-1 
promotes nonalcoholic fatty liver disease
Sokrates Stein,1,2 Vera Lemos,1,3 Pan Xu,1 Hadrien Demagny,1 Xu Wang,4 Dongryeol Ryu,4 Veronica Jimenez,5 Fatima Bosch,5 
Thomas F. Lüscher,2 Maaike H. Oosterveer,6 and Kristina Schoonjans1
1Laboratory of Metabolic Signaling, Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. 2Center for Molecular Cardiology, University  
of Zurich, Zurich, Switzerland. 3Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal. 4Laboratory of Integrative and Systems Physiology, Institute of Bioengineering, School of Life 
Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. 5Center of Animal Biotechnology and Gene Therapy and Department of Biochemistry and Molecular Biology, School of Veterinary 
Medicine, Universitat Autònoma de Barcelona, Bellaterra, and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.  
6Department of Pediatrics, Center for Liver Digestive and Metabolic Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Authorship note: S. Stein and V. Lemos contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Submitted: November 11, 2015; Accepted: November 22, 2016.
Reference information: J Clin Invest.  
https://doi.org/10.1172/JCI85499.
Downloaded from http://www.jci.org on January 18, 2017.   https://doi.org/10.1172/JCI85499
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 jci.org
mental Figure 1, A and B; supplemental material available online 
with this article; https://doi.org/10.1172/JCI85499DS1) (10, 11), 
in LRH-1 K289R versus LRH-1 WT livers. Similarly, we did not 
observe differences in Srebf1a and Srebf1c expression in 2-, 6-, or 
12-hour–refed LRH-1 K289R and LRH-1 WT mice (Supplemental 
Figure 1C). Taken together, these data suggest that LRH-1 K289R 
induces SREBP-1 signaling primarily at the posttranscriptional 
level independently of early insulin-AKT signaling.
Enhanced de novo lipogenesis in LRH-1 K289R mice. To verify 
whether the increased expression of lipogenic genes is accompa-
nied by hepatic fat accumulation, we next quantified hepatic tri-
glyceride content in LRH-1 K289R and LRH-1 WT mice. The con-
tent of neutral lipids and triglycerides was significantly increased 
in LRH-1 K289R compared with LRH-1 WT livers upon refeeding 
(Figure 1, D and E). Of note, plasma triglycerides and free fatty 
many SREBP-1 target genes was increased in 6-hour–refed LRH-1 
K289R compared with LRH-1 WT livers, whereas SREBP-2 targets 
were not altered (Figure 1A). Although no changes in Srebf1 mRNA 
(Figure 1B) or uncleaved precursor SREBP-1 (Figure 1C) could 
be observed between both genotypes, refed LRH-1 K289R livers 
displayed significantly more of the cleaved and transcriptionally 
active SREBP-1 protein in comparison with the LRH-1 WT livers 
(Figure 1C), indicating that the posttranslational processing and 
maturation of SREBP-1 is increased in LRH-1 K289R mice. We 
then performed acute insulin challenges as well as shorter 2-hour 
refeeding experiments to analyze whether early signaling events 
could explain the increased SREBP-1 activity. Insulin did not 
induce an additional increase in AKT phosphorylation or a con-
sistent induction of early response genes, such as activating tran-
scription factor 3 (Atf3) or early growth response 1 (Egr1) (Supple-
Figure 1. LRH-1 K289R mice display increased de novo lipogenesis. (A) Heat map showing the expression of genes involved in de novo fatty acid and cho-
lesterol synthesis in refed WT and K289R mice. Normalized expression values are in log2 scale. SREBP-1, depicting mainly SREBP-1 target genes; SREBP-2, 
mostly SREBP-2 target genes; NS, transcripts that are not significantly changed between the indicated genotypes. For all other transcripts P < 0.05. (B) 
Hepatic mRNA expression of Srebf1 in K289R and WT mice. n = 10 per genotype. (C) Left, immunoblots of precursor and cleaved (cl) SREBP-1, SCD1, HSP90, 
and P62 in hepatic lysates of WT or K289R livers. Right, graph displaying the ratio of cleaved to precursor SREBP-1. (D) Representative images of liver 
sections of K289R or WT mice stained with oil red O to visualize neutral lipids. Scale bar: 200 μm. (E) Quantification of hepatic triglyceride content in WT 
and K289R mice. n = 10 per group. (F and G) Plasma triglyceride (TG) and free fatty acid (FFA) contents in WT and K289R mice. n = 10 per group. (H–J)  
Fractional de novo synthesis rates of palmitate (H), stearate (I), and oleate (J) in WT and K289R mice. n = 6 per group. Error bars represent mean ± SEM.  
*P < 0.05, **P < 0.01 relative to WT within each nutritional state; §P < 0.001 refed relative to fasted mice, as determined by unpaired Student’s t test (A) 
or 2-way ANOVA with Bonferroni’s post-hoc test (B, C, E–J). WT, LRH-1 WT; K289R, LRH-1 K289R mice.
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recently implicated in the shuttling of lipids between the plasma 
and endoplasmic reticulum membrane (12–14). The expression of 
Osbpl3, and to a lesser extent Osbpl1a, was robustly induced in LRH-1 
K289R livers, while that of most other OSBP family members did 
not differ between the 2 genotypes (Figure 2A). Of interest, overex-
pression of certain oxysterol-binding proteins has been suggested as 
increasing SREBP-1 processing and hepatic lipogenesis (15). Analy-
sis of livers of LRH-1 K289R versus LRH-1 WT mice confirmed the 
enhanced expression of Osbpl3 mRNA during fasting and refeeding 
(Figure 2B), while the expression of other OSBP family members 
did not differ between the 2 genotypes (Supplemental Figure 2A). 
Notably, the expression of Osbpl3 was high during fasting and then 
reduced upon refeeding (Figure 2B). This postprandial suppression 
of Osbpl3 mRNA expression was also observed upon overexpres-
sion of Osbpl3 in mice using an adenovirus (Supplemental Figure 
2B), suggesting that during the refed state, Osbpl3 is regulated by 
posttranscriptional mechanisms occurring independently of LRH-1. 
Despite this feeding-dependent regulation of the mRNA, hepatic 
Osbpl3 mRNA levels were consistently higher in the LRH-1 K289R 
acids did not show significant alterations between LRH-1 K289R 
and LRH-1 WT mice (Figure 1, F and G). To verify whether the 
enhanced expression of lipogenic genes translates into increased 
de novo lipogenesis, animals received 13C-acetate prior to sacri-
fice to quantify de novo lipogenesis (6). In line with the increased 
lipogenic gene expression, de novo synthesis of palmitate (C16:0), 
stearate (C18:0), and oleate (C18:1) was significantly higher in 
LRH-1 K289R compared with LRH-1 WT livers (Figure 1, H–J). Of 
note, chain elongation of preexisting fatty acids was not altered 
between the 2 genotypes (Supplemental Figure 1, D and E). Collec-
tively, these data show that LRH-1 K289R mice display increased 
de novo lipogenesis and that enhanced activation of SREBP-1 like-
ly contributes to this process.
SUMOylation-defective LRH-1 drives the expression of Osbpl3. We 
next analyzed the transcriptome of livers from refed LRH-1 K289R 
and LRH-1 WT mice and searched for transcripts that are linked to 
SREBP-1 processing. One of the top hits on the list of genes that was 
increased in LRH-1 K289R compared with LRH-1 WT livers cor-
responded to Osbpl3, a member of a class of lipid transfer proteins 
Figure 2. Osbpl3 is a direct LRH-1 target gene and overexpressed in LRH-1 K289R mice. (A) Heat map showing the hepatic expression of oxysterol-binding 
protein family members in WT and K289R mice. Normalized expression values are in log2 scale. (B and C) Expression of Osbpl3 mRNA in hepatic lysates 
of fasted and refed WT and K289R mice (B) and the fold change between the genotypes (C). n = 4 per fasted, 2-hour–, or 12-hour–refed groups, and n = 5 
per 6-hour–refed groups. (D) Expression levels of OSBPL3 protein in hepatic lysates of fasted and refed WT and K289R mice. (E) Schematic showing the 
genomic area containing the Osbpl3 gene and the sites used for ChIP-qPCR experiments (mouse genome assembly mm10). (F and G) Binding of LRH-1 to 
the different Osbpl3 promoter sites assessed by ChIP analysis using genomic DNA from fasted WT (F) and refed WT livers (G). n = 5 WT fasted, n = 5 WT 
refed. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, §P = 2 × 10–7 relative to WT, as determined by unpaired Student’s t test (A), or 
1-way (C) or 2-way (B, F, G) ANOVA with Bonferroni post-hoc test. TSS, transcription start site.
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LRH-1 target genes, including lipogenic genes, are coregulated by 
members of the LXR subfamily (20–22), we assessed the possibil-
ity that the LRH-1 mutant may modulate the recruitment of LXRα 
to its target genes, Abca1, Chrebp, and Srebf1. Although recruit-
ment of LXRα was detected on these promoters in the genom-
ic lysates of LRH-1 K289R and LRH-1 WT livers, no differences 
were observed between both genotypes, suggesting that LXRα 
binding is not altered due to the LRH-1 K289R mutation (Sup-
plemental Figure 3A). Furthermore, Hepa 1.6 and AML-12 cells 
treated with the LXR agonist GW3965 did not alter Osbpl3 expres-
sion (Supplemental Figure 3, B and C), indicating that Osbpl3 
expression is not regulated by LXR.
Osbpl3 silencing rescues the steatotic phenotype of LRH-1 K289R 
mice. To establish whether the increased expression of OSBPL3 in 
LRH-1 K289R livers is causatively linked to exacerbated de novo 
lipogenesis, we performed in vivo overexpression and silencing 
experiments. Adenoviral overexpression of OSBPL3 increased 
mice in all nutritional states, but were particularly high under 
6-hour–refeeding conditions (Figure 2C), and these differences 
were translated into similar changes at the protein level (Figure 2D).
To investigate whether Osbpl3 is directly controlled by LRH-1, 
we first analyzed the Osbpl3 genomic region in available ChIP-Seq 
data for potential LRH-1–binding sites (16, 17). We identified 3 
main sites from the ChIP-Seq data from Holmstrom et al. (sites 1–3; 
ref. 16), and 3 additional sites with an LRH-1 consensus sequence 
close to one of the transcription start sites of the Osbpl3 gene (sites 
4–6) were identified by computational analysis (Figure 2E). We 
then performed site-specific ChIP analysis to evaluate whether 
these sites are bound by LRH-1 in fasted and refed mice. LRH-1 was 
recruited at different sites under both nutritional conditions (Fig-
ure 2, F and G), suggesting that Osbpl3 is a direct LRH-1 target gene.
Based on the fact that LRH-1 and the nuclear receptor liver X 
receptor (LXR) have been shown to crosstalk in the regulation of 
hepatic acute-phase response proteins (18, 19) and that various 
Figure 3. Osbpl3 silencing rescues the lipogenic phenotype of LRH-1 K289R mice. (A) Immunoblots of OSBPL3, HSP90, precursor and cleaved SREBP-1, 
P62, and HDAC3 in hepatic lysates of fasted or refed WT plus Ad-GFP or refed WT plus Ad-OSBPL3 livers. (B–D) Hepatic mRNA expression of Osbpl3 (B), 
Srebf1 (C), and Fasn (D) in refed K289R and WT mice. WT, n = 3; K289R siScr or K289R siOsbpl3, n = 9 per genotype. (E) Immunoblots of OSBPL3, FASN, 
β-actin, precursor and cleaved SREBP-1, and PARP1 in hepatic lysates of refed K289R siScr or K289R siOsbpl3 livers. (F) Hepatic expression of OSBPL3, 
FASN, SCD1, and HSP90 in livers of ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. (G) Hepatic mRNA expression of genes involved in de novo 
lipogenesis in ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. n = 3 per genotype. (H) Quantification of hepatic triglycerides in hepatic lipid 
extracts from ad libitum–fed WT, K289R siScr, and K289R siOsbpl3 mice. n = 3 per genotype. (I and J) Hepatic mRNA expression of Osbpl3 (I) and Fasn 
(J) in 6-hour–refed WT, K289R, or K289R mirOsbpl3 mice. n = 3 per genotype. (K) Representative oil red O staining in liver cryosections from refed K289R 
mirScrambled or K289R mirOsbpl3 mice. Scale bars: 100 μm. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 relative to K289R siScr, 
as determined by 1-way ANOVA with Bonferroni’s post-hoc test (B–D, G–J). WT, LRH-1 WT; K289R siOsbpl3, LRH-1 K289R mice injected with Osbpl3- 
siRNA complexes; K289R siScr, LRH-1 K289R mice injected with scrambled-siRNA complexes; K289R mirOsbpl3, LRH-1 K289R mice injected with AAV8 
viral vectors containing an miRNA targeting Osbpl3.
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expression levels of the lipogenic enzymes acetyl–coenzyme A 
carboxylase alpha (Acaca), Fasn, Scd1, and glycerol-3-phosphate 
acyltransferase (Gpam) were often normalized to values observed 
in LRH-1 WT mice (Figure 3G), suggesting that Osbpl3 silencing 
rescues the lipogenic phenotype of LRH-1 K289R mice. In line 
with the reduced expression of lipogenic genes, Osbpl3 silencing 
also decreased hepatic triglyceride and neutral lipid content (Fig-
ure 3H). As an additional approach to silence Osbpl3, we injected 
mice with an AAV8 viral vector containing an miRNA targeting 
Osbpl3 in the liver. Here again, we observed a robust silencing of 
Osbpl3, which was accompanied by the suppression of Fasn and a 
striking reduction of hepatic lipid droplets (Figure 3, I–K).
Finally, we also examined whether other mechanisms, direct-
ly or indirectly regulated by LRH-1, may contribute to the lipo-
genic phenotype. Of interest, both hepatic glucose-6-phosphate 
content (6) and VLDL secretion (23) were unchanged between 
SREBP-1 cleavage in refed LRH-1 WT mice (Figure 3A), suggest-
ing that elevated OSBPL3 levels promote SREBP-1 activation. We 
next silenced Osbpl3 in LRH-1 K289R mice using siRNAs in LRH-1 
K289R mice under fast-refeeding conditions. The hepatic mRNA 
expression of Osbpl3 showed a clear trend of effective silencing 
(Figure 3B), while Srebf1 expression was not altered (Figure 3C). 
Importantly, we observed a robust decrease in OSBPL3 protein 
along with a reduction in the maturation of SREBP-1 and a blunted 
expression of the fatty acid synthase (FASN) transcript and pro-
tein in the livers of refed LRH-1 K289R mice treated with siOsbpl3 
(Figure 3, D and E). We next assessed the effect of Osbpl3 silenc-
ing under normal-fed conditions. Western blot analysis revealed 
reduced OSBPL3 expression (Figure 3F) and a robust decrease in 
the lipogenic proteins FASN and stearoyl–coenzyme A desaturase 
1 (SCD-1) in ad libitum–fed LRH-1 K289R mice treated with siOsb-
pl3 compared with control mice (Figure 3F). Of interest, mRNA 
Figure 4. LRH-1 K289R mice develop NAFLD upon HFHS diet feeding. (A) Representative images of liver sections of K289R or WT mice stained with 
H&E or oil red O to visualize the tissue structure and neutral lipids, respectively. Black scale bar: 200 μm; white scale bar: 50 μm. (B and C) Quantification 
of triglyceride content in plasma (B) and in hepatic lipid extracts (C) in WT and K289R mice. WT, n = 7; K289R, n = 10. (D and E) Plasma levels of ALAT (D) 
and ASAT (E) in mice fed a HFHS diet. WT, n = 7; K289R, n = 10. (F and G) Expression of Osbpl3 mRNA (F) and protein (G) levels in livers of WT and K289R 
mice fed chow and HFHS diets. n = 9 per genotype. (H) Heat map displaying the expression of Osbpl3 as well as markers of matrix degradation, fibrosis, 
and inflammation in mice that were classified as LFL responders, LFH responders, HFL responders, and HFH responders according to the development 
of NAFLD/NASH upon chow or high-fat diet feedin g (24). (I) Expression of OSBPL3 and markers of matrix degradation, fibrosis, and inflammation in 
transcriptomic data from human patients that were categorized for mild or advanced NAFLD (25). Normalized expression values are in log2 scale. Error bars 
represent mean ± SEM. **P < 0.01, ***P < 0.001 relative to WT; §P < 0.001 refed relative to fasted mice, as determined by unpaired Student’s t test (B, D, 
E) or 2-way ANOVA with Bonferroni’s post-hoc test (C, F).
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LRH-1 K289R and LRH-1 WT mice (Supplemental Figure 4, A–C), 
making it unlikely that these processes account for the exacerbat-
ed lipid accumulation in liver.
Together, these data suggest that the LRH-1-OSBPL3 signal-
ing axis contributes to the increased maturation of SREBP-1, the 
induction of lipogenic enzymes, and the hepatic accumulation of 
triglycerides observed in LRH-1 K289R mice.
LRH-1 K289R mice are prone to developing NAFLD upon lipo-
genic diet feeding. Excessive de novo lipogenesis contributes to the 
development of NAFLD, a condition that can eventually progress 
to NASH (1, 3). In order to investigate whether LRH-1 affects the 
development of NAFLD, LRH-1 K289R and LRH-1 WT mice were 
fed a highly lipogenic HFHS diet or a chow diet for 17 weeks, and 
then sacrificed under normal-fed conditions. Stainings of hepatic 
sections with H&E and oil red O revealed that LRH-1 K289R mice 
developed a stronger steatotic phenotype compared with LRH-1 
WT mice fed a HFHS diet (Figure 4A). While plasma cholester-
ol levels were unchanged (Supplemental Figure 5A), triglyceride 
content in plasma (Figure 4B) or in VLDL fractions (Supplemen-
tal Figure 5B) was reduced in HFHS-fed LRH-1 K289R mice. This 
reduction was accompanied with a robust accumulation of hepatic 
triglycerides (Figure 4C) as well as an induction of plasma levels of 
the enzymes alanine transaminase (ALAT) and aspartate amino-
transferase (ASAT) in the HFHS-challenged LRH-1 K289R mice 
(Figure 4, D and E). Similar to our earlier observations in normal 
chow diet conditions (Figure 2, A–D), Osbpl3 mRNA and OSBPL3 
protein were significantly induced in LRH-1 K289R compared 
with LRH-1 WT mice fed a HFHS diet (Figure 4, F and G), while 
the expression of other Osbp genes did not differ between the gen-
otypes (Supplemental Figure 5C).
The development of hepatic steatosis in mice is known to be 
highly heterogeneous (24). Therefore, we analyzed the data from a 
study in which mice were fed a chow or high-fat diet and then clas-
sified according to the development of NAFLD/NASH into low-
fat low (LFL) responders, low-fat high (LFH) responders, high-fat 
low (HFL) responders, and high-fat high (HFH) responders (24). 
Interestingly, the expression of Osbpl3 was significantly induced 
in the HFH responders along with markers of inflammation and 
Figure 5. LRH-1 K289R mice display increased inflammation and early signs of fibrosis upon HFHS diet feeding. (A) Representative images of liver 
sections of K289R or WT mice stained with sirius red or CD45 to visualize collagen depositions and CD45-positive cells, respectively. Scale bars: 200 μm. CV, 
central vein. (B–E) Hepatic mRNA expression of genes involved in inflammation (B), matrix degradation (C), fibrosis (D), and stellate cells (E) in K289R and 
WT mice. n = 9 per genotype. (F) Graphical presentation showing how the LRH-1/OSBPL3 axis drives the accumulation of hepatic lipids. Error bars represent 
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 relative to WT within each diet, as determined by 2-way ANOVA with Bonferroni’s post-hoc test (B–E).
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necrosis (Figure 4H) and was by far the most strikingly increased 
Osbp among all family members (Supplemental Figure 5D). We 
also analyzed OSBPL3 expression in 2 cohorts of NAFLD/NASH 
patients. In the first cohort, livers were categorized as showing 
mild or advanced NAFLD (25). In the second study, subjects had 
livers ranging from healthy controls to showing steatosis and fur-
ther to NASH (26). OSBPL3 expression was low in healthy livers, 
but increased in advanced stages of NAFLD/NASH and clustered 
with markers of fibrosis (Figure 4I and Supplemental Figure 6), 
suggesting that OSBPL3 could be a novel biomarker for advanced 
liver diseases, such as NASH. Taken together, these data show that 
Osbpl3 is markedly increased in LRH-1 K289R mice as well as in 
mice and humans with NAFLD/NASH.
LRH-1 K289R mice display increased inflammation and early 
signs of fibrosis in response to lipogenic diet feeding. Given the strong 
steatotic phenotype and the high levels of ALAT and ASAT mark-
ers in LRH-1 K289R mice fed a HFHS diet as well as the cluster-
ing of Osbpl3 with genes involved in inflammation and fibrosis 
in mice and humans with NAFLD, we next analyzed inflamma-
tory and fibrotic markers in LRH-1 K289R and LRH-1 WT mice. 
Stainings of hepatic sections with sirius red and CD45 revealed 
that, in contrast with LRH-1 WT mice, LRH-1 K289R mice devel-
oped small fibrotic lesions and accumulated CD45-positive 
immune cells upon HFHS feeding (Figure 5A). Moreover, LRH-1 
K289R livers displayed higher levels of the inflammatory genes 
Tnfα, monocyte chemoattractant protein-1 (Mcp1 or Ccl2), and 
macrophage inflammatory protein-1 α (Mip1α or Ccl3) (Figure 
5B), indicating increased inflammation in livers of HFHS-fed 
LRH-1 K289R mice. The expression of MMPs, such as Mmp2 
and Mmp13, as well as early markers of fibrosis, such as α-1 type I 
collagen (Col1a1) and Tgfb1, was also elevated in LRH-1 K289R 
in comparison with LRH-1 WT mice fed a HFHS diet (Figure 5, 
C and D). Hepatic stellate cells are the primary hepatic cell type 
promoting fibrogenesis (27). The expression of different hepatic 
stellate cell markers, such as desmin (Des), glial fibrillary acidic 
protein (Gfap), and reelin (Reln), was also increased in HFHS-
fed LRH-1 K289R compared with LRH-1 WT mice (Figure 5E), 
suggesting that HFHS-treated LRH-1 K289R mice exhibit early 
signs of NASH.
Previous studies showed that LRH-1 and the SUMOylation 
machinery might affect the hepatic acute phase response (APR) 
(18, 19, 28). While induction of the APR by short exposure of LPS 
led to reduced hepatic expression of Crp and Tnf in LRH-1 K289R 
compared with LRH-1 WT mice, it did not alter the hepatic expres-
sion of other APR and inflammatory genes (Supplemental Figure 
7A). Moreover, no difference in plasma IL-6, MCP-1 (also known 
as CCL-2), or TNF-α could be observed in LPS-challenged LRH-1 
K289R and LRH-1 WT mice (Supplemental Figure 7B), suggesting 
that the APR is likely not driving the observed inflammatory phe-
notype in our NAFLD-model.
Taken together, these data show that SUMOylation-defective 
LRH-1 promotes the development of NAFLD and displays early 
signs of NASH in mice fed a HFHS diet. This process is at least 
partially driven by the LRH-1-OSBPL3 signaling axis, which con-
tributes to increased maturation of SREBP-1, the induction of lipo-
genic enzyme expression, and hepatic triglyceride accumulation 
in LRH-1 K289R mice (Figure 5F).
Discussion
In this study, we analyzed the contribution of a selective LRH-1 
gain of function on hepatic de novo lipogenesis and fatty liver 
development and identified Osbpl3 as a critical component in the 
regulation of this process. While the hepatic expression of Osbpl3 is 
normally low in mice under basal conditions, LRH-1 K289R mice 
express high levels of this specific OSBP family member. Consis-
tent with our observations, the analyses of independent mouse 
and human transcriptomic data sets revealed that Osbpl3 expres-
sion is often induced in NAFLD/NASH. Our work furthermore 
strengthens the putative role of OSBPL3 in SREBP-1 maturation. 
As a consequence, LRH-1 K289R mice display increased de novo 
lipogenesis and accumulation of triglycerides upon refeeding 
in a manner that is independent of enhanced LXRα recruitment 
or activity. Importantly, silencing of OSBPL3 in vivo reverts the 
increased lipogenesis observed in these animals. Moreover, when 
exposed to a lipogenic HFHS diet, LRH-1 K289R mice develop 
NAFLD accompanied by early signs of NASH, most likely as a con-
sequence of chronic fat accumulation (1, 3).
The excessive accumulation of hepatic lipids and increased de 
novo lipogenesis could also have other causes. A previous study 
using liver-specific Lrh-1 knockout mice showed that LRH-1 pro-
motes glucokinase expression, hence regulating glycolysis and de 
novo lipogenesis (6). However, we did not observe a difference 
in hepatic glucose-6-phosphate content between LRH-1 WT and 
LRH-1 K289R mice, suggesting that the selective gain of function 
of LRH-1 driven by the K289R mutation does not increase substrate 
availability for the glycolytic pathway. Based on the finding that 
the primary corepressor of LRH-1 affects microsomal triglyceride 
transfer protein levels and consequently hepatic VLDL-triglyceride 
secretion (23), we also performed in vivo VLDL-secretion assays, 
but could not detect any difference between refed LRH-1 K289R 
and LRH-1 WT mice. Finally, LRH-1 SUMOylation has been linked 
to the induction of the hepatic APR (18, 19, 28), which could explain 
the excessive inflammation observed in the livers of mice receiv-
ing a chronic HFHS diet. To study the APR in vivo, we challenged 
LRH-1 WT and LRH-1 K289R mice with lipopolysaccharide for 2.5 
hours. Besides the reduction in Crp and Tnf, the inflammatory sig-
nature was comparable between the genotypes, suggesting that the 
exacerbated inflammatory phenotype of the LRH-1 K289R mice is 
most likely not driven by changes in the APR.
While the induction of SREBP-2 processing has been well 
described, the mechanisms that trigger SREBP-1 processing are 
less well understood (29). Insulin receptor/AKT/mTOR signaling 
is considered one of the main pathways triggering SREBP-1 sig-
naling (30). A recent study showed that insulin promotes SREBP-1 
activation and de novo lipogenesis via mTORC1-dependent 
and -independent mechanisms (31). Others proposed that while 
insulin signaling is required for SREBP-1 activation in insulin- 
resistant conditions, it is not critical for inducing the feeding- 
dependent induction of SREBP-1 under physiological conditions 
(32, 33). In breast epithelial cells, the expression of oncogenic 
forms of the PI3K or K-Ras are sufficient to induce SREBP-1 matu-
ration and de novo lipogenesis through induction of mTOR signal-
ing (34). Whereas these and many other studies demonstrate that 
the expression of Srebf1 and the posttranslational maturation of 
SREBP-1 can be triggered by insulin signaling, other downstream 
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old male mice were initially fasted for 24 hours, followed by refeeding 
for 12 hours (8 pm to 8 am), 6 hours (2 am to 8 am), or 2 hours (6 am 
to 8 am), and finally sacrificed together at 8 am to avoid confounding 
effects of the circadian rhythm. To induce a chronic hepatic steatosis, 
male mice were fed ad libitum with a HFHS diet (TD.08811, Harlan 
Laboratories) for 17 weeks and sacrificed at 9 am. To study the APR, 
male mice fed a chow diet received an intraperitoneal injection of 
either 500 μl PBS or 40 μg LPS dissolved in 500 μl PBS. Mice were 
sacrificed 2.5 hours after injection and tissues collected.
Subcellular fractionation of liver tissues and Western blotting. From 
50 to 100 mg of liver pieces were incubated in 400 μl of hypotonic buf-
fer (10 mM HEPES-KOH, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM 
DTT, protease and phosphatase inhibitor cocktails; Roche) and lysed 
with 10 strokes in a Dounce homogenizer. The supernatant fraction 
containing mainly cytoplasmic proteins was collected after centrifuga-
tion (14,000 g for 5 minutes, 4°C), and the pellets were washed twice 
with hypotonic buffer. The pellets were resuspended in 100 to 200 μl 
of hypertonic buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1 % 
NP-40, protease and phosphatase inhibitor cocktails) for 30 minutes 
on ice. The supernatant containing mainly nucleoplasm and mem-
brane fractions was collected by centrifugation (2,000 g for 5 minutes, 
4°C), and the remaining insoluble pellet containing mainly chromatin 
was resuspended in 100 μl of hypertonic buffer and sonicated. Before 
running SDS-PAGE, protein lysates were boiled for 5 minutes at 95°C. 
The following proteins were used for Western blotting: anti-Hsp90, 
anti–SREBP-1, and anti-P62 (BD Biosciences catalog 610418, 557036, 
and 610497); anti-OSBPL3 (Novus Biologicals, catalog NBP-155151), 
anti-FASN (Abcam, catalog ab22759), anti-SCD1 (Thermo Fisher, 
catalog A13996), anti–α-tubulin, anti-PARP1, and anti–β-actin (San-
ta Cruz Biotechnology Inc., catalog sc-5286, sc-7150, and sc-47778). 
Anti–SREBP-1, anti-P62, and anti-PARP1 were blotted on nuclear/
membrane fractions and all other antibodies on cytoplasmic fractions.
Gene expression and analysis. RNA was extracted from the livers of 
mice that were fasted for 24 hours followed by 6 hours of refeeding, 
LRH-1 WT (n = 6) and LRH-1 K289R (n = 6). Extraction was performed 
using TRIZOL (Invitrogen) and purified with the RNeasy Cleanup Kit 
for Microarray Analysis (QIAGEN). For quantitative reverse-tran-
scription PCR (RT-qPCR), cDNA was generated using the QuantiTect 
Reverse Transcription Kit (QIAGEN) and analyzed by qPCR using a 
LightCycler 480 Real-Time PCR System (Roche) and the primers list-
ed in Supplemental Table 1. Expression data were normalized to 36b4 
or B2m mRNA levels. Microarray analysis was performed using the 
Affymetrix MouseGene 1.0 ST array and normalized using the robust 
multi-array average (RMA) method. All original microarray data were 
deposited in the NCBI’s Gene Expression Omnibus (GEO GSE89877). 
Heat maps were generated using GENE-E (http://www.broadinstitute. 
org/cancer/software/GENE-E/index.html), and rows were clustered 
using the one minus Pearson correlation metric.
ChIP-PCR. ChIP analysis was performed as described previous-
ly, with minor modifications (9). ChIPed DNA was purified using the 
PCR Clean-up Extraction Kit (Macherey-Nagel), after which qPCR 
was performed as described previously (47). Data were normalized to 
the input (fold differences = 2– (Ct-sample – Ct-input)). ChIP primer sequences 
are listed in Supplemental Table 2. For LXR ChIP assays, an anti-LXRα 
antibody (Abcam, catalog ab41902) was used. For LRH-1 ChIP exper-
iments, a custom LRH-1 antibody was generated. A synthetic peptide 
([H]-QEQSNRNRQEKLSAFG-[NH2]) was used to immunize 2 rab-
or parallel pathways exist. One recent example is the induction of 
SREBP-1 processing upon depletion of phosphatidylcholine, whose 
synthesis is dependent on S-adenosylmethionine, a methionine 
derivative that is generated in the one-carbon cycle (35). We did 
not observe a difference in AKT phosphorylation between LRH-1 
WT and LRH-1 K289R mice, suggesting other signaling pathways 
to induce the processing of SREBP-1. Indeed, our current study 
highlights the existence of an alternative mechanism of SREBP-1 
activation involving a SUMO-dependent LRH-1/OSBPL3 pathway.
The first oxysterol-binding proteins were identified, puri-
fied, and cloned in the 1980s (36–38). Recent studies suggest that 
OSBPs act as sterol transfer and/or sensor proteins that may also 
play important roles in cell signaling (39, 40). OSBPL3, a mem-
ber of subfamily III, contains a conserved sterol-binding OSBP 
homology domain (OHD) as well as a phosphatidylinositol lipid 
species–binding pleckstrin homology (PH) domain and two 2-phe-
nylalanines in an acidic tract (FFAT) domains that bind to the ves-
icle-associated membrane protein–associated (VAMP-associated) 
protein (VAP) (39, 41, 42). Recently, it has been shown that this 
last interaction can activate R-RAS, thus reorganizing the actin 
cytoskeleton and affecting cell polarity and cell-cell adhesion (43). 
Future studies will be necessary to dissect the exact mechanisms 
by which OSBPL3 modulates SREBP-1 processing, but its associa-
tion with the ER could indicate a possible site of regulation.
In addition to the identification of OSBPL3 as a target of LRH-1, 
our study also highlights the existence of complex regulatory 
mechanisms to which OSBPL3 is subjected. We observed a discrep-
ancy between mRNA and protein levels of OSBPL3 between fast-
ing and refed conditions despite its persistent increase in LRH-1 
K289R mice. The marked reduction in mRNA levels upon refeed-
ing was also noticed when OSBPL3 was overexpressed using an 
adenovirus, indicating that additional posttranscriptional mecha-
nisms independent of LRH-1 regulate the expression of OSBPL3. 
Moreover, while the expression of OSBPL3 is low in healthy livers, 
it is increased in NAFLD, suggesting that this protein could be a 
novel biomarker for NAFLD.
In this study, we described a function of LRH-1 in the devel-
opment of fatty liver disease. It is noteworthy that other nuclear 
receptors also contribute to the development of NAFLD by affect-
ing steatosis, glucose homeostasis, inflammation, and/or fibrosis 
in the liver. For instance, while activation of LXRs or pregnane 
x receptor (PXR) promotes lipogenesis and the development of 
NAFLD, activation of other nuclear receptors such as PPARs 
or farnesoid X-activated receptor (FXR) has opposite effects 
(reviewed in ref. 44). Clinical trials performed in NASH patients 
using PPARγ or FXR agonists showed that the beneficial effects 
observed on hepatic steatosis and inflammation were accom-
panied by adverse effects on obesity and hypercholesterolemia, 
respectively (45, 46), highlighting the functional complexity of 
nuclear receptors (44). Therefore, the development of drugs tar-
geting specific nuclear receptor targets, such as OSBPL3, might 
provide alternative therapeutic options for treating NAFLD.
Methods
Animal studies. Congenic C57BL/6J LRH-1 WT or LRH-1 K289R (9) as 
well as C57BL/6J Lrh-1hep–/– and Lrh-1hep+/+ mice (6) were kept under nor-
mal housing conditions. For fast-refeeding protocols, 12- to 16-week-
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Immunohistochemistry. Liver sections were cut into 5-μm–thick seri-
al cryosections for oil red O staining to visualize neutral lipids or paraffin 
cryosections to stain collagen with sirius red, CD45-positive cells using 
rat anti-CD45 antibody (eBioscience, catalog 30-F11), or H&E.
Statistics. Data are expressed as mean ± SEM. Comparison of differ-
ences between 2 groups was assessed using unpaired 2-tailed Student’s 
t tests. Multiple group comparisons were assessed by ANOVA and Bon-
ferroni’s post-hoc t tests. P < 0.05 was considered statistically significant.
Study approval. All animal procedures were approved by the 
Swiss authorities (Canton of Vaud, animal protocols ID 2380, 2561, 
and 2768) and performed in accordance with École Polytechnique 
Fédérale de Lausanne institutional guidelines.
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bits (AbFRONTIER). The antiserum with the highest ELISA titer was 
selected and used in ChIP experiments. The preimmunization serum 
from the same rabbit was used as a negative control.
LXR agonist treatment. Hepa 1.6 (ATCC, catalog CRL1830) or 
AML-12 (ATCC, catalog CRL2254) cells were treated with 1 μM of 
GW3965 (Selleckchem), a dual LXRα and LXRβ agonist, for 6 hours 
in full medium.
In vivo siRNA transfection. siRNA sequences are listed in Supple-
mental Table 4. HPLC-purified siRNAs (3 nmol, Microsynth) were tail-
vein injected into each recipient mouse using in vivo-JetPEI (Polyplus) 
according to the manufacturer’s instructions. Mice were fast-refed as 
described above and sacrificed 2 days after injection.
Adenoviral infection. Osbpl3 cDNA was cloned into a pENTR/ 
D-TOPO plasmid (Invitrogen; the Topo primer is listed in Supple-
mental Table 3) and then subcloned in the pAd/CMV-DEST plasmid 
(Invitrogen). After linearization with PacI, the construct was trans-
fected into HEK 293A cells to produce the adenoviruses. Mice were 
tail-vein injected with Ad-gfp or Ad-Osbpl3, 2.5 × 109 PFU, fast-refed as 
described above, and sacrificed 3 days after injection.
AAV8 miRNA injection. The Osbpl3-siRNA sequence (Supplemen-
tal Table 4) was engineered to create a pre-miRNA sequence target-
ing Osbpl3, which was cloned into an AAV vector construct driven by 
the liver-specific hAAT promoter. AAV8 mirOsbpl3 viral vectors were 
generated and titrated as described previously (48, 49) and injected 
into jugular vein under isoflurane anesthesia (5 × 1011 vg). Two weeks 
after the injection, mice were fasted for 24 hours followed by 6 hours 
refeeding, then sacrificed, and tissues were snap-frozen.
Lipid analyses and plasma parameters. Hepatic lipids were extract-
ed according to the Bligh and Dyer protocol (50). Triglycerides, free 
fatty acids, and cholesterol contents in plasma and/or hepatic lipid 
fractions were quantified using enzymatic assays (Roche). To asses 
fatty acid synthesis rates in vivo, mice received sodium [1-13C] ace-
tate via their drinking water (2%) 24 hours prior to sacrifice. Fatty 
acids derived from hepatic lipid extracts were liberated, derivatized, 
and subjected to gas chromatography–mass spectrometry (GC-MS) 
analysis in order to calculate the fractional synthesis rates from the 
incorporation of 13C-acetate as described previously (51). ASAT and 
ALAT concentrations in blood were determined using standard clin-
ical chemistry methods.
VLDL secretion assay and glucose-6-phosphate quantification. The 
VLDL secretion assay was performed as described previously (51). 
Thirteen-week-old male LRH-1 K289R or LRH-1 WT mice were sub-
jected to the fasting-refeeding protocol and treated with 50 mg/ml 
poloxamer 407 (Sigma-Aldrich, catalog 16758) 8 hours after refeed-
ing was initiated. Blood samples were collected once before and every 
hour after poloxamer treatment to determine the triglyceride content. 
Glucose-6-phosphate content was determined using enzymatic assays 
as described previously (6).
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Figure S1 
Figure S1. Lrh-1 K289R mice do not show changes in the early insulin response. (A, B) 
Phospho and total AKT immunoblots (A), and mRNA expression of early response genes (B) 
in livers from fasted WT or K289R mice that were injected with PBS or insulin 10 min prior to 
sacrifice. n = 3 for PBS groups, 4 for insulin groups. (C) Hepatic expression of the two 
Srebf1 isoforms, Srebf1a and Srebf1c, in fasted and refed WT and K289R mice. n = 4 per 
genotype. (D, E) Fractional chain elongation (CE) of pre-existing palmitate to hepatic 
stearate (D) and oleate (E). n = 6 per genotype. Error bars represent means ± S.E.M. WT, 
Lrh-1 WT; K289R, Lrh-1 K289R mice. 
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Figure S2 
Figure S2. Osbpl3 is a direct transcriptional target of LRH-1. (A) Hepatic mRNA 
expression of oxysterol binding protein family members in fasted or 6-hour-refed K289R and 
WT mice. n = 10 per genotype. (B) Osbpl3 expression in hepatic lysates of fasted or refed 
mice infected with Ad-GFP or Ad-OSBPL3. n = 2 per fasted group, n = 5 for refed group. 
Error bars represent means ± S.E.M. *p<0.05, **p<0.01 and ***p<0.001 relative to WT, as 
determined by two-way ANOVA with Bonferroni post-hoc test (A, B). WT, Lrh-1 WT; K289R, 
Lrh-1 K289R mice. 
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Figure S3. 
 
Figure S3. Crosstalk between LXR and LRH-1 pathways. (A) LXR chromatin 
immunoprecipitation on hepatic lysates from WT and K289R mice. n = 6 per genotype. (B, C) 
Expression of Osbpl3 and Abcg1 in Hepa 1.6 (B) or AML-12 (C) cells upon treatment with 
the LXR agonist GW3965. n = 3 per treatment. Error bars represent means ± S.E.M. 
***p<0.001 relative to WT, as determined by unpaired Student’s t-test (B, C). WT, Lrh-1 WT; 
K289R, Lrh-1 K289R mice. 
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Figure S4 
Figure S4. No change in glucose-6-phosphate production and VLDL secretion in Lrh-1 
K289R mice. (A) Quantification of glucose-6-phosphate (glucose-6-P) in hepatic lysates of 
fasted or refed WT and K289R mice. n = 4 WT fasted, 7 K289R fasted, 7 WT refed, and 6 
K289R refed. (B, C) Plasma triglyceride synthesis over time (B), and triglyceride production 
rate (TGPR) in WT and K289R mice (C). n = 7 per genotype. Error bars represent means ± 
S.E.M. ***p<0.001 refed mice relative to fasted mice, as determined by two-way ANOVA 
with Bonferroni post-hoc test (A). WT, Lrh-1 WT; K289R, Lrh-1 K289R mice. 
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Figure S5 
 
Figure S5. Lrh-1 K289R mice develop NAFLD upon HFHS diet feeding. (A) Plasma 
cholesterol levels in WT and K289R mice fed a HFHS diet. WT, n = 7; K289R, n = 10 per 
genotype. (B) Triglyceride (TG) content in lipoprotein subfractions. VLDL, very-low density 
lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein. n = 1 pooled sample 
from 7 mice per genotype. (C) Hepatic mRNA expression of oxysterol binding protein family 
members in K289R and WT mice upon chow or HFHS feeding. n = 9 per genotype. (D) 
Heatmap displaying the expression of oxysterol binding protein family members as well as 
markers of matrix degradation, fibrosis, and inflammation in mice that were classified as low-
fat low (LFL) responders, low-fat high (LFH) responders, high-fat low (HFL) responders, and 
high fat high (HFH) responders according to the development of NAFLD/NASH upon chow 
or high-fat diet feeding (1). Normalized expression values are in Log2 scale. Error bars 
represent means ± S.E.M. ***p<0.001 relative to WT, as determined by two-way ANOVA 
with Bonferroni post-hoc test (C). WT, Lrh-1 WT; K289R, Lrh-1 K289R mice. 
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Figure S6 
 
Figure S6. Expression of OSBPL3 in NASH patients. Expression of OSBPL3 and markers 
of matrix degradation, fibrosis, and inflammation in transcriptomic data from human subjects 
that had livers ranging from healthy controls to steatosis and further to NASH (2). Arrow 
indicates OSBPL3. Normalized expression values are in Log2 scale. 
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Figure S7 
 
Figure S7. Hepatic acute phase response in Lrh-1 WT and K289R mice. (A) Hepatic 
expression of the indicated acute phase response genes in WT and K289R mice that were 
challenged with either PBS or lipopolysaccharide (LPS) for 2.5 hours. n = 5 PBS-treated 
groups, n = 6 LPS-treated groups. (B) ELISA assays to determine the plasma content of IL-6, 
MCP-1 or TNF-α. n = 5 PBS-treated groups, n= 6 LPS-treated groups. **<0.01 and 
***p<0.001 relative to WT, as determined by two-way ANOVA with Bonferroni post-hoc test 
(A). WT, Lrh-1 WT; K289R, Lrh-1 K289R mice. 
  
A
B
Crp
PBS LPS
0.0
0.5
1.0
1.5
R
el
at
iv
e 
ex
pr
es
si
on
***
Fgb
PBS LPS
0
10
20
30
Hp
PBS LPS
0
2
4
6
8
Serpine 1 (Pai1)
PBS LPS
0.0
0.1
0.2
0.3
0.4
WT
K289RTnf
PBS LPS
0
5
10
15
20
**
Hamp (Hepcidin)
PBS LPS
0
5
10
15
20
Apcs (Sap)
PBS LPS
0.0
0.1
0.2
0.3
TNF-
PBS LPS
0
50
100
150
200
(p
g/
m
l)
IL-6
PBS LPS
0
100
200
300
400
(p
g/
m
l)
MCP-1 (CCL-2)
PBS LPS
0
1000
2000
3000
(p
g/
m
l)
Il1b
PBS LPS
0.00
0.03
0.06
0.09
R
el
at
iv
e 
ex
pr
es
si
on
WT
K289R
  
 
Table S1. Q-PCR primer table. 
Gene Forward (5’ to 3’ sequence) Reverse (5’ to 3’ sequence) 
36B4 AGATTCGGGATATGCTGTTGG AAAGCCTGGAAGAAGGAGGTC 
Acaca CCATCCAAACAGAGGGAACATC CTACATGAGTCATGCCATAGTGGTT 
Acly GCCAGCGGGAGCACATC CTTTGCAGGTGCCACTTCATC 
Acta2 CCCAGACATCAGGGAGTAATGG TCTATCGGATACTTCAGCGTCA 
Apcs GGACCAAGCATGGACAAGCTA TGTCTGACAAAAGGCTTCTGAAAG 
Atf3 GGTCGCACTGACTTCTGAGG CTCTGGCCGTTCTCTGGA 
B2m TTCTGGTGCTTGTCTCACTG TATGTTCGGCTTCCCATTCT 
Col1a1 TGTTCAGCTTTGTGGACCTC TCAAGCATACCTCGGGTTTC 
Col1a1 AACCCTGCCCGCACATG CAGACGGCTGAGTAGGGAACA 
Crp CCCTCTTCAGATCCTTTCCT GCCCTCCTGATAGATTATCC 
Des CTCGGAAGTTGAGAGCAGAGA GTGAAGATGGCCTTGGATGT 
Egr1 TGGGATAACTCGTCTCCACC GAGCGAACAACCCTATGAGC 
Elovl6 AACTTGGCTCGCTTGTTCAT CCAATGGATGCAGGAAAACT 
Fasn AGCTTCGGCTGCTGTTGGAAGT TCGGATGCCTCTGAACCACTCACA 
Fgb GTATCTCATCCAGCCTGACA CATCCTGACGGTTCTGTATG 
Gfap CCTTCTGACACGGATTTGGT ACATCGAGATCGCCACCTAC 
Gpam GCTATCATGTCCACCCACATTG ACTTCCTCCTTCATCACAAAGAAGTC 
Hamp GCTGCCTGTCTCCTGCTTCT AGCTCTGTAGTCTGTCTCATCTGTTG 
Hp GAAGCAATGGGTGAACACAG TGCCTTTGGCATCCATAGAG 
Il1b CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA 
Mcp1/Ccl2 AGGTCCCTGTCATGCTTCTG GCTGCTGGTGATCCTCTTGT 
Mip1a/Ccl3 GTGGAATCTTCCGGCTGTAG ACCATGACACTCTGCAACCA 
Mmp13 CTTCTTCTTGTTGAGCTGGACTC CTGTGGAGGTCACTGTAGACT 
Mmp2 CAAGTTCCCCGGCGATGTC TTCTGGTCAAGGTCACCTGTC 
Mmp3 ACATGGAGACTTTGTCCCTTTTG TTGGCTGAGTGGTAGAGTCCC 
Mmp9 CTGGACAGCCAGACACTAAAG CTCGCGGCAAGTCTTCAGAG 
Osbp2 TGTGGTGGAGTTCACTGTTG CAAGGCTATCCGTGTGATGA 
Osbpl2 TCTATATTTATGTTGAAGTTGTGTGGA CTTGGGTGTCAGAGGGTTG 
Osbpl3 TCAATCCTTCCACGACTTCC CGGTGTGTCTCAAAAGTTGGT 
Osbpl5 AGAAAGGCCTCCTCCTTCAT GGCCCTGAGCATCTTGTCT 
Osbpl9 TCCAAGGGACTAGGCTGGTA CAACAAATAGCATGGTAGAATCAA 
Ppib CAGGGGAGATGGCACAGGAG CGGCTGTCTGTCTTGGTGCTCTCC 
Reln ACATGAGAGGCCACCACACT CTTCTCAGAGCATTGGAGGC 
Scd1 CCGGAGACCCCTTAGATCGA TAGCCTGTAAAAGATTTCTGCAAACC 
Scd1 CTGTACGGGATCATACTGGTTCCC CAGCCGAGCCTTGTAAGTTCTGTG 
Serpine 1 TGGCTCAGAGCAACAAGTTCAA TCAAAGGGTGCAGCGATGAACA 
Srebf1a GCCGGCGCCATGGACGAGCTGGCC CAGGAAGGCTTCCAGAGAGGAGGC 
Srebf1c GGAGCCATGGATTGCACATT  GGCCCGGGAAGTCACTGT 
Tgfb1 TGACGTCACTGGAGTTGTACGG GGTTCATGTCATGGATGGTGC 
Tnf GTAGCCCACGTCGTAGCAAAC AGTTGGTTGTCTTTGAGATCCATG 
Vim GGATTCCACTTTCCGTTCAA GAAATTGCAGGAGGAGATGC 
  
  
 
Table S2. ChIP primer table. 
Gene Forward (5’ to 3’ sequence) Reverse (5’ to 3’ sequence) Refe-rence 
Abca1 GCTTTCTGCTGAGTGACTGAACTAC GAATTACTGCTTTTTGCCGCG (3) 
Actin GCGGCCAACGCCAAAACTCTCC GGCCCCGCGCCGCTCACTCAC  
Chrebp TCTGTGGATCGTGAACCCTATTT TTCGTCCTCGGGTGGCAACGGGGGACA (4) 
Gapdh AGTGCCAGCCTCGTCCCGTAGACAAAATG AAGTGGGCCCCGGCCTTCTCCAT  
Osbpl3-site1 ATTTGCCAGGCACTACCAAC TCCCCGGAAAGGTAAGAGTT  
Osbpl3-site2 TCCTCTACCCCACACTTTGAG CCTTCCCATCTCCCATGCTCC  
Osbpl3-site3 TTGGCATCCAAAACACACTG ACATTTCCCCGACTTCATCA  
Osbpl3-site4 TCATGTGTGGCAGGTTTTGT ATAAAAGCCACCCCTTCCAT  
Osbpl3-site5 CCCAGCTTCTCAGCATCTTC CTCAATCCTCTTGCCTCTGC  
Osbpl3-site6 CCTTCTCCCCTTTTCTCTGC ACGGATCTTGACTGGAGCAC  
Srebf1 GAACCAGCGGTGGGAACACAGAGC GACGGCGGCAGCTCGGGTTTCTC (3) 
  
Table S3. Cloning primer table. 
Gene Forward (5’ to 3’ sequence) Reverse (5’ to 3’ sequence) 
Osbpl3 Topo CACCATGAGTGACGAGAAGAATCTCG TCACCATAAGACGGGATGGT 
 
 
Table S4. siRNA table (HPLC purified). 
Gene Sense sequence (5’ to 3’ sequence) Overhangs 
Osbpl3 siRNA AAG UUG GUU UCA CCU UCA ATT dTdT	
Scrambled siRNA ACA GAC GGA GAC GCA CAC CTT dTdT	
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Abstract 
During fasting, adipose tissue-derived fatty acids overload the liver and activate pathways for 
their utilization and systemic re-distribution. When the oxidative capacity of the liver is 
compromised, fat builds up inside hepatocytes and the liver becomes steatotic. The nuclear 
receptor homolog-1 (LRH-1, NR5A2) is a pivotal regulator of hepatic intermediary 
metabolism, however, very little is known about its role in coordinating fasting-induced 
responses to coordinate fatty acid metabolism. Here, we have assessed the biological 
consequences of a loss of function of LRH-1 in livers subjected to an overnight fasting. Mice 
with a specific deletion of LRH-1 in hepatocytes (Lrh-1 hep-/- mice) developed fasting-induced 
steatosis. This condition was accompanied by mitochondrial dysfunction with consequent 
reduction in fatty acid oxidation. Moreover, we observed that an as of yet uncharacterized 
liver-specific mitochondrial solute carrier (SLC25A47), is downregulated in Lrh-1 hep-/- livers. 
These changes were attributed to direct transcriptional regulation of Slc25a47 by LRH-1. 
Restoring Slc25a47 expression in hepatocytes significantly improved mitochondrial function, 
increased fatty acid degradation, and rescued the steatotic phenotype of LRH-1 deficient 
livers. These findings suggest that LRH-1 is important for the coordination of nutritional 
responses in the liver and point to a putative role of SLC25A47 in fasting-induced 
mobilization of energy.  
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Figure legends 
Figure 1. Lrh-1 hep-/- mice display fasting-induced steatosis. (A) Representative oil red O 
stainings of Lrh-1 hep+/+ and Lrh-1 hep-/- mice in fed and fasted conditions to visualize neutral 
lipids. Scale bar: 200 µm. (B) Body weight of fed and fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. 
(C, D) Liver (C) and epididymal white adipose tissue (D) mass normalized to body weight of 
Lrh-1 hep+/+ and Lrh-1 hep-/- mice in both fed and fasted conditions. (E) Quantification of hepatic 
triglyceride (TG) in lipid extracts of fed and fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (F, G) 
Plasma free fatty acids (FA, F) and TG (G) levels in fed and fasted Lrh-1 hep+/+ and Lrh-1 hep-/- 
mice. Error bars represent mean ± S.E.M. *p<0.05 and ***p<0.001 relative to Lrh-1 hep+/+ 
mice, as determined by one-way ANOVA with Bonferroni post-hoc test.  
 

 7 
Figure 2. LRH-1 regulates mitochondrial transcripts. (A) Vulcano plot depicting in red the 
significant representation of mitochondrial transcripts among all genes in fasted Lrh-1 hep+/+ 
and Lrh-1 hep-/- mice liver microarray. FC, fold change. (B) Gene ontology (GO, cellular 
compartment) of genes downregulated in livers from fasted Lrh-1 hep-/- in comparison with 
Lrh-1 hep+/+ mice. (C) Heat map of the most significant downregulated mitochondrial genes 
(from B) in fasted Lrh-1 hep-/- livers, FC > 1.4 (WT/KO) and P< 1x104. (D) Pathway 
enrichment analysis (KEGG) of proteins downregulated in Lrh-1 hep-/- livers 
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Figure 3. Lrh-1hep-/- mice present mitochondrial dysfunction. (A) Oxygen consumption 
rate (OCR) of fresh liver homogenates from fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice by high-
resolution respirometry in the presence of succinate, ADP (SA) and rotenone (ROT) – 
state3ADP. (B) OCR of fresh liver homogenates from fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice in 
the presence of fatty acid oxidation (FAO) substrates, palmitoyl- and octanolyl-carnitine, and 
ADP. (C) Oleic acid oxidation assay in the liver of fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (D) 
Liver acyl-carnitines content in fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (E) Hepatic ATP level 
of fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (F) Immunoblots of mitochondrial complexes 
subunits ATP5A (CV), UQCRC2 (CIII), MTCO1 (CIV), SDHB (CII) and VDAC as a loading 
control in isolated mitochondria from fasted Lrh-1 hep+/+ and Lrh-1 hep-/- livers. (G) In-gel activity 
of mitochondrial complexes (I, II and IV) from Lrh-1 hep+/+ and Lrh-1 hep-/- fasted liver 
mitochondria. Complex I (purple); Complex IV (brown); complex II (blue). (H) Quantification 
of the bands in (G) normalized to coomassie blue staining bands. Error bars represent mean 
± S.E.M. and *p<0.05, **p<0.01 relative to Lrh-1 hep+/+ mice, as determined by Student’s t-
test.  
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Figure 4. Slc25a47 is a direct transcriptional target of LRH-1. (A) Heat map depicting 
LRH-1 target genes expression between fasted Lrh-1 hep+/+ and Lrh-1 hep-/- livers. 
Normalized values are in log2 scale. (B, C) Slc25a47 gene (B) and protein (C) expression 
levels in the liver of fasted Lrh-1 hep+/+ and Lrh-1 hep-/- mice. (D) University of California at 
Santa Cruz (UCSC) genome browser (mm9) view displaying the occupancy of mouse 
Slc25a47 by LRH-1 and IgG. Significant peaks are underlined in red. (E) Binding of LRH-1 to 
Slc25a47 promoter region as assessed by Chip analysis using genomic DNA from Lrh-1 
hep+/+ and Lrh-1 hep-/- livers. Error bars represent mean ± S.E.M. ***p<0.001 relative to Lrh-1 
hep+/+ mice, as determined by student’s t-test.  
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Figure 5. Slc25a47 rescues the steatotic phenotype of the Lrh-1hep-/- fasted livers. (A) 
Gene expression of Slc25a47 in Lrh-1 hep+/+ and Lrh-1 hep-/- mice transduced with AAV8-Empty 
or AAV8-Slc25a47. (B, C) Hepatic ATP level (B) and triglyceride (TG) content (C) in Lrh-1 
hep+/+ and Lrh-1 hep-/- mice transduced with AAV8-Empty or AAV8-Slc25a47. (D) 
Representative oil red O stainings in the liver of Lrh-1 hep+/+ and Lrh-1 hep-/- mice transduced 
with AAV8-Empty or AAV8-Slc25a47. (E) Oxygen consumption rate (OCR) in liver 
mitochondria of Lrh-1 hep-/- transduced with AAV8-Empty or AAV8-Slc25a47 by high-
resolution respirometry in response to substrates (succinate, rotenone and ADP – SRA, 
State3ADP), oligomycin (Oligo, State4o) and the uncoupler carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP, State3u) in freshly isolated liver mitochondria from 
AAV8-empty and AAV8-Slc25a47 transduced  Lrh-1 hep-/- mice. (F) In-gel activity of 
mitochondrial complexes (I, II and IV) from Lrh-1 hep+/+ and Lrh-1 hep-/- fasted liver 
mitochondria. Complex I (purple); Complex IV (brown). (G) Graphical presentation showing 
how LRH-1 regulates Slc25a47 leading to normalization of lipid accumulation by enhancing 
the breakdown of fatty acids. Error bars represent mean ± S.E.M. *p<0.05, **p<0.01, and 
***p<0.001 relative to Lrh-1 hep+/+ or Lrh-1 hep-/- mice as indicated; determined by student’s t-
test.  
 
 
 
 
 
A
Figure 5
B
G
Lrh-1 hep+/+ Lrh-1 hep-/- + empty Lrh-1 hep-/- + Slc25a47 
C
D
E F Lrh-1 hep-/-
Empty
IV
IV2
I
I+III2
I+III2+IV1
(I+III)n
Slc25a47
0
5
10
15
H
ep
at
ic
 T
G
 (µ
g/
m
g 
tis
su
e)
*** *
Lrh-1 hep+/+ 
Lrh-1 hep-/- + Empty 
Lrh-1 hep-/- + Slc25a47
0
10
20
30
40
50
AT
P 
le
ve
l (
R
LU
/m
g 
Li
ve
r)
* **
I
II
Q III
Cyt c
IV V
H+ H+ H+ H+
ADP + Pi
ATP 
SLC
25A47
Matrix
Intermembrane space
Mitochondria
Nucleus
LRH-1 Slc25a47
mitochondrial 
respiration
fatty acid 
oxidation
Decreased 
lipid accumulation
0
2
4
6
R
el
at
iv
e 
ex
pr
es
si
on
*
***
Slc25a47
SRA Oligo FCCP
0
200
400
600
O
C
R
 (p
m
ol
/s
//m
g 
pr
ot
ei
n)
State3ADP State4o State3u
*

 15 
 
Figure S1. Lrh-1 hep-/- mice do not present different white adipose tissue lipolysis rate. 
(A, B) Ex vivo lipolysis-associated glycerol (A) and free fatty acids (FA) (B) released from 
Lrh-1 hep+/+ and Lrh-1 hep-/- white adipose tissue explants. Error bars represent mean ± S.E.M. 
***p<0.001 relative to Forskolin-treated group.  
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Figure S2. Slc25a47-overexpression in the liver of Lrh-1 hep-/- mice increases 
mitochondrial complexes activity. (A) Gene expression of Slc25a47 in Lrh-1 hep+/+ and Lrh-
1 hep-/- mice transduced with AAV8-Empty or AAV8-Slc25a47. (B) Liver weight of Lrh-1 hep+/+ 
and Lrh-1 hep-/- mice transduced with AAV8-Empty or AAV8-Slc25a47. (C) Quantification of 
the bands in Figure 5G normalized by coomassie blue staining bands. Error bars represent 
mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 relative to Lrh-1 hep/- + AAV8-Empty.  
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Supplemental Table 1: Sequence of primers used 
Gene Forward (5’ to 3’ sequence) Reverse (5’ to 3’ sequence) 
36b4 AGATTCGGGATATGCTGTTGG AAAGCCTGGAAGAAGGAGGTC 
B2m TTCTGGTGCTTGTCTCACTG TATGTTCGGCTTCCCATTCT 
Slc25a47 GGGCCATTGGAGGAGTCTG CTCTTGACGATACGTGTCCCG 
16S (gDNA) CCGCAAGGGAAAGATGAAAGAC TCGTTTGGTTTCGGGGTTTC 
HK2 (gDNA) GCCAGCCTCTCCTGATTTTAGTGT GGGAACACAAAAGACCTCTTCTGG 
 
 
 
Supplemental Table 2: Chip-qPCR primer sequences 
Gene Forward (5’ to 3’ sequence) Reverse (5’ to 3’ sequence) 
Slc25a47prom #1 CCAGATGTCACAAAGCCAGA TCGCCCTGACAGTTTGTCTA 
Slc25a47prom #2 CGAGGGGTCATCCCTAGTTT CAGTTCAGGGGCTCAAAGAC 
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Abstract 
Mitochondria are the hub of intermediary metabolism. SLC25 family of mitochondrial 
transporters are the dictators of mitochondrial metabolic pathways by controlling almost all 
metabolites that go in and out of the mitochondria. Here, we have assessed the function of 
an uncharacterized SLC25 family member, SLC25A47, and evaluated its potential 
therapeutical role in a pathological condition such as nonalcoholic fatty liver disease 
(NAFLD). From all the members of the SLC25 family, SLC25A47 is the one that holds the 
highest expression in the liver and furthermore it is liver-specific. We found that SLC25A47 is 
significantly different in both sequence and structure from the closest members of the family, 
presenting a new loop in the matrix, possible site of regulation. Of note, SLC25A47 is 
induced upon fasting and correlates with fatty acid degradation. Increasing its expression in 
vivo by AAV8 transduction improves significantly mitochondrial function. Overexpression of 
SLC25A47 in the liver of a mouse model of NAFLD decreased lipid accumulation by 
enhancing mitochondrial fatty acid oxidation. Collectively, our study confirms the importance 
of SLC25 family by characterizing the function of SLC25A47 whose liver specificity 
strengthens it as a very relevant target for liver diseases such as NAFLD minimizing possible 
side effects.    
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Figure legends 
Figure 1. Slc25a47 is a liver-specific mitochondrial inner membrane carrier. (A) Heat 
map depicting the relative mouse Slc25 family transcripts abundance in heart, testis, brain, 
cerebellum, liver and kidney. (B, C) Expression level of Slc25a47 transcript (B) and protein 
(C) levels in different mouse tissues. (D) Immunoblots of SLC25A47 in liver mitochondria 
lysates after permeabilization with increasing amount of digitonin. PINK1 and VDAC for the 
OMM, OPA1 and SDHA for the IMM and HSP60 for the matrix are used as controls. (E) 
FLAG immunofluorescence staining of alpha mouse liver 12 (AML12) cells overexpressing 
FLAG-tagged SLC25A47. DAPI is used to stain nuclei. Scale bar: 10 µm. (F, G) Protein 
alignment of SLC25A47 within species (F) and between SLC25A47 and its closest homologs 
(G). Similarity color code: green, high homology; red, low homology. (H) 3-D structure of 
SLC25A47 depicting the new loop. Color code of the amino acids charge (right panel): blue, 
positive; white, neutral; red, negative. Rectangle emphasizes the loop specific to SLC25A47. 
Error bars represent mean ± S.E.M.  
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Figure 2. Slc25a47 is induced upon fasting. (A) Representation of Slc25a47 genomic 
area binding/occupancy by Pol II assessed by Chip-seq at ZT2 (9am) and ZT18 (1am). (B) 
Heat map displaying the expression of genes important under fed and fasted conditions 
during circadian rhythm. (C) Gene expression analysis of Slc25a47 in the liver of fed and 
24h-fasted mice (7am - 7am). (D) Pathway enrichment (KEGG) of genes positively 
correlating with Slc25a47 in 42 BXD mouse strains. BXD mouse strains were fed CD and 
sacrificed under fasting conditions. (E) Correlation network (pearson’s r) between Slc25a47 
and top 20 most significant positively correlating genes. Thickness of the line is associated 
with higher significance. Error bars represent mean ± S.E.M. ***p<0.001 relative to Fed 
condition, as determined by Student’s t-test. 
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Figure 3. Slc25a47 improves mitochondrial function in vivo. (A) Gene expression of 
mitochondria-related genes, Tfam, Pgc1a, Nrf-1 in AAV8-Empty and AAV8-Slc25a47 
transduced livers. (B) Oxygen consumption rate (OCR) in response to substrates (succinate, 
rotenone and ADP – SRA, State3ADP), oligomycin (Oligo, State4o) and the uncoupler carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, State3u) in freshly isolated liver 
mitochondria from AAV8-Empty and AAV8-Slc25a47 transduced mice. (C) In-gel activity of 
mitochondrial complexes (CIV+CI) in AAV8-Empty and AAV8-Slc25a47 transduced liver 
mitochondria. CI activity (purple); CIV activity (brown). (D) Immunoblot of mitochondrial 
complexes after blue-native polyacrylamide gel electrophoresis (BN-PAGE) fasted AAV8-
Empty and AAV8-Slc25a47 transduced liver mitochondria. (E) Immunoblots of mitochondrial 
complexes subunits ATP5A (CV), UQCR2 (CIII), MTCO1 (CIV), SDHB (CII), NDUFB8 and 
NDUFS3 (CI), and mitochondrial protein VDAC. HSP90 was used as loading control. Error 
bars represent mean ± S.E.M. *p<0.05, **p<0.01 and ***p<0.001, as determined by 
Student’s t-test. 
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Figure 4. Slc25a47 is downregulated in NAFLD and its recovery rescues hepatic 
steatosis. (A) Liver gene expression of Slc25a47 in diet-induced NAFLD model (high-fat, 
high-sucrose diet – HFHS - for 18 weeks). Mice fed a chow diet are depicted as “healthy”. 
(B) Corrgram (pearson’s r) of Slc25a47 with hepatic lipid species assigned as anti-NAFLD 
and pro-NAFLD markers. (C) Representative images of liver sections of AAV8-Empty and 
AAV8-Slc25a47 transduced mice fed HFHS for 7 weeks stained with hematoxylin and eosin 
(H&E) to visualize tissue structure. Scale bar: 200 µm. (D) Hepatic triglyceride (TG) content 
of HFHS-fed AAV8-Empty and AAV8-Slc25a47 transduced mice. (E) Scheme demonstrating 
experimental design for AAV8-Empty and AAV8-Slc25a47 in vivo transduction in mice fed 
choline-deficient diet (ChD) for 4 weeks. (F) Respiratory exchange ratio (RER) measured 
through indirect calorimetry (24h) in ChD-fed AAV8-Empty and AAV8-Slc25a47 transduced 
mice. (G) Hepatic mRNA expression of Slc25a47 in ChD-fed AAV8-Empty and AAV8-
Slc25a47 transduced mice. (H) Oxygen consumption rate (OCR) of fresh liver homogenates 
from ChD- AAV8-Empty and AAV8-Slc25a47 transduced mice. Fatty acid oxidation (FAO) 
substrates (palmitoyl-, octanoyl-carnitine with malate - POM) were added in the presence of 
ADP, followed by succinate (SUC) and rotenone (ROT) to achieve State3ADP. (I) 
Quantification of FAO-driven respiration assessed in (H). (J) Hepatic ATP level of ChD-fed 
AAV8-Empty and AAV8-Slc25a47 transduced mice. (K) Hepatic mtDNA/nDNA (16S/HK2) 
ratio of ChD-fed AAV8-Empty and AAV8-Slc25a47 transduced mice. Error bars represent 
mean ± S.E.M. *p<0.05 and ***p<0.001 relative AAV8-Empty, as determined by Student’s t-
test. §adjusted p-value<0.05, relative to the night period. 
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Figure S1. SLC25A47 is a liver-specific mitochondrial carrier also in humans. Human 
tissue expression profile of SLC25A47 from https://www.gtexportal.org/home/.  
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Figure S2. Slc25a47 is conserved between species and increases mitochondrial 
complexes expression. (A) Correlation network (pearson’s r) between Slc25a47 and top 20 
most significant negatively correlating genes found in BXD mouse strains liver microarray. 
Thickness of the line is associated with higher significance. (B) Scheme showing 
experimental design for in vivo AAV8-mediated gain-of-function of SLC25A47 in mice. (C, D) 
No changes in body weight (C) as well as liver and epididymal white adipose tissue (eWAT) 
mass (D) of fasted AAV8-Empty and AAV8-Slc25a47 transduced mice. Error bars represent 
mean ± S.E.M.  
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Figure S3. Overexpression of Slc25a47 in the liver doesn’t affect body mass. (A, B) 
Body weight (A) and liver and epididymal white adipose tissue (eWAT) mass (B) in choline-
deficient diet (ChD)-fed AAV8-Empty and AAV8-Slc25a47 transduced mice. (C, D) Plasma 
triglyceride (TG, C) and free fatty acids (FA, D) content in ChD-fed AAV8-Empty and AAV8- 
Slc25a47 transduced mice. (E) Hepatic triglyceride (TG) content of ChD-fed AAV8-Empty 
and AAV8-Slc25a47 transduced mice. Error bars represent mean ± S.E.M. *p<0.05 relative 
to AAV8-Empty.  
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Supplemental Table 1: Sequence of primers used 
Gene Forward (5’ to 3’ sequence) Reverse (5’ to 3’ sequence) 
36b4 AGATTCGGGATATGCTGTTGG AAAGCCTGGAAGAAGGAGGTC 
B2m TTCTGGTGCTTGTCTCACTG TATGTTCGGCTTCCCATTCT 
Slc25a47 GGGCCATTGGAGGAGTCTG CTCTTGACGATACGTGTCCCG 
Tfam AAGTGTTTTTCCAGCATGGG GGCTGCAATTTTCCTAACCA 
Pgc1a AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG 
Nrf-1 CGGAGTGACCCAAACTGAAC TGCCGTGGAGTTGAGGATGT 
16S (gDNA) CCGCAAGGGAAAGATGAAAGAC TCGTTTGGTTTCGGGGTTTC 
HK2 (gDNA) GCCAGCCTCTCCTGATTTTAGTGT GGGAACACAAAAGACCTCTTCTGG 
 
 
 
 
 
 
 
 
 
 
 
 
 
